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Abstract 
Bloodstream infection (BSI) is a common condition and associated with 
increased mortality, extended length of stay and increased hospital costs. 
Initial treatment is often empirical because several days may elapse before 
the presence or absence of BSI is microbiologically confirmed. A thorough 
knowledge of risk factors and clinical signs and symptoms that are 
suggestive of BSI would improve the assessment of risk of BSI in the 
individual patient, and could lead to a more timely start of an adequate 
empirical antimicrobial therapy.  
Various risk factors, symptoms and laboratory variables are associated 
with BSI, including age, intravascular catheters, a focus of infection, chills, 
white blood cell count, C-reactive protein (CRP) and procalcitonin (PCT). 
To evaluate the dependency between these indicators of BSI, multiple 
logistic regression (MLR), risk stratification or decision tree models have 
been used. However, these models change dependent of the variables 
included. The majority of models for prediction of BSI did not analyse CRP 
and PCT, but in the few studies where CRP or PCT was included, they 
were always independent predictors of BSI. Other drawbacks of the use of 
models for prediction of BSI are the validity that is limited to the patient 
population of the model and the poor reproducibility in other settings. In this 
review we describe risk factors and clinical and laboratory variables that are 
predictive of BSI in non-neutropenic adult patients, and discuss the use of 
models for bedside prediction of BSI. 
 
Clinical prediction of BSI 
 
11 
Introduction 
Bloodstream infection (BSI) is a serious condition that can be community- 
or hospital-acquired. It is estimated that 7-18% of patients in the medical 
department and 7-9% of patients presenting to the emergency department 
have BSI, and that BSI is acquired by up to 19% of patients admitted to the 
intensive care unit (ICU) [1-8]. Estimates of the excess mortality that can be 
attributed directly to BSI fall most often between 25-60% and are inversely 
related to the severity of underlying illness [4,9-12]. Furthermore, BSI is 
associated with a considerable prolonged length of ICU and hospital stay, 
and increased hospital costs [13-18]. 
Appropriate antimicrobial therapy improves the outcome of BSI 
significantly and reduces length of stay [16,19,20]. When BSI is clinically 
suspected, treatment is usually started empirically after drawing blood for 
culture; additional samples of the probable source of infection are usually 
also obtained for microbiological testing. However, it may take several days 
before the presence or absence of an infectious agent is microbiologically 
confirmed. As a result, overtreatment will occur in a considerable number of 
patients falsely suspected of infection, while the initiation or change of 
antimicrobial treatment will be delayed in those patients who are less 
severely ill and do not have a clear focus of infection or who were already 
treated with antibiotics [21]. This inadequate use of empirical antibiotics 
should be avoided as much as possible because it contributes to mortality 
and the emergence of a resistant flora [19,20,22]. 
The host response to (systemic) microbial infection is summarised in the 
Systemic Inflammatory Response Syndrome (SIRS) criteria, while sepsis is 
traditionally defined as the combination of SIRS plus a microbiologically 
confirmed infection (table 1) [23]. As such, patients presenting with this 
syndrome should be clinically suspected of having infection and possibly 
BSI. However, many non-infectious conditions such as trauma, burns, 
major surgery, and pulmonary embolism may elicit clinical signs of SIRS in 
the absence of infection, while microbiological cultures may be false-
negative for various reasons resulting in a lack of sensitivity of the definition 
of the sepsis syndrome [2,12,24-26].  
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Recently, an alternative approach to SIRS and sepsis has been 
suggested: the PIRO concept. PIRO, stages patients across four domains 
where the P stands for predisposition, I for infection, R for (inflammatory) 
response, and O for organ dysfunction [27-30]. This concept might improve 
the choice of interventions in patients with sepsis, but its clinical value is yet 
unclear. Therefore, a thorough knowledge of the predictive value of clinical 
and laboratory parameters is important for a risk assessment in the 
individual patient.  
 
Table 1. Definitions of the clinical host response to infection 
 
Systemic inflammatory response syndrome (SIRS) 
Two or more of the following: 
Temperature > 38 °C or < 36 °C 
Heart rate > 90/min 
Respiratory rate >20/min (PaO2<32 torr) 
White cell counts >12 or <4x109/L or >10% immature bands 
 
Severe SIRS 
SIRS + signs of organ hypoperfusion/dysfunction such as: 
Acute mental changes 
Oxygenation disturbance (PaO2<70-75 torr) 
Hyperlactataemia and metabolic acidosis 
Oliguria (<0.5 mL/kg for at least one hour) 
Coagulation disturbances 
 
Sepsis 
SIRS + microbiologically confirmed infection 
 
Severe sepsis/sepsis syndrome 
Sepsis + one or more signs of organ hypoperfusion/dysfunction  
 
Septic shock 
Sepsis + one or more signs of organ dysfunction, and 
hypotension despite adequate fluid resuscitation or the need for 
vasopressor therapy 
 
NOTE. These definitions were according to American College of Chest Physicians and 
Society of Critical Care Medicine (ACCP/SCCM) consensus criteria [23]. 
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In this review we describe risk factors and evaluate clinical and laboratory 
variables that are predictive of BSI, and discuss the design of different 
models that integrate these variables for bedside prediction of BSI. We 
limited this review to patients in the general medical or emergency services 
and those admitted to the ICU and do not consider patients with an 
impaired immune system due to haematological malignancies, use of 
immunosuppressive medication or chemotherapy-induced neutropenia. The 
clinical presentation of BSI in these patients is very heterogeneous and 
related to the functional state of the immune system [31,32]. As such, this 
category of patients warrants a separate evaluation.  
Search strategy and selection criteria 
Data for this review were identified through searches of the PubMed 
database up to February 16 2007. Search terms included “bacteraemia”, 
“bloodstream infection”, “prediction”, “predictor”, “risk factor” and “(decision) 
model”. Cited references in the selected articles were screened and 
pertinent articles retrieved. Papers published in the English or Dutch 
language were reviewed. 
Risk factors for BSI 
Several predisposing factors are associated with BSI (table 2). An 
increasing age is associated with a higher risk of BSI. The risk for 
bacteraemia in hospitalised patients that are 85 years or more of age is 
more than twice than that of patients in the age group of 65-84 years [44]. 
The increased risk of BSI associated with higher age may reflect the 
increasing prevalence of underlying co-morbidity that predisposes to 
acquiring BSI, such as diabetes mellitus, renal and liver disease. 
Intravascular catheters provide a port d’entrée for microorganisms to enter 
the bloodstream and thus pose a risk factor for BSI. The same applies for 
patients on haemodialysis, intravenous drug abusers, and patients who 
have undergone invasive procedures in the ICU. 
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Table 2. Risk factors for bloodstream infection in different patient populations 
Patient population or setting OR / RR Reference 
   
Intensive care unit 
  
Age - 33-35 
Underlying endocrine disease 3.4 – 5.9 34,36 
Underlying malignancy 7.5 34 
Immunocompromised status 2.2 – 7.8 5,34,37 
Chronic alcohol abuse 5.6 34 
Surgical patient 0.7-2.9 5,37 
Intravascular catheters/devices 2.2 – 22 33,36,37 
Parenteral nutrition 5.9-8.7 36-38 
On haemodialysis 1.7-209 5,34 
Length of stay - 35-37 
   
Hospitalised patients   
Age - 39-41 
Immunosuppressive drugs 2.1 42 
Intravenous drug abuse 3.6 1 
Intravascular catheters 2.4-4.7 1,39,41 
Urinary catheter 5.4-5.9 41,43 
On mechanical ventilation 2.5 39 
Length of stay 2.3 if >10 days 39,40 
   
Emergency department   
Age 1.03/year 44,45 
Underlying malignancy 3.1 7 
Underlying pulmonary disease 0.1 7 
   
Admissions to the medical ward   
Age 1.01/year 46-49 
Underlying malignancy 2.0 46 
Underlying endocrine disease 2.2 46,47 
Intravascular catheters 2.5 – 2.9 49 
   
Patients with sepsis syndrome   
Underlying liver disease 1.9 50 
Transplantation patient 7.4 50 
Corticosteroid use 3.2 50 
Intravenous drug abuse 1.9 50 
Intravascular catheters 2.1 50 
On mechanical ventilation 1.5 50 
On haemodialysis 1.8 50 
   
NOTE. Data are univariate odds ratio (OR) or relative risk (RR) for bloodstream infection.
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 Clinical signs and symptoms of BSI 
Signs and symptoms that are suggestive of BSI on presentation are 
summarised in table 3. An important factor that clearly increases the risk of 
BSI is the clinical suspicion or the microbiological documentation of a local 
infection at the onset of symptoms [49-51,57]. However, the absence of an 
infectious focus does not eliminate the risk of bacteraemia, because 
bacteraemia may also primarily represent an intravascular infection. 
Bossink et al. show that the clinical presentation of BSI may be different in 
patients with and without a focus of microbiological infection [49]. For 
example, the white blood cell count (WBC) was considerably elevated in 
patients with BSI complicating a local infection but almost normal in 
patients with primary bacteraemia. Also, the peak temperature was much 
higher in case of primary BSI whereas in secondary BSI the temperature 
was almost similar to patients without infection [49]. As such, primary and 
secondary BSI may comprise two different entities with different sets of 
independent predictors. Another strong predictor of BSI is the patient’s 
report of chills. Chills result from an increased production of pyrogenic 
cytokines that reset the hypothalamic thermoregulatory center and lead to 
an elevation in body temperature. Various studies show that the risk of BSI 
is a 3-4 fold higher when chills are reported [44,45,52,53]. This relative risk 
increases with the degree of chills that is experienced and can be as high 
as 12 in patients that feel extremely cold with rigors and generalised bodily 
shaking despite a thick blanket [45]. The presence of chills is associated 
more strongly with Gram-negative bacteraemia than Gram-positive BSI, 
although the difference does not seem to be large enough to be of 
influence on choice of empirical therapy [53,58].  
Patients with fever require a higher degree of suspicion of BSI, which 
increases with the height of body temperature [1,38,39,42]. In addition, the 
course of fever may be of prognostic value with persisting fever despite 
treatment as an ominous sign [59,60]. As such, the response of fever to 
administration of antipyretics may be a useful indicator of infection. The 
lack of temperature response to acetaminophen may be indicative of 
primary bacteraemia and infection in children, but this is unclear in adult 
patients [61,62].  
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Table 3. Clinical signs and symptoms predictive of bloodstream infection 
 
Patient population or setting OR/RR or AUC Reference 
 
   
Focus of 
infection Hospitalised patients 
2.6 – 3.3 1,51 
 Intensive Care Unit 4.3 37 
 Patients with sepsis syndrome 2.1 50 
Chills Emergency department 1.9-7.5 44,52 
 Patients with sepsis syndrome 2.2-3.2 50 
 Hospitalised patients 2.5-4.7 43,53 
 Medical patients 4.2 46 
    
Temperature Hospitalised patients 2.3 if >37.8°C 
2.5 if >38.5°C 
5.3 if >39.0°C 
1,38-
40,42,43 
 Medical patients 0.60-0.68 46,54,55 
 Emergency department 1.5 /ºC 7,45 
Heart rate Febrile medical patients 0.58 55 
  1.9 if >90/min 39 
 Hospitalised patients - 40 
Blood pressure Elderly in the emergency 
department 
3.2 if <100 44 
 Hospitalised patients - 1,40 
 Patients with sepsis syndrome - 56 
Altered mental 
status 
Hospitalised patients 2.3 39 
 
Elderly in the Emergency 
department 
2.9 44 
 Patients with sepsis syndrome 1.6 50 
Oliguria Intensive care unit 34 36 
 Medical patients 4.3 22 
 Patients with sepsis syndrome 1.3 50 
    
NOTE. The univariate odds ratio (OR) or relative risk (RR) are given for dichotomous 
variables, and the area under the curve (AUC) for the receiver operating characteristics 
(ROC) curve for prediction of bloodstream infection are given for continuous variables. If no 
ROC curves were generated for a continuous variable, the OR or RR for a specific cut-off, if 
provided, was included in this table. 
 
Other physical signs that are predictive of BSI are an elevated heart rate 
and low blood pressure [7,51]. Despite being associated with the 
development of shock, these vital signs have inferior value for prediction of 
BSI compared to body temperature and thus have limited impact on clinical 
management [39,49]. Also, the respiratory rate is not independently 
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predictive of BSI in many patients, including patients with community-
acquired pneumonia [7,44,50,63,64]. The lack of predictive value of 
respiratory rate is probably related to the many different illnesses and 
underlying conditions that can cause changes in respiratory rate. 
Interestingly, despite their limited individual predictive value for infection, 
respiratory rate, heart rate and blood pressure are all criteria of SIRS, 
which may account at least in part for the lack of specificity of this 
syndrome. 
Patients presenting with altered mental status have a doubled likelihood 
of bacteraemia than patients presenting with normal consciousness. This 
was especially demonstrated in elderly patients in the Emergency 
Department, although a broad definition of confusion, lethargy or coma was 
used in that study [44]. On the other, mental status alterations had no 
predictive value for BSI in several studies of younger patients or patients 
admitted to the medical ward, probably due to the low prevalence of BSI in 
these patient populations [7,49]. Finally, the observation of oliguria 
aspecific marker of BSI and should mainly be regarded as indicator of poor 
prognosis [36,50,65]. 
Laboratory variables and BSI 
Various laboratory variables related to the inflammatory response have 
predictive value for BSI (table 4). The traditional markers of systemic 
infection are the erythrocyte sedimentation rate (ESR), WBC, and C-
reactive protein (CRP). However, an elevated ESR does not add to the 
likelihood of BSI in most patient populations [8,49,67]. In one study, ESR 
greater than or equal to 30 mm/h was associated with bacteraemia in 
patients with unexplained fever [47]. However, the authors did not 
determine CRP levels or perform logistic regression analysis to assess 
dependency between indicators. In another study, ESR had some 
discriminative power for bacteraemia in hospitalised patients with 
community-acquired fever, but the predictive value was inferior to that of 
CRP and procalcitonin (PCT) [66]. Therefore, determination of the ESR 
does not seem to have a role in prediction of BSI, especially when the CRP 
is available.  
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Table 4. Laboratory variables with predictive value for bloodstream infection 
 Patient population or setting AUC Reference 
Blood cells    
ESR Department of medicine 0.65 47,66 
 Hospitalised patients - 1 
White cell count Intensive care unit 0.66 67 
 Patients in the medical ward 0.56-0.60 8,46,47,54, 
55,68 
 Emergency department 0.50 44,69 
 Hospitalised patients - 1,39,40,51 
Neutrophil count Admissions to the medical ward 0.66 46-48 
 Hospitalised patients - 1,41 
 Emergency department - 44 
 Patients with sepsis syndrome - 50 
Platelet count Hospitalised patients 0.57 41 
 Febrile medical patients - 49 
 Patients with sepsis syndrome - 56 
 
   
Acute phase reactants    
C-reactive protein Medical emergency department 0.85 7,57 
 Admissions to the medical ward 0.68-0.72 49,69 
 Hospitalised patients - 40,51 
Albumin Hospitalised patients 0.64 40,41 
 Febrile medical patients - 46,49,68 
 Critically ill trauma patients - 37 
sPLA2  Febrile patients suspected of 
infection 
0.84 70 
 Febrile medical patients 0.61 54 
Procalcitonin Medical emergency department 0.70-0.85 57,69,71 
 Febrile patients suspected of 
infection 
0.82 70 
 Febrile medical patients 0.70-0.83 55,66 
 Intensive care unit 0.64-0.80 67,71 
 Hospitalised patients - 51 
 
   
NOTE. Data are the area under the receiver operating characteristics curves (AUC) for 
discrimination between patients with and without bloodstream infection. ESR, erythrocyte 
sedimentation rate; sPLA2, secretory phospholipase A2. 
 
That a raised WBC can be used as a predictor for BSI was demonstrated 
in several studies. A large study by Wyllie and colleagues shows that 
lymphocyte and neutrophil counts are even stronger predictors of 
bacteraemia than WBC in adult emergency admissions to the medical or 
infectious diseases ward of their hospital [8,48]. They show that the odds of
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presence of bacteraemia are related to the height of the neutrophil count. In 
addition, they identified a subgroup of patients with high risk of bacteraemia 
but who presented with lymphopenia and normal WBC and neutrophil 
counts. This has also been observed in elderly patients and shows that not 
only determination of the WBC, but also the characterization of different 
white blood cell fractions is important [43,73]. Finally, a low platelet count 
and diffuse intravascular coagulation are associated with BSI, but their 
value is mainly (negative) prognostic, especially if persistent under 
antimicrobial treatment [74-78]. 
The acute-phase reactant CRP is produced by the liver upon stimulation 
by IL-6 and has been shown to be raised in BSI in many patient populations 
[24,48,51,57,66,72]. Although CRP is a sensitive marker of BSI, single CRP 
values should not be interpreted as a specific tool to diagnose BSI, 
because a raised CRP level can also be caused by other conditions such 
as trauma, ischaemic cardiac disease and surgery [79-81]. Therefore, the 
course of CRP is much more predictive of (systemic) infection, with a high 
suspicion of ongoing infection in case of rising CRP concentration [70,82]. 
Recently it was shown that the daily measurement of CRP is useful in the 
identification of non-resolving BSI after initiation of antimicrobial therapy 
and that the course of CRP is a better predictor of outcome than body 
temperature or white blood cell count [82]. In contrast to CRP, albumin 
concentrations are reduced during severe infection due to capillary leakage 
and reduced albumin synthesis. Thus, the albumin concentration behaves 
as a negative acute phase reactant and hypoalbuminemia is a reasonable 
predictor of BSI [37]. The interpretation of normal CRP and albumin levels 
should be cautious in patients with severe liver disease, because the 
hepatic response to cytokines for production of acute-phase reactants is 
reduced in these patients and may thus negatively influence the predictive 
values of CRP and albumin for BSI [83,84].  
Procalcitonin, the pro-hormone of calcitonin, provides an alternative 
predictor of BSI for CRP and might have the strongest discriminative power 
of the laboratory variables included in table 3. Nevertheless, determination 
of PCT provides a sensitive tool to predict BSI with a high negative 
predictive value, which rates BSI as unlikely in patients with normal PCT 
levels [66]. However, like CRP, PCT is not a very specific marker of 
infection and blood levels can be elevated in many non-infectious 
conditions [66,85,86]. Several studies compared the predictive values of 
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CRP and PCT for (systemic) infection. In general, the performance of PCT 
was better or at least equal to that of CRP [66,70,72,87-89]. PCT provides 
only a substitute for CRP, because the combination of both markers does 
not increase the likelihood of BSI, except in the ICU setting. However, PCT 
is currently not widely used in clinical practice, to our knowledge. Very 
interesting in this context are recent studies that show that PCT guided 
therapy of respiratory tract infections reduces antibiotic usage compared to 
the standard clinical evaluation including determination of WBC and CRP 
[90-92]. Similar studies are highly warranted to evaluate the cost-
effectiveness of clinical interventions guided by PCT or CRP in patients 
suspected of BSI. Elevated levels of various markers can be observed 
during BSI, including lactate, creatinin, bilirubin, aspartate aminotransferase 
(ASAT), alanine aminotransferase (ALAT), alkaline phosphatase and 
electrolyte changes [40,42,46,49,51,93]. These mediators are not specific 
for infection and elevations of circulating levels of these factors are more 
strongly related to organ dysfunction as a result of severity of disease and 
underlying conditions. As such, persisting high levels of these mediators 
under antimicrobial treatment are associated with a negative prognosis, 
especially in case of hyperlactataemia, but do not have predictive value for 
BSI [76,85,94]. 
Multivariate models for clinical prediction of BSI 
Many risk factors and clinical and laboratory markers are associated with 
a higher risk of BSI, but the predictive values change with the type of 
patient and the setting in which they are used. The highest clinical impact of 
predictors can be expected in patient populations with a relatively low initial 
risk of BSI. In these patients, symptoms such as chills strongly increase the 
likelihood of BSI, while their absence only confirms the initial risk 
assessment. However, in clinical practice, the total risk for BSI is estimated 
from the sum of risk factors and symptoms, because multiple variables are 
gathered at the same time and may even be contradictive. The main issue 
in this regard is the evaluation of the dependency between individual 
factors. For example, the presence of chills and an elevated neutrophil 
count are separately predictive of BSI in patients with sepsis, but do not 
change the likelihood of BSI in the presence of a documented local 
infection [50].  
  
Table 5. Logistic regression models designed to predict bloodstream infection 
Patient population Number of patients (BSI) Variables included in the model 
Sensitivity 
(%) 
Specificity 
(%) AUC Reference 
Febrile medical patients 300 (53) Focus of clinical infection, devices, temperature, WBC, platelet count, albumin 95 44 0.84 49 
Febrile medical patients 244 (52) 675 (111) 
Chills, functional status, diagnosis of UTI, renal 
failure, albumin 85 73 
0.63-
0.67 46,68 
Patients with sepsis 
syndrome 881 (283) 
Focus of infection, antibiotics use, liver disease, 
catheter, altered mental status - - 0.69 50 
Patients clinically 
suspected of sepsis 465 (197) 
Temperature, systolic blood pressure, platelet count 62 62 - 56 
Hospitalised patients 1007 (74), 559 (61), 675 (111) 
Fatal disease, acute abdomen, drug abuse, major 
comorbidity, chills, temperature - - 
0.56-
0.72 1,41,68 
Hospitalised patients 500 (89) Age, CVC, LOS, temperature, HR, WBC - - 0.72 39 
Hospitalised patients 739 (144) Age, LOS, temperature, WBC, SBP, CRP, 
creatinine - - 0.73 40 
Hospitalised patients 200 (50) Focus of infection, hospital-acquired, WBC, CRP, PCT - - - 51 
Hospitalised older 
patients 558 (46) 
Removal of bladder catheter, fever, chills, shock, 
NC, LC - - 0.79 43 
Patients admitted to the 
ICU 4933 (189) 
Neurosurgical or trauma admission, surgical patient, 
APACHE II score - - 
 
0.68 5 
Critically ill patients 1158 (51) Age, LOS, haematocrit - - 0.87 35 
Critically ill trauma 
patients 361 (55) 
Focus of infection, microbial resistance, 
immunosuppressive agents, blood transfusion, 
CVC, chest tube, LOS, albumin 
60 97 - 37 
Elderly emergency 
patients 215 (79) Vomiting, altered mental status, neutrophils 37 87 - 44 
NOTE. Studies were included in this table if the multiple logistic regression (MLR) analysis had included both risk factors and clinical and 
laboratory variables. BSI, bloodstream infection; AUC, area under the curve; WBC, white blood cell count; UTI, urinary tract infection; CVC, 
central venous catheters; LOS, length of stay; HR, heart rate; SBP, systolic blood pressure; CRP, C-reactive protein; PCT, procalcitonin; NC, 
neutrophil count, LC, lymphocyte count. 
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Several studies have been performed with multiple logistic regression 
(MLR), risk stratification and decision tree models to evaluate the relation 
between individual clinical and laboratory markers of BSI [1,7,46,49,50,95-
97]. Different variables were included in each study, which resulted in 
different sets of predictors in the MLR models (table 5). Temperature was 
incorporated most frequently, but was only included in less than 50% of the 
models. Focus of infection and WBC were predictors in four of the models 
(31%) and age, length of stay and albumin in three (23%). Unfortunately, 
CRP and PCT were not included in MLR analysis in most studies. 
However, in case CRP (2 studies) or PCT (1 study) were included, they 
appear as independent predictors which suggests an important role in the 
prediction of BSI [40,51]. The performance of the MLR models is highly 
variable with sensitivities ranging from 37-85% and specificities of 46-97%. 
Also, the reproducibility of these models in other settings is variable as 
shown for the models by Bates et al. and by Leibovici et al. [1,41,46,68]. 
This highlights that the performance of MLR models is patient population-
dependent. Another disadvantage of MLR models is that they are difficult to 
translate into clinical practice. The design of a risk scale or computerised 
decision-support system provides an alternative approach [7,50,96]. Such 
models are reasonably accurate and reproducible in other patient cohorts. 
Finally, a decision tree with binominal endpoints (‘BSI present’ or ‘BSI 
absent’) might be used to predict BSI [97]. In a recent study we showed 
that such a decision tree can have a high negative predictive value and 
may be more accurate for the prediction of BSI than MLR models [97]. 
Thus, the design of a risk score or decision tree is not only more useful for 
the clinician, but may also result in a more accurate prediction than MLR 
models. General drawbacks of models for prediction of BSI are the validity 
that is limited to the derivation patient population of the model, the poor 
reproducibility in other settings and that the models change dependent of 
the variables included, [42,68,73]. Difficult models or complex decision 
trees should be avoided because they may result in incorrect treatment due 
to incorrect calculations. A positive development in this regard is the 
increasing use of (handhold) computer systems and electronic patient files 
which enable risk calculations at the bedside. Although sceptics believe 
that any data can be fit with a model and that a model can not compete with 
reality, the design and validation of prediction models provides us with 
more understanding of complex problems in clinical practice.
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Perspectives and conclusions 
The search for THE single predictor of BSI in the individual patient 
remains an odyssey, but several clinical and laboratory factors are clearly 
predictive of BSI. Many new, experimental markers in blood are evaluated 
for prediction of BSI, including pro- and anti-inflammatory cytokines, 
neutrophil degradation products, and bacterial DNA [54,55,98-100]. 
Although these mediators have predictive value for BSI, it is questionable 
whether they will supplement or replace the routine clinical and laboratory 
predictors. To ensure clinical applicability, determination of circulating 
levels of these new mediators should be achieved rapidly, within a few 
hours, and at a low cost. The major difficulty of using laboratory variables to 
predict BSI is the changing predictive value over time related to the kinetics 
of each marker. Therefore, each marker will have its maximal predictive 
value at a different stage in the infection. For example, CRP level or white 
blood cell count may be normal if the patient is evaluated in the early phase 
of infection, but very high one day later, while PCT reaches its peak value 
only 8 hours after the start of infection [54,55,82,100,101]. This could 
explain, in part, the different predictive values of these markers that are 
observed in different patient populations. For example, infection will be 
suspected at an earlier phase in the ICU where patients are monitored daily 
than in patients presenting to the emergency department with community-
acquired fever since several days. Because of marker kinetics, attention 
has started to shift from the interpretation a single determination of a 
variable to monitoring the course of a marker and interpreting a set of 
markers [102-104]. With an increased knowledge of the kinetics and 
dynamics of laboratory markers, BSI may be predicted based on changes 
of the specific marker over time [82]. Clearly, this is only clinically relevant if 
the time interval over which the change is observed is small. As such, 
changes in laboratory markers may be incorporated in future decision 
models that stratify patients to risk of BSI and support the clinicians in their 
choice of therapy. 
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Abstract  
New techniques have emerged for the detection of bacteria in blood, 
because the blood culture as gold standard is slow and insufficiently 
sensitive when the patient has previously received antibiotics or in the 
presence of fastidious organisms. DNA-based techniques, hybridisation 
probes, and PCR-based detection or protein-based detection by mass 
spectroscopy are aimed at rapid identification of bacteria and provide 
results within 2 hours after the first signal of growth in conventional blood 
cultures. Also, detection of microorganisms directly in blood by pathogen-
specific or broad-range PCR assays (eubacterial or panfungal) shows 
promising results. Interpretation is complex, however, because of detection 
of DNA rather than living pathogens, the risk of interfering contamination, 
the presence of background DNA in blood, and the lack of a gold standard. 
As these techniques are emerging, clinical value and cost-effectiveness 
have to be assessed. Nevertheless, molecular assays are expected 
eventually to replace the current conventional microbiological techniques 
for detection of bloodstream infections. 
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Introduction 
Bacteraemia, the presence of bacteria in the bloodstream, was 
recognised more than a century ago. In 1897, Libman described two cases 
of bacteraemia in children with streptococcal disease presenting with 
bloody diarrhoea [1]. Nine years later, he published a study of a series of 
more than 700 blood cultures with guidelines on how they should be carried 
out [2]. Since then, detection methods for bloodstream infections have 
evolved, with the development of standard protocols to obtain blood 
samples, improvement of culture media, and the introduction of automated 
systems for the detection of bacterial or fungal growth. Blood cultures have 
a central role in microbiological laboratories as the gold standard for the 
detection of bloodstream infections in patients with fever. The further 
development of methods to detect bloodstream infections is focused on 
improving sensitivity, increasing speed of diagnosis, and reducing inhibitory 
effects of antibiotics. Faster diagnosis of bloodstream infections permits 
earlier implementation of appropriate antimicrobial treatment and reduces 
morbidity and mortality. During the past few decades, various methods 
have been proposed to optimise detection of bloodstream infections; those 
based on molecular detection, including fluorescent hybridisation probes 
and PCR, seem the most promising. The advent of molecular techniques 
heralds a new era in the detection of bacteraemia, which necessitates a 
thorough reassessment of current concepts and ingrained beliefs on how 
and when the newer molecular techniques might make a clinical difference. 
Rationale 
Detection of bacteria in blood has an important role in diagnosis for a 
febrile patient: to establish the presence of infection (thereby excluding a 
non-infectious cause of fever), to reassure the clinician about the chosen 
empirical therapy, and to streamline antibiotic treatment after assessment 
of the antibiotic sensitivity of the isolate (figure 1). Blood cultures have 
traditionally been the gold standard and are of great diagnostic value in 
settings for which establishment of a microbiological diagnosis is difficult, 
for instance for endocarditis, biliary-tract, endovascular, or graft infections, 
or in assessment of fever of unknown origin.  
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Figure 1. The role of blood cultures in the management of the febrile patient. BSI, 
bloodstream infection 
*BSI possible can be considered in a patient whose blood cultures test false-negative, if the 
patient has previously used antibiotics, or in the presence of fastidious microorganisms. 
 
Also, blood cultures are of diagnostic value in deep-seated infections, 
which require invasive procedures for samples for culture to be obtained. 
For example, in patients who have undergone median sternotomy, the 
detection of pathogens in blood cultures is predictive of the presence of 
postoperative mediastinitis, especially when Staphylococcus aureus is 
isolated; thus, the blood culture obviates the need for resternotomy to 
obtain material for microbiological culture [3]. Blood cultures also constitute 
an important epidemiological tool on which to base empirical therapy. Up-
to-date knowledge of the most common pathogens of bloodstream 
infections in infection-prone hospital departments, such as intensive care or 
haematology, will guide the clinician in the initial treatment of a patient with 
fever. However, the value of routine blood cultures as a general diagnostic 
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test for clinical management is limited to certain disorders because of the a-
priori chance of the presence of certain pathogens, delay in results, poor 
sensitivity for fastidious organisms, and use of antibiotics before blood 
samples are drawn. Furthermore, most routine blood cultures are not cost-
effective in these cases [4,5]. One reason for the limited value of blood 
cultures in certain disorders is the high or low a-priori chance of isolation of 
certain pathogens in blood culture and the subsequent influence of the 
results on clinical management. Escherichia coli is isolated from urine 
cultures of more than 90% of cases of uncomplicated acute pyelonephritis 
in pregnant and non-pregnant women, but blood cultures, despite the high 
yield, seldom provide additional information over urine cultures that leads to 
treatment alteration [6-8]. The value of blood cultures in community-
acquired pneumonia has also been questioned. The yield of blood cultures 
increases with the severity of pneumonia (5–10% in non-severe to 16–27% 
in severe cases); in a study of 209 patients with community-acquired 
pneumonia, the likelihood that blood cultures would change antibiotic 
therapy was zero in non-severe cases and 10–20% in severe cases. The 
role of blood cultures in non-severe community-acquired pneumonia 
therefore seems limited [9,10].  
A second limitation of blood cultures is the delay before results become 
available; the delay can be 2 days or longer. Changes in antibiotic therapy 
for pyelonephritis and community-acquired pneumonia are more frequently 
guided by clinical response than by culture results [6,10,11]. Other 
disorders in which blood cultures have little influence on clinical 
management include acute pelvic inflammatory disease, fever after 
hysterectomy, cellulitis, and urinary-tract infection in children [12-15]. 
Munson and colleagues showed that most therapeutic interventions occur 
immediately after collection of blood samples for culture and that the 
number of interventions decreased rapidly with time [16]. A small proportion 
of initiations or discontinuations of therapy occur after notification of gram-
stain results of positive cultures; release of susceptibility data appears to 
have limited effect on antimicrobial management [16]. Also, when slow-
growing organisms such as Mycobacterium tuberculosis or fastidious 
organisms such as Bartonella spp are suspected, empirical therapy will 
have been initiated long before culture results become available. If patients 
deteriorate or do not respond to initial empirical therapy (i.e., with persisting 
fever), physicians are likely to make an empirical change in therapy before 
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culture results are available. Therefore, improvement in the speed of 
diagnosis is essential to increase the clinical benefit of detection of 
bloodstream infections. Sensitivity of blood cultures for slow-growing and 
fastidious organisms can be poor. Blood cultures miss fastidious organisms 
that are important causes of community-acquired pneumonia, such as 
Legionella pneumophila, Chlamydia pneumoniae, and Mycoplasma 
pneumoniae [17]. In addition, culture diagnosis of invasive fungal infections 
has low sensitivity and results are not available for many days in some 
cases. Because these infections occur frequently in neutropenic patients, 
mortality from untreated infections is high. Also for diagnosis of bartonella 
endocarditis, the yield of blood cultures is poor [18]. A fourth and frequently 
encountered problem of blood cultures is that their sensitivity decreases 
greatly when blood samples are taken after the start of antimicrobial 
therapy [19,20]. Neutropenic patients who receive prophylactic antibiotics 
and develop fever have a high risk of bloodstream infections, but diagnosis 
is challenging because blood cultures remain negative in many cases [21]. 
Also, when initial microbiological cultures are in progress and patients 
deteriorate or have sustained fever, clinicians can reflexively order 
successive blood cultures despite antimicrobial treatment [22]. These 
cultures have a low yield and rarely identify pathogens other than those 
from blood drawn before antibiotic treatment [23]. To overcome the 
inhibitory effect of antibiotics on blood cultures, special culture media have 
been developed, including resin-containing culture fluids [24-27]. With use 
of these media, there is some reduction of the inhibitory effect of antibiotics 
on bacterial growth in culture and a modest increase in sensitivity. 
Interpretation of a contaminated blood culture can be difficult, especially in 
the case of fever in a neutropenic patient with a central venous line and 
broad antibiotic prophylaxis. In this setting, the interpretation of a blood 
culture in which Staphylococcus epidermidis grows is different from that for 
a sepsis patient. The risk of contamination of the blood samples can be 
kept to a minimum by thorough skin antisepsis, an adequate venapuncture 
protocol, and dedicated phlebotomists [28,29]. Handling and interpretation 
of contaminated blood cultures is beyond the scope of this review and has 
been described elsewhere [30]. This discussion of the associated problems 
should not be interpreted as a plea for the complete abandonment of 
routine blood cultures. A positive blood culture remains an important 
diagnostic clue or confirmation for the clinician. Instead, we argue that 
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attention should be focused on other techniques to improve the clinical 
usefulness of detection of bacteria in blood (figure 2). The development of 
new diagnostic techniques is aimed at increasing sensitivity and specificity 
(especially for slow-growing or non-cultivable organisms), decreasing the 
turnaround time, and reducing the inhibitory effects of antibiotics on the 
detection of pathogens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Techniques for laboratory detection of bloodstream infections. Abbreviations: 
FISH, fluorescence in situ hybridization; LCR, ligase chain reaction; bDNA, branched DNA; 
T-RFLP, terminal restriction fragment length polymorphism; SSCP, single strand 
conformation polymorphism. 
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Molecular techniques are becoming more and more useful to decrease 
laboratory turnaround times so that results can be available to the clinician 
at an earlier stage. After the detection of bacteria by conventional blood 
culture, identification and assessment of antibiotic sensitivity takes at least 
a further 24 hours. However, with molecular assays identification can be 
obtained within 2–6 hours. Another approach is the direct detection of 
bacteria in blood without culture at all.  
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Nucleic-acid-based detection with PCR assays is done after isolation of 
bacterial DNA from whole blood. Many molecular techniques have been 
developed for detection and identification of pathogens, but only a few are 
applicable on growth-positive blood cultures or directly on blood (table 6). 
 
Table 6. Advantages and disadvantages of detection methods for bloodstream 
infection 
Method Advantages Disadvantages 
   
Blood culture Antimicrobial susceptibility 
data 
Detection of living bacteria 
Time-consuming 
Inhibition by antibiotics 
Low sensitivity for 
fastidious organisms 
   
Molecular identification 
after growth in blood 
culture medium  
(e.g. FISH, PCR) 
Faster identification of 
living bacteria 
No susceptibility data (yet) 
Pathogen-specific 
identification 
Quite time-consuming 
   
Direct molecular 
detection in blood  
(e.g. pathogen-specific  
or broad-range PCR) 
Rapid detection and 
identification 
No inhibitory influence of 
antibiotics 
High sensitivity 
Quantification of bacterial 
DNA load possible 
No susceptibility data (yet) 
Risk of laboratory 
contamination 
Background bacterial DNA 
in blood 
Detection of bacterial DNA 
instead of living bacteria 
   
Identification of pathogens in growth-positive blood cultures 
Techniques for the identification of pathogens can be divided into two 
categories: hybridisation based and amplification based. Among the 
hybridisation techniques suited for detection of pathogens in positive blood 
cultures are hybridisation assays with probe matrices and fluorescent in-
situ hybridisation (FISH). Hybridisation probe assays use oligonucleotide 
probes that are less than 50 bases long to prevent self hybridisation; the 
probes have chemiluminescent or fluorescent labels. They complement the 
sequence of small-subunit rRNA and form a duplex molecule if the target 
sequence is present. The resulting labelled duplex molecule can be 
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detected. Amplification techniques can be subdivided into those that 
amplify a target—PCR, the ligase chain reaction (LCR), and isothermal 
amplification (e.g., transcription mediated amplification [TMA] and nucleic-
acid-sequence-based amplification [NASBA]) techniques—and those with 
signal amplification, such as the branched DNA (bDNA) technique. In 
hybridisation probe assays, luminescence is a measure of the binding of 
labelled DNA probes to target ribosomal RNA (rRNA) and hence for the 
presence of target nucleic acid. Unbound DNA is hydrolysed and therefore 
loses its chemiluminescence. These assays allow identification of many 
pathogens within 60 min at the level of genus, species, or both, depending 
on the matrices used [31]. Polymicrobial infections can be identified by the 
simultaneous detection of two different chemiluminescence patterns or can 
be suspected by comparison of the strengths of genus-specific or species-
specific probe signals in relation to the signal obtained with an all-bacteria 
probe. It is a sensitive and specific technique that merits further evaluation 
in clinical practice. In the future, it might be replaced by a more sensitive 
matrix fixed hybridisation technique in which the probes are fixed on a 
carrier rather than in solution.  
For FISH, slides of growth-positive cultures are prepared on which 
permeabilisation of cells is achieved followed by hybridisation to 
fluorochrome-labelled oligonucleotide probes targeted to rRNA. The binding 
of the oligonucleotide probe to target RNA results in fluorescence and is 
visualised by microscopy (figure 3). FISH allows identification within 2·5 h 
of more than 95% of most bacteria and yeasts commonly found in blood 
[32-34]. Some bacteria are identified only at the genus level because no 
species-specific probes are available. An example is Streptococcus 
viridans, for which fluorescence is seen with the streptococcal probe but not 
with species-specific probes. In these assays, a eubacterial probe is always 
included as control to identify the presence of bacteria for which no further 
identification is possible. This precaution is needed owing to problems in 
the design of probes for certain pathogens and the low cost-effectiveness 
of designing probes for pathogens that are rarely found in blood cultures, 
such as Bacteroides fragilis and Lactococcus lactis [32]. An example of 
bacteria for which there are problems with probe design is coagulase-
negative staphylococci; no probe specific for all these microorganisms can 
be designed on the basis of 16S rRNA sequences.  
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Figure 3. Fluorescent microscopy (100x) of microorganisms in blood cultures after FISH. 
NOTE. (A) Coagulase-negative staphylococci stained with a staphylococcus genus-specific 
probe labelled with fluorescein 5’-isothiocyanate. (B) Pseudomonas aeruginosa is identified 
with a species-specific probe with Cy3 label. 
 
In this case, identification of coagulase-negative staphylococci can be 
achieved by exclusion, when there is a positive fluorescent signal with a 
staphylococcus genus-specific probe together and a negative signal with a 
S. aureus specific probe [35]. 
Among the different amplification-based techniques for identification, 
PCR is the most commonly used. To allow amplification of bacterial DNA 
from growth-positive blood cultures, sodium polyanetholesulfonate, a PCR 
inhibitor, needs to be neutralised. This anticoagulant used in blood cultures 
has anticomplement activities, but it copurifies with DNA during isolation. It 
can be removed by use of guanidine hydrochloride-benzyl alcohol DNA 
extraction [36]. Other components are known to reduce inhibitory effects on 
DNA amplification, such as addition of bovine serum albumin [37]. Because 
the amplification step is at the core of the PCR assay, PCR-based 
identification of pathogens in growth-positive blood cultures is especially 
useful when the bacterial load is low or subculturing takes time, as is the 
case for mycobacteria or fungi [38,39]. A multiplex PCR assay allows rapid 
identification of the genus Mycobacterium and species M avium, M 
intracellulare, and M tuberculosis [40]. This facility is especially useful in 
people with AIDS and can improve treatment outcome [40]. Rapid 
identification is also useful for invasive pathogens associated with severe 
morbidity and mortality such as methicillin-resistant S. aureus.  
A B 
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Figure 4. The principle of pyrosequencing. This figure was modified and published with 
permission from Biotage AB. A sequencing primer is hybridised to a target DNA template 
and extended by DNA polymerase. Four deoxynucleotide triphosphates (dNTP) are added 
sequentially and, if incorporated, pyrophosphate (PPi) is released. PPi is then converted to 
ATP by ATP sulfurylase, driving the conversion of luciferin to oxyluciferin and generating 
light. The intensity of the light signal is proportional to the number of nucleotides 
incorporated. Apyrase continuously degrades unincorporated dNTPs and excess ATP. 
When degradation is complete, the next dNTP is added. The complementary DNA strand is 
thus synthesised and the sequence is determined from the signal peaks in the pyrogram. 
APS, adenosine 5´ phosphosulfate; dNMP, deoxyribonucleotide monophosphate. 
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Routine cultures and susceptibility testing after initial growth in blood 
cultures take 24–48 h, but the time can be reduced to 2 h by PCR by 
inclusion not only of detection of a gene specific for S. aureus, but also the 
mecA gene, which encodes the penicillin-binding protein for methicillin 
resistance [41-43]. PCR has additional value for routine clinical 
identification of Streptococcus pneumoniae in blood cultures because of the 
fastidious nature of this organism [44]. Identification of specific pathogens 
growing in blood cultures is particularly useful when the differential 
diagnosis involves only a few pathogens, as in suspected fungal and 
mycobacterial infection, or when there is a specific suspicion such as for 
methicillin-resistant S. aureus [38,40,41]. Universal identification of bacteria 
growing in blood cultures in routine diagnosis is less practicable because 
the only possible approach is a multiplex PCR assay. Different sets of 
multiplex PCR assays would have to be designed because the range of 
possible causative bacteria to be detected depends on the specific clinical 
conditions (for instance, pneumonia or abdominal infection). Thus, different 
clinical presentations would require different multiplex PCR assays to be 
cost-effective. Also, an algorithm of consecutive PCR assays can be used 
to identify the most common bacteria in blood cultures [45]. Alternatively, 
universal bacterial amplification followed by capillary DNA sequencing 
analysis, or by the recently developed light-emission-based 
pyrosequencing technique as illustrated in figure 4, could provide 
identification within 3–5 h of culture. This approach is useful for diagnosis 
confirmation when unusual or unexpected pathogens are identified in blood 
culture by conventional methods. Examples of this approach have been 
reported during the past few years (Pasteurella pneumotropica, Moraxella 
atlantae, and Tsukamurella spp) [46-48]. At present, general application of 
multiplex PCR or broad-range amplification followed by sequencing 
analysis of microorganisms after growth detection in conventional blood 
culture does not give much clinical benefit or cost effectiveness compared 
with conventional identification techniques because they are time-
consuming and laborious. However, their practicability will improve in the 
near future. Other techniques that involve an amplification step for rapid 
identification of bacteria in blood cultures are LCR, isothermal transcription-
mediated amplification, and the bDNA assay.  
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Both LCR and isothermal amplification were first described in 1989 [49,50]. 
Although these techniques are well known and used for viral-load detection 
in infections with, for example, HIV and hepatitis C virus, they are not 
applied for the detection or identification of bacteria in blood cultures 
[51,54]. LCR has only been used for the detection of M tuberculosis in 
respiratory specimens, and the isothermal transcription-mediated technique 
has only been used for rapid identification of Candida species in blood 
culture [55-57]. The bDNA assay is also widely used for the detection of 
viruses and the measurement of viral load, but its use for bacteria has been 
described only once for the detection of the mecA gene of S. aureus grown 
in blood [58-60]. Terminal restriction-fragment length polymorphism (T-
RFLP) analysis and single-strand conformation polymorphism (SSCP) 
analysis are mostly used for typing of microorganisms. They have rarely 
been used for the identification of pathogens grown in blood cultures 
[61,62]. In summary, molecular identification of pathogens after an initial 
growth step in blood culture media can be achieved most easily with either 
hybridisation-based or amplification based techniques. Although initial 
growth in blood cultures is required, most of these assays substantially 
shorten time to identification of pathogens or detection of specific 
resistance genes. Hybridisation-based techniques are the most promising, 
since they provide identification of most pathogens within 2 h. However, 
these methods can be technically difficult and require advanced detection 
systems and skills of laboratory staff as for other molecular techniques 
such as bDNA, PCR, and LCR (table 7). Although molecular identification 
provides more rapid diagnosis of bacterial infections most commonly found 
in blood cultures, the clinical effect of the shorter turnaround time is still not 
apparent. More studies are needed to show the clinical benefit, desirability, 
and cost-effectiveness of routine implementation of molecular identification 
techniques on positive blood cultures in the general microbiology 
laboratory. 
Direct molecular detection of pathogens in blood 
PCR was first used directly to detect bacteria in blood in 1993. Two 
pathogen-specific PCR assays were described, for Salmonella typhi and M 
avium [63,64]. The numbers of clinical samples tested were small, but the 
sensitivities were 92% and 80% compared with blood culture.  
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The main advantage of PCR detection directly on blood is the avoidance of 
a time-consuming culture step and therefore a substantial reduction in 
turnaround time even compared with PCR identification after detection of 
growth in blood cultures. Several further pathogen-specific PCR assays 
directly applicable to blood samples have been developed over the past 
decade; these include PCR assays for the detection of M. tuberculosis, E. 
coli, and Neisseria meningitidis [65–68]. 
 
Table 7. Technical characteristics of methods for detection and identification of 
bloodstream infections 
 
Technique 
Broad 
applicability 
Time to 
identification, h* 
Skills 
required 
 
Costs 
     
Culture     
Blood culture† 0 32-48 0 0 
     
Molecular 
identification 
    
Hybridisation probes 
(including FISH) 
- 28-30 ++ + 
Pathogen-specific 
PCR 
- 28-30 + + 
Broad-range PCR  
and sequencing 
+ 32-34 ++ ++ 
LCR/NASBA - 28-30 + + 
bDNA - 28-30 + + 
TRFLP - 32-34 +++ ++ 
     
Direct molecular 
detection 
    
Pathogen-specific 
PCR 
- 1-4 + + 
Broad-range PCR  
and sequencing 
+ 8 ++ ++ 
     
Protein-based 
detection 
    
Spectroscopy + 24 ++ + 
     
*From the point of obtaining blood cultures.  
†Blood culture characteristics are defined as the standard: positive/negative effects shown 
by + or –. 
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Pathogen-specific PCR detection of S. pneumoniae in whole blood has 
received a lot of attention because culture based diagnosis can be difficult. 
Several studies have shown improved detection of S. pneumoniae by PCR 
in patients with histories suggesting this infection, radiological evidence of 
pneumonia, treatment with antibiotics, and negative blood cultures [69-71]. 
Although these cases suggest that PCR detection of S. pneumoniae in 
blood is useful, caution is needed because nasopharyngeal carriage can 
affect PCR results. 30% of healthy children who were nasopharyngeal 
carriers of S. pneumoniae had positive results when their blood was tested 
by PCR. However, blood cultures were not obtained in that study, so we 
cannot assess whether the positive PCR results were due to true transient 
bacteraemia or to contamination by pneumococcal DNA from the 
nasopharynx [72,73]. Because the prevalence of nasopharyngeal carriage 
of S. pneumoniae decreases with age, there is less difficulty in adults. 
Detection of bacteria in blood after administration of antibiotics when blood 
cultures remain negative was shown in experimentally induced E. coli 
bacteraemia in rats [65]. The detection rate of bacteria by blood cultures fell 
to 10% 25 min after intravenous administration of cefotaxime, whereas the 
PCR detection rate was still 100% at that time and it decreased slowly over 
time. Another setting in which pathogen-specific PCR is useful is when 
rapid diagnosis is needed because life-threatening infection is suspected, 
such as in case of invasive fungal infections. PCR assays for specific 
detection of invasive aspergillosis or candidaemia show good sensitivity 
(79–100%) [74-76]. The major disadvantage of pathogen-specific PCR 
assays, however, is that they are applicable only when a specific infection 
is suspected, and therefore they are not useful in general diagnosis of 
febrile patients. To overcome this problem, multiplex PCR assays have 
been designed in which several pathogen-specific PCRs are done 
simultaneously. An example is the assay for blood and cerebrospinal fluid 
described by Corless and colleagues for detection of the three most 
common causes of meningitis and septicaemia in children: N. meningitidis 
(sensitivity 88%), S. pneumoniae (91%), and Haemophilus influenzae 
(100%) [77]. For the universal detection of bacteria in blood, several so-
called broad-range PCR assays have been developed. They are based on 
amplification of the 16S or 23S rRNA gene, which is present in all bacteria. 
Various bacterial species have different numbers of copies of these genes, 
related to their growth rate.  
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A PCR based on the conserved regions of the 16S rRNA gene in principle 
creates the possibility of detecting any bacterial DNA present in blood. After 
amplification, the amplicons can be identified by different methods such as 
capillary sequencing analysis, pyrosequencing, or hybridisation with 
specific probes. A panfungal PCR assay based on amplification of the 18S 
rRNA gene for detection of fungi in blood has been described [78]. Several 
studies with broad-range PCR have been carried out (table 8), but results 
are difficult to interpret. Broad-range PCR results were shown to correlate 
well with results of blood cultures in neonates and in injection-drug users 
with sensitivities and specificities of 87–100% [78-81]. These studies were 
done in very distinct groups of patients, and the numbers of culture-positive 
cases were small. By contrast, broad-range PCR showed poor specificity in 
other studies; bacterial DNA was detected in more than 25% of culture-
negative blood samples from neutropenic patients with fever during 
chemotherapy or bone marrow transplantation, from febrile adult patients in 
intensive care, and from critically ill surgical patients after multiple trauma, 
major operation, or solid-organ transplantation [82-85]. The clinical 
interpretation of studies with broad-range PCR for detection of bacteria in 
blood is difficult for several reasons. A “positive” PCR signal with negative 
culture results might be false, but it could also be true, as a result of the 
higher sensitivity of the PCR, which can be due to detection of low numbers 
of bacteria, fastidious microorganisms, or microorganisms that grow poorly 
or not at all owing to previous use of antibiotics. By definition, a new 
diagnostic test cannot be shown to be better than the classic gold standard, 
in this case the blood culture. The value of PCR results needs to be 
assessed in the clinical context of the patient; there has to be a thorough 
assessment of the likelihood that a result is correct, which includes follow-
up of the patient after the result has been obtained. PCR results can be 
assumed to be true positives when a focus of infection with the same 
pathogen is identified, or when blood cultures obtained at a different time 
are positive. [82-84]. PCR results should be assumed to be probably 
positive if the identified microorganism is a known causative pathogen for 
the infection of interest in patients under antimicrobial treatment. 
  
 
 
Table 8. Characteristics of studies on direct detection of bacteraemia in blood with broad-range PCR  
Ref Patients studied Number of blood cultures 
Number of 
patients 
Number of 
culture positive 
Sensitivity 
(%) 
Specificity 
(%) 
 
 
     
77 Injection-drug users presenting to 
emergency departments 51 51 15 87 87 
78 Newborn infants at risk for early onset 
sepsis 33 33 4 100 93 
79 Infants in neonatal intensive care 548 548 25 96 99 
80 Surgical patients with multiple trauma, 
major operation, or solid organ 
transplantation 
30 30 4 100 58 
81 Intensive-care patients 197 126 28 54 72 
82 Children with neutropenia after 
chemotherapy for malignant disorder 
or bone-marrow transplantation 
90 90 11 82 75 
83 Intensive-care patients 101 84 22 68 87 
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A second problem in the clinical interpretation of broad-range PCR results 
is that the technique detects all bacterial DNA present in blood, including 
not only that of living bacteria, but also that of dead and even degraded 
bacteria. This feature possibly gives greater sensitivity, but clinical 
interpretation and the consequences of detection of bacterial DNA in blood 
have rarely been addressed. Furthermore, a background amount of 
bacterial DNA might be present in blood of patients without true 
bacteraemia or even in blood of healthy individuals. Such background DNA 
would be difficult to identify as such and could interfere with the detection of 
DNA from true pathogens present in the blood [86,87]. A third problem with 
broad-range PCR is the increased risk of laboratory contamination in 
addition to contamination introduced when the blood sample is obtained. 
This risk is present in several steps of the broad-range PCR procedure, 
from the taking of the blood sample, the isolation of the DNA, and the 
actual performance of the PCR assay. Chlorhexidine bottles used for skin 
disinfection and the tubes containing edetic acid used for collection of 
whole blood for PCR can be contaminated before use [88-90]. Even the kits 
used for isolation of DNA from the blood sample and the PCR reagents 
themselves can be contaminated during their manufacture.  
 
 
 
 
 
 
 
 
Figure 5. Example of real-time quantitative PCR (TaqManTM). Primers bind to single 
stranded target DNA followed by binding of a probe. The probe is an oligonucleotide with 
fluorescent label (R, e.g., FAM) that consists of a reporter dye that is quenched in proximity 
of a quencher (Q, e.g., TAMRA). Taq polymerase extends the new strand and cleaves the 
probe releasing reporter from quencher. The resulting fluorescence (Delta Rn) is measured 
in each PCR cycle and plotted against the cycle number. Amplification signals from clinical 
samples are compared to standard signals from samples with known quantity to calculate 
initial DNA count. 
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Contamination of columns used for DNA extraction with legionella DNA has 
been described twice [91,92]. In addition, we identified nucleic-acid 
isolation kits used on the automated MagNA Pure LC Isolation Robot as the 
source of contamination with DNA from Burkholderia spp [93]. A well-known 
problem is the contamination of the enzyme basis of the PCR, the Taq 
polymerase, with DNA from the E. coli from which the enzyme is extracted 
[94,95]. Also, in fungal PCR assays, commercially available products can 
be a source of contamination in addition to airborne spore inoculation and 
carry-over contamination [96]. These problems can be solved, but the 
solutions are beyond the scope of this review. The main issue is that, as 
with culture, contamination must always be suspected when unexpected 
pathogens are identified by broad-range PCR. Studies that simultaneously 
identify the presence of DNA and rRNA as a measure of viability could 
provide useful information about the relevance of detection of DNA in 
blood. We still need to learn to interpret the clinical value of molecular 
detection of microorganisms in blood. Prospective studies are needed to 
assess specifically the benefits and drawbacks of PCR detection of 
bacteraemia in the clinical management of patients with infection. 
Protein-based identification of microorganisms 
A completely different approach to the identification of bacteria in blood is 
that provided by vibrational spectroscopy. No extraction, amplification, or 
labelling step is needed for this technique. It is based on vibrational 
spectra, which reflect the protein composition of a sample and can be 
detected by Raman or Fournier transformed infrared spectroscopy. With 
these techniques, Maquelin and co-workers correctly identified 92% and 
98% of pathogens in growth-positive blood cultures [97]. Spectroscopy is a 
new approach for bacterial identification that appears promising as a 
diagnostic technique in the microbiological laboratory. Its value for the 
detection of bloodstream infections remains to be determined. 
Perspective 
After more than a century of use, the accepted widespread use of 
conventional blood cultures is under pressure. Improvement of culture 
techniques to increase sensitivity and speed of detection seems to have 
reached its maximum, and progress is negligible. In many cases, blood 
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culture is too slow or insufficiently sensitive (for fastidious organisms and in 
patients receiving antimicrobial treatment); therefore it has lost importance 
as a diagnostic tool. Development of other options is essential to improve 
the clinical benefit of detection of pathogens in blood. A step forward was 
made with molecular techniques aimed at identification of bacteria in 
growth-positive blood cultures. At this moment the most promising are 
those based on (fluorescent in situ) hybridisation probes. However, the 
initial growth step is still required and could take too long for these 
techniques to be cost-effective and to have a substantial effect on clinical 
management. These issues need to be investigated thoroughly in future 
studies. The most promising development to decrease turnaround time, the 
delay until correct antimicrobial administration, and inhibitory effects of 
antibiotics in diagnosis of bloodstream infections is the direct detection of 
bacteria in whole blood with multiplex or broad-range PCR assays. Clinical 
interpretation of these assays is still complicated because of detection of 
DNA rather than living bacteria, lack of an appropriate gold standard, the 
presence of background bacterial DNA in blood, and the possibility of 
laboratory contamination.  
A recent development that might prove very valuable for the future of 
PCR diagnosis on whole blood is so-called quantitative real-time 
amplification. The real-time technique is rapidly replacing the more 
conventional diagnostic amplification assays in microbiology laboratories 
because amplification and detection occur simultaneously in a closed 
system, which is faster and reduces risk of contamination. This technique is 
based on the measurement of a fluorescent signal generated during each 
amplification cycle of the PCR (figure 5). The signal intensity is then related 
to a standard curve of fluorescence values generated by amplification of 
known quantities of DNA. The larger the amount of DNA present in the 
sample to be analysed, the earlier the amplification cycle in which the 
fluorescent signal is detected. As such quantitative PCR permits calculation 
of bacterial load. Measurement of viral load has proven valuable in the 
investigation and treatment of infections with HIV, hepatitis C virus, and 
other viruses. By analogy, a bacterial load could allow monitoring of the 
effect of antimicrobial therapy -i.e., in endocarditis- or distinction between 
infection (high load) and contamination (low load) [98,99]. A few studies 
published so far have assessed bacterial load. The Meningococcal load on 
admission in patients with meningococcal sepsis or meningitis was shown 
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to correlate well with severity of disease. The quantities of DNA detected 
ranged between 2·2x 104 and 1·6x 108 copies of DNA per mL blood (median 
1·6x 106/mL) [100,101]. However, the load did not seem to predict duration 
of clinical symptoms and did not decline in association with antimicrobial 
treatment. In a study on invasive S. pneumoniae infection, the amount of 
bacterial DNA detected in blood was much lower than the amount of 
meningococcal DNA in the previous study (8,0x 103 to 5,4x 105 copies/mL). 
The sensitivity of the assay in that study, however, was only 69% (11/16) 
[102]. Whether real-time quantitative amplification will obtain a place in the 
microbiological diagnosis of bloodstream infections remains to be seen. A 
major limitation of all molecular techniques used for detection and 
identification of bacteria in blood or blood cultures is the lack of the 
simultaneous provision of the antimicrobial susceptibility pattern. The 
number of resistance markers that can be targeted by molecular techniques 
is increasing very rapidly. Many bacterial resistance genes are already 
routinely detected, such as mecA for methicillin-resistant S. aureus, and 
rpoB/KatG/inhA for rifampicin/isoniazid resistance in M. tuberculosis 
[41,58,103]. Detection of all known resistance makers, already more than 
100, would require a large number of assays for each sample (PHMS, 
personal communication).  
As understanding of the bacterial genome progresses, and with the 
advent of microarray-based techniques the simultaneous detection, 
identification, and determination of antimicrobial sensitivity of bacteria in 
blood could become available in the not too distant future. Despite the 
remaining difficulties, we expect that molecular assays will eventually 
replace the current conventional microbiological techniques for detection of 
bloodstream infections. 
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Abstract 
Objective: To determine the contribution of a blood culture service to the 
diagnosis of fever in a resource-poor setting and to identify clinical 
predictors of specific bloodstream infections (BSI). 
Methods: In a descriptive, prospective study at the Medical Wards at 
Queen Elizabeth Central Hospital, Blantyre, Malawi, we tried to identify a 
specific cause of fever in febrile patients, comparing the use of routinely 
available diagnostic methods with the same methods plus blood culture. 
Clinical predictors of specific BSIs were sought. 
Results: A total of 352 patients admitted with fever (axillary temperature ≥ 
37.4°C) or a history of fever within the last 4 days were enrolled. 
Tuberculosis was the diagnosis most commonly suspected initially on 
clinical grounds (28%), followed by lower respiratory tract infection (16%), 
malaria (12%) and gastroenteritis (5%). Blood cultures were positive in 128 
patients (36%); Mycobacterium tuberculosis was the most commonly 
isolated organism (57 patients). In most cases the diagnosis of tuberculosis 
had already been made using routinely available diagnostic methods, 
including chest radiography. In all 16 cases of Streptococcus pneumoniae 
bacteraemia, infection with this agent was clinically suspected, usually on 
the basis of pulmonary symptoms and signs. In contrast, in 30 of 65 
patients (65%) with non-typhi salmonellae (NTS) bacteraemia, there were 
no symptoms or signs specifically suggestive of this diagnosis. Fever ≥ 
39°C and splenomegaly predicted NTS bacteraemia with an odds ratio of 
8.4 (95% confidence interval 3.4–20.6, P < 0.001).  
Conclusion: BSIs are common among patients admitted with fever. While 
BSI with mycobacteria and S. pneumoniae can usually be predicted on 
clinical grounds and with routinely available diagnostic methods, NTS 
bacteraemia often presents as a primary BSI without localizing symptoms 
and signs. Splenomegaly in this population indicates NTS bacteraemia 
rather than malaria. 
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Introduction 
Febrile illness is a common clinical presentation in patients admitted to 
medical wards in Sub-Saharan Africa. Although infectious diseases have 
always been a major cause of admission [1-3], ranking of the most likely 
diagnoses may have changed during the last two decades as a result of the 
HIV pandemic. In a recent study, 70% (88% in age group 30–40 years) of 
all admissions to the medical wards at Queen Elizabeth Central Hospital 
(QECH), Blantyre, were HIV seropositive [4]. The HIV pandemic has a 
major effect on the global burden of tuberculosis (TB). Increased 
frequencies of clinical malaria and parasitaemia have also been reported in 
HIV-infected individuals, especially in those patients with advanced 
immunosuppression [5,6]. Bacteraemias, particularly by Streptococcus 
pneumoniae and non-typhi salmonellae (NTS), are a major cause of 
morbidity and mortality in HIV-infected patients in African medical wards [7-
9]. The diagnosis of these infections can only be confirmed by blood 
culture, which is routinely available in very few hospitals in tropical Africa. 
Finding clinical markers of bacteraemia in patients presenting with fever 
would improve empirical management, including the use of appropriate 
antibiotics. We studied how blood culture results influence diagnosis and to 
what extent clinical parameters can predict the outcome of blood cultures in 
patients admitted with fever to the medical wards of QECH in Blantyre, 
Malawi. 
Methods 
Study design 
This prospective study was conducted between February and May 2000 
in QECH, the largest government hospital in Malawi and the main provider 
of secondary health care in Blantyre and surrounding districts. On two 
random days per week all adults (age ≥14 years) admitted to the medical 
wards were considered for the study. Patients were eligible if they had an 
axillary temperature ≥37,4 °C, or were in shock (pulse ≥120 beats/min and 
systolic blood pressure <100 mmHg) or if they reported a history of fever in 
the last 4 days. After counselling and informed consent, a full history was 
taken and a physical examination conducted. Before any antibiotic 
treatment was started, a venous blood sample was collected for full blood 
count, thick film for malaria parasites, HIV serology and culture for bacteria 
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and mycobacteria. A chest X-ray was taken for all patients within 1 day of 
admission. From those with cough three sputum samples were collected 
and examined for acid-fast bacilli (AFB). Additional investigations were 
undertaken when clinically indicated, and treatment was given according to 
standard practice in our department. Patients were reviewed daily. Initially 
patients were diagnosed according to the routinely available diagnostic 
tools and a list of most important diagnoses was made. Diagnoses were 
later revised according to blood culture results.  
 
Clinical definitions 
Patients were defined as having AIDS on admission on the basis of the 
expanded WHO surveillance criteria for AIDS in Africa [1-0]. Clinical 
malaria was defined as a documented febrile illness with parasites in the 
blood film, or other identified aetiology (including no growth on blood 
culture) and resolution of fever on antimalarial treatment (normally 
sulphadoxine–pyrimethamine). Patients were diagnosed as having 
bacteraemia after isolation of a known pathogen in the blood culture. 
Patients who had a positive blood culture only, without clinical or 
radiological signs of focal disease, were designated as having a primary 
bloodstream infection (BSI). Patients were classified as smear-positive, 
smear-negative or extrapulmonary TB according to guidelines of the 
National Tuberculosis Control Programme of Malawi. Pneumonia was 
defined as an episode of acute cough (<1 week), accompanied by 
consolidation on a chest X-ray and sputum-smears negative for AFB; 
patients presenting with similar criteria but without radiological evidence of 
consolidation were diagnosed as other lower respiratory tract infections. 
Patients were diagnosed as having Pneumocystis carinii pneumonia (PCP) 
if the clinical picture was suggestive (dry cough, breathlessness, paucity of 
chest findings, typical chest X-ray and response to treatment with high dose 
cotrimoxazole) [11]. Meningitis was diagnosed on the basis of 
cerebrospinal fluid characteristics. Gastroenteritis was diagnosed when the 
patient complained of diarrhoea and vomiting. Patients with febrile illness of 
other origin were classified as other febrile illness; if no focus could be 
identified the fever was regarded as of unknown aetiology. Ethical approval 
for the study was obtained from the University of Malawi College of 
Medicine Research and Ethics Committee.  
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Laboratory procedures 
A full blood count was performed using a Coulter Onyx Analyzer. Blood 
samples were tested for HIV using Abbot Determine (Dainabot Company, 
Tokyo, Japan) and confirmed by the Unigold test (Trinity Biotech, Bray, 
Ireland). Thick films for malaria parasites were stained with Field’s stain 
and malaria parasites were counted against 200 leucocytes. Final 
calculation of the number of parasites per microlitre assumed an average 
leukocyte count of 10.000 leucocytes/µL. All slides were read by two 
independent microscopists blinded to clinical data; discrepancies of >10% 
were checked by a third microscopist. For bacterial culture 5 ml blood were 
added to a single blood culture bottle (50 mL Brain Heart Infusion Broth 
containing sodium polyanethol sulphonate, E&O Laboratories, UK) and 
incubated overnight at 37°C before venting. Cultures were examined 
macroscopically every day, followed by Gram staining if turbid or 
haemolysed. Routine subcultures on to sheep blood agar were performed 
for all bottles after 18–24, 36–48 hours and finally after 7 days. Isolates 
were identified according to standard techniques, including sero-
agglutination (Pro-Lab Diagnostics, Merseyside, UK and Murex Biotech, 
Dartford UK) and biochemical tests (API strips, BioMerieux UK Ltd, 
Basingstoke, UK). Mycobacterial blood cultures were performed as 
described by Lewis et al [12]. 
 
Statistical analysis 
Data were double-entered into EPI-INFO version 6.04b, validated and 
analysed using SPSS 10.07. Categorical data were compared with the chi-
square test with Yates’ correction, and Fisher’s exact test, where 
appropriate. Continuous variables were compared with the t-test or 
Wilcoxon two-sample test. Using logistic regression, indicators of 
bacteraemia and malarial parasitaemia were identified and odds ratios 
(OR) with 95% confidence intervals were calculated. Subsequently, a 
multivariate analysis was performed adjusting for the indicators found, to 
identify independent clinical predictors. 
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Results 
During the study period 637 patients were admitted to the medical wards, 
of whom 367 met the inclusion criteria; 352 (96% of those eligible) gave 
consent and were enrolled in the study; 44% were men. On admission, all 
patients were febrile except 17, who gave a history of fever; nine patients 
had shock and were febrile. The distribution of recorded temperatures was 
37.4–37.9°C in 67 patients (19%), 38.0–38.4°C in 80 (23%), 38.5–38.9°C in 
54 (15%) and ≥39°C in 134 (38%).  
 
Table 9. Initial diagnosis for 352 study patients using routinely available diagnostic 
methods by category in numbers and according to HIV status 
 
Diagnosis 
Total 
(n = 352) 
HIV-pos 
(n = 291) 
HIV-neg 
(n = 61) 
Odds ratio 
(95% CI) 
     
Tuberculosis† 100‡ 94 6 4.4 (1.8-12.8) 
 Smear-positive 27 27 0 undefined 
 Smear-negative 48 43 5 * 
 Extrapulmonary 25 24 1 * 
Lower respiratory tract infection 55 49 6 * 
 Pneumonia 27 25 2 * 
 PCP 5 5 0 undefined 
 Other 23 19 4 * 
Malaria 42 31 11 * 
Meningitis 17 13 4 * 
 
Cryptococcus neoformans 4 4 0 undefined 
 Pyogenic 8 5 3 * 
 Tuberculous 3 2 1 * 
 Viral 2 2 0 undefined* 
Gastroenteritis 18 18 0 undefined 
Other§ 33 20 13 0.34 (0.15-0.76) 
Unknown febrile illness 87 66 21 * 
     
NOTE. Only the most likely main diagnosis is listed. Odds ratios were calculated comparing 
the likelihood of a diagnosis in HIV-positive and –negative individuals. Abbreviations: CI, 
confidence interval; PCP, Pneumocystis carinii pneumonia. 
*Not significant. 
†Six patients with smear-positive and five patients with smear-negative pulmonary 
tuberculosis were also diagnosed with extrapulmonary tuberculosis. 
‡Another three patients with tuberculosis are also listed under meningitis. 
§These include urinary tract infection, abscesses and pelvic inflammatory disease. 
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A total of 291 patients (83%) were HIV-infected, of whom 162 met the 
criteria for AIDS on admission (56%). More women than men were HIV-
infected (88% vs. 77%; p=0.005). Respiratory tract related findings were by 
far the most common clinical presentation: 69% of patients presented with 
cough, 32% had a cough for >1 month, and 62% had shortness of breath. 
Chest X-rays were abnormal in 65% with infiltrative changes in 85% and 
consolidation in 25%. Twelve per cent of study patients died in hospital 
(12% of those who were HIV positive and 11% of those who were HIV 
negative; p=0.90). Table 9 shows initial diagnoses. TB was the most 
common diagnosis with 103 cases (29%); six patients with smear-positive 
and five patients with smear-negative pulmonary TB also had 
extrapulmonary TB. Lower respiratory tract infections were the second 
commonest initial diagnosis (16%), followed by malaria (12%), 
gastroenteritis (5%) and meningitis (5%). In 33 (9%) patients another febrile 
illness was diagnosed, such as urinary tract infection or pelvic inflammatory 
disease. In 87 patients (25%) the cause of the febrile illness remained 
unknown; this was more common in those who were HIV negative (23% in 
HIV positive and 34% in HIV negative, p = 0.053). This group had a similar 
mean temperature as those for whom a clinical diagnosis could be made 
(38.6°C vs. 38.5°C, respectively). Pathogens were isolated from blood 
cultures of 128 patients (36%); 73 patients had bacteraemia (21%), 59 
mycobacteraemia (17%) and one fungaemia; six patients had dual 
infections. Of the 59 mycobacterial isolates, M. tuberculosis was the most 
common with 57 positive cultures (16% of all study patients); the other two 
were atypical mycobacteria. NTS were isolated in 46 cases (13%) and S. 
pneumoniae in 16 (5%). Of those with bacteraemia 19% (14/73) died, 
compared with 9% (25/279) of those without (OR 2.4, 95% CI 1.1–5.2). 
Table 10 shows the most commonly isolated pathogens and the 
corresponding initial diagnosis (if any). In six of 57 cases (11%) of M. 
tuberculosis mycobacteraemia, an initial diagnosis other than TB had been 
made; in seven (12%) others who had no focal signs, TB was strongly 
suspected but not confirmed before blood cultures (primary 
mycobacteraemia). In the remaining 44 a diagnosis of TB was made using 
routinely available diagnostic methods.  
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Table 10. Frequency of isolation of most important pathogens from blood cultures 
and corresponding initial diagnoses: total number, and number (%) that are HIV 
positive 
Pathogen Initial diagnosis Number HIV positive 
    
M. tuberculosis  57 55 (96) 
 Tuberculosis 44 42 (96) 
 Other LRTI 5 5 
 Gastroenteritis 1 1 
 Primary 7 7 
Non-typhi salmonellae 
 46 44 (96) 
 
S. typhimurium (n=28) Pneumonia 3 3 
 Gastroenteritis 2 2 
 Meningitis 2 2 
 Lung abscess 1 1 
 Primary 20 20 
 
S. enteritidis (n=16) Gastroenteritis 4 4 
 Pneumonia 1 1 
 PCP 1 1 
 Tuberculosis 1 1 
 Primary 9 8 (89) 
 
Salmonella species (n=2) Tuberculosis 1 1 
 Primary 1 0 
Streptococcus pneumoniae  16 13 (81) 
 Pneumonia 9 7 (78) 
 Other LRTI 1 1 
 Tuberculosis 1 1 
 Meningitis 1 1 
 Peritonitis 1 1 
 Primary 3 2 (67) 
Escherichia coli  4 4 (100) 
 Primary 4 4 
Others*  11 8 (78) 
 Other LRTI 2 2 
 Tuberculosis 2 2 
 Meningitis 1 1 
 Pyelonephritis 1 1 
 Primary 5 2 (40) 
    
NOTE. Six patients had dual infections – five with M. tuberculosis and other bacteria (two S. 
pneumoniae, one salmonella species, P. aeruginosa and K. pneumoniae); one patient with 
S. enteritidis and S. pneumoniae. LRTI, lower respiratory tract infection; PCP, Pneumocystis 
carinii pneumonia. 
*These include: Mycobacterium species (2), K. pneumoniae (2), P. aeruginosa, S. aureus, 
P. mirabilis, S. pyogenes, S. typhi, C. neoformans, Flavibacterium spp. 
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Forty-two patients (58% of the total number of patients with bacteraemia) 
had a primary BSI as a single final diagnosis; in another five patients 
bacteraemia was a second, unsuspected diagnosis (one patient with 
meningitis, three with TB, one with PCP). S. pneumoniae bacteraemia was 
present in 16 cases; in 14 respiratory infection was suspected, one patient 
who also had evidence of respiratory infection presented with 
pneumococcal peritonitis and the remaining patient had pneumococcal 
meningitis. In one case there was co-infection with TB. For NTS 
bacteraemia the majority (65% of cases) were primary BSI; in four patients 
there was an unsuspected co-infection with cryptococcal meningitis, TB 
(two patients) or PCP, respectively.  
Primary BSI and clinical malaria (42 cases each) were the third 
commonest diagnosis after TB and LRTI (55 cases). Malaria parasites were 
seen in thick films of 69 patients (20%); all films showed Plasmodium 
falciparum; three also showed Plasmodium malariae. The median parasite 
density was 19 500/µL (range 100–657 900). This did not significantly differ 
between the group of 42 patients (12% of total) in whom a diagnosis of 
clinical malaria was made and the 27 patients with other clinical diagnoses. 
Nine patients with malarial parasitaemia also had positive blood cultures: 
five with bacteria (three with S. typhimurium and two with E. coli) and four 
with mycobacteria. Bacteraemia was less common in parasitaemic patients 
than those without parasitaemia (OR 0.25 [95% CI 0.1–0.6]). Fifty-seven 
patients (83%) with parasitaemia were HIV-infected; there was no 
significant association between HIV status and the presence or level of 
parasitaemia (p=0.99 and 0.83, respectively), nor with the clinical diagnosis 
of malaria (p=0.36). Patients with AIDS were less likely to have been 
admitted for clinical malaria (p<0.001) or parasitaemia (p<0.001) than 
patients without AIDS. 
Eighteen patients (5%) had gastroenteritis as the initial diagnosis; of 
these six (34%) had NTS bacteraemia and seven (39%) had P. falciparum 
parasitaemia. Gastroenteritis was associated with S. enteritidis BSI (OR 7.7 
[95% CI 7.2–26.8], p=0.006). Six of 10 patients presenting with jaundice 
had bacteraemia (OR 6.3 [95% CI 1.7– 22.7], Fisher’s exact test p=0.007). 
While the level of fever was not associated with mycobacteraemia (p=0.9), 
patients with high fever (≥39°C) were more likely to have NTS bacteraemia 
(OR 2.2 [95% CI 1.2–4.0], p=0.02), particularly in combination with 
splenomegaly (OR 8.4 [95% CI 3.4–20.6], p<0.001). 
Chapter 2 
68 
However, these combined clinical features were only present in 15 of 46 
(32%) patients who were diagnosed as NTS bacteraemia. There was no 
association between level of fever and/or splenomegaly and malaria. 
Indicators of bacteraemia and malarial parasitaemia are summarised in 
table 11. Using logistic regression (excluding laboratory investigations), 
independent clinical predictors were identified (table 12). Splenomegaly 
was an independent predictor for NTS bacteraemia, but not for malarial 
parasitaemia. A similar analysis of mycobacteraemia in the patients in this 
study is reported elsewhere [12]. 
 
Table 12. Independent clinical predictors of bacteraemia and parasitaemia in 
patients at QECH 
 Prevalence in study 
population (%) OR* 95% CI P-value 
     
All bacteraemia     
 Splenomegaly 30 2.8 1.6–5.0 <0.001 
 Oral thrush 24 1.9 1.0–3.6 0.040 
 Fever >1 month 38 0.43 0.22–0.84 0.014 
 Abnormalities on 
chest examination 
39 1.9 1.1–3.5 0.029 
NTS bacteraemia     
 Splenomegaly 30 4.9 2.4–10 <0.001 
 Head-neck  
lymphadenopathy 
34 0.30 0.12–0.73 0.008 
SP bacteraemia     
 Chronically ill 68 0.25 0.08–0.80 0.020 
 Jaundice 3 8.7 1.3–57 0.023 
Other bacteraemia     
 Reported weight loss 57 0.13 0.03–0.65 0.013 
Parasitaemia     
 Oral thrush 24 0.04 0.006–0.32 0.002 
 Gastroenteritis 5 4.5 1.3–16 0.020 
 Breathlessness 62 0.44 0.22–0.89 0.023 
 Cough 69 0.46 0.23–0.94 0.033 
     
Abbreviations: OR, odds ratio; CI, confidence interval; NTS, non-typhi salmonellae; SP, 
Streptococcus pneumoniae. 
*After adjusting for indicators in table 11. 
  
Table 11. Indicators of bacteraemia and malarial parasitaemia in study patients admitted at the medical wards at QECH 
 
Indicator 
NTS bacteraemia 
(n = 46) 
SP bacteraemia 
(n = 16) 
Other bacteraemia 
(n = 11) 
All bacteraemia 
(n = 73) 
Malaria parasitaemia 
(n = 69) 
      
Chronically ill† * * * * 0.42 (0.25–0.72) 
Fever >1 month * * * * 0.46 (0.25–0.83) 
Fever ≥39°C 2.2 (1.2–4.0) * * 2.1 (1.2–3.5) * 
Reported weight loss * * 0.24 (0.06–0.89) * 0.40 (0.23–0.69) 
Cough * 1.1 (1.0–1.1) * * 0.25 (0.14–0.43) 
Cough <3 weeks * 4.3 (1.5–13) * * 0.55 (0.30–1.0) 
Pleuritic chest pain * * * * 0.36 (0.20–0.63) 
Shortness of breath * 1.1 (1.0–1.1) * * 0.25 (0.14–0.43) 
Antimalarials <2 weeks 2.4 (1.2–4.5) * * 2.0 (1.2–3.4) * 
Antibiotics <2 weeks * * * * 0.38 (0.21–0.68) 
Jaundice 4.7 (1.3-17) 5.8 (1.1–30) * 6.3 (1.7–23) * 
Oral thrush * * * 1.8 (1.0–3.1) 0.073 (0.017–0.30) 
HN lymphadenopathy 0.36 (0.16–0.80) * * * 0.46 (0.25–0.86) 
Chest exam abnormal * 6.3 (1.7–23) * 2.0 (1.2–3.5) 0.30 (0.16–0.57) 
Hepatomegaly * * * * 0.49 (0.24–1.0) 
Splenomegaly 3.8 (2.0–7.2) * * 2.5 (1.5–4.2) * 
Gastroenteritis 3.7 (1.3–10) * * * 2.8 (1.0–7.5) 
HIV-infected 5.3 (1.2–12.2) * * * * 
AIDS on admission * * * * 0.31 (0.17–0.56) 
Anaemia (haemoglobin <7 g/dL) 2.2 (1.1–4.5) * * * * 
Leukopenia (WBC<5.0 x109/L) * * * 2.1 (1.0–4.4) 2.3 (1.3–3.9) 
Thrombocytopenia‡ 4.8 (2.3–10) * * 2.5 (1.4–4.4) 4.3 (2.4–7.8) 
Chest X-ray abnormal * 7.3 (0.94-53) * 3.8 (1.1–13) 0.13 (0.071–0.25) 
      
Note: NTS, non-typhi salmonellae; SP, Streptococcus pneumoniae; HN, head-neck; WBC, white blood cell count. 
*Not significant 
†Defined as presence of either diarrhoea >1 month, fever >1 month, reported weight loss or impaired daily activity. 
‡Defined as platelet count <150 x109/L 
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Discussion 
This study confirms earlier findings of a high prevalence of HIV infection 
and AIDS among patients admitted to the medical wards [4]. As has been 
described from several other areas in Sub-Saharan Africa, infections with 
M. tuberculosis, S. pneumoniae and NTS are more common than the 
opportunistic infections encountered in the developed world [8,13,14]. 
Tuberculosis was the most important cause of fever at our hospital, with the 
majority having disseminated disease as suggested by the presence of 
mycobacteraemia. Eighty-nine per cent of TB patients could be diagnosed 
using routine methods and protocols as used in our wards and identifying 
the presence of mycobacteraemia did not improve outcome [12]. 
Bacteraemia was common and primary BSI came third in the list of 
diagnoses. Compared with other studies, we found a relatively high 
prevalence of bacteraemia (21% of enrolled patients) and a high case-
fatality rate (19%) [15-19]. It is likely that the case fatality rate in hospitals 
without blood culture facilities would even be higher. This is particularly 
worrying in the case of NTS bacteraemia, the most commonly isolated 
bacterial pathogen, as this infection usually presents as a primary infection 
without localizing signs. Streptococcus pneumoniae bacteraemia occurred 
in patients in whom this pathogen would be suspected as they presented 
with respiratory signs, meningitis or peritonitis, confirming findings of Gilks 
et al [20]. Escherichia coli bacteraemia was uncommon but not suspected 
in all four cases; two of these had a positive blood film for malaria. Only 42 
(61%) of patients with P. falciparum parasitaemia had clinical malaria as 
the sole diagnosis (12% of the total number of patients). Finding a positive 
blood film should not deter the clinician from pursuing or treating for 
another more common and potentially fatal infection. Of the independent 
clinical predictors, splenomegaly on physical examination seems most 
useful in clinical practice. Medical practitioners in Malawi commonly believe 
that splenomegaly primarily implies malaria. In our study of an adult 
population with a high prevalence of HIV infection, splenomegaly was 
associated with NTS bacteraemia rather than malaria, and appropriate 
antibiotic therapy should be instituted. Similarly, the presence of oral 
candidiasis implies HIV infection and makes bacteraemia more likely than 
malaria. For clinical practice in many hospitals in Sub-Saharan Africa the 
clinician should be guided by knowledge of the most prevalent diagnoses 
that will be largely HIV related. It is not uncommon for a patient to present 
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with two illnesses, one of which could be a bacteraemia that cannot be 
diagnosed with confidence by clinical examination and basic laboratory 
tools. As it is unlikely that a blood culture service will become widely 
available, monitoring of infection with common pathogens and 
determination of antimicrobial-resistance pattern in a central facility are 
crucial. For peripheral hospitals it may be advisable to treat any patient not 
responding to treatment for their initial diagnosis with broad-spectrum 
antibiotics. 
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Abstract 
Setting: Adult medical wards of a central hospital in Blantyre, Malawi. 
Objective: To measure the prevalence and outcome of mycobacteraemia 
in febrile hospitalised adults, and to determine what proportion could be 
identified using routine methods; to assess clinical indicators of 
mycobacteraemia, and the usefulness of a diagnostic trial of anti-
tuberculosis treatment. 
Design: We prospectively examined adults admitted with fever or a history 
of fever. All had blood cultured for bacteria and mycobacteria, chest X-ray 
and sputum-smears. 
Findings: Mycobacterium tuberculosis was the commonest cause of blood 
stream infection (BSI), affecting 57 of 344 patients (17%). In 44 (77%) 
patients with mycobacteraemia, tuberculosis was identified using routine 
investigations; it was not suspected in six (11%). Strong clinical indicators 
of mycobacteraemia were anaemia, HIV seropositivity, cough, chronic fever 
and a clinical diagnosis of AIDS on the day of admission. Of nine patients 
selected for a therapeutic trial of tuberculosis treatment, six had 
mycobacteraemia, of whom five died during the trial. Mortality on short-
course chemotherapy, on the tuberculosis ward after 1 month was similar 
whether patients had mycobacteraemia (21%) or not (32%). 
Conclusion: Tuberculosis can be identified with routine methods in most 
patients with mycobacteraemia. If treated, mycobacteraemia has as good 
an early outcome as tuberculosis without mycobacteraemia. Strengthening 
of basic facilities is likely to improve detection and treatment of 
mycobacterial disease. 
Clinical indicators of mycobacteraemia 
75 
Introduction 
Mycobacteraemia was described as a feature of tuberculosis 80 years 
ago [1]. Only in the era of the acquired immune-deficiency syndrome (AIDS) 
has it become recognised as common [2-4]. Recent studies where human 
immunodeficiency virus (HIV) and tuberculosis abound have shown that 
Mycobacterium tuberculosis may be the commonest organism in 
bloodstream infection (BSI), with prevalence among febrile adult in-patients 
ranging from 9 to 12% [5-8]. Mycobacterial culture is slow, and many 
patients will die or be discharged before culture is positive [5,9–11]. Culture 
is expensive and not routinely available in sub-Saharan Africa. Mortality 
rates in those who do not receive treatment may be as high as 80% [5,12]. 
None of the published studies had sufficient clinical information to 
determine whether tuberculosis could be diagnosed in these patients 
without using blood cultures; very few patients were investigated by sputum 
examination or chest X-ray (CXR) [5–8,12]. It has been suggested that 
better microbiology services in developing countries would improve 
detection of tuberculosis (TB), but this would be unnecessary if the 
available, and cheaper, investigations were equally or more useful clinically 
[7]. Mycobacteraemia has been associated with chronic symptoms of 
cough, fever and weight loss, with oral thrush, anaemia, low CD4+ or total 
lymphocyte counts and hepatosplenomegaly [2,5,6,8,12,13]. The clinical 
spectrum may range from acute fulminating infection, in which patients may 
die before tubercles are seen on CXR, through to chronic infection in 
miliary disease [14]. It is not known where in this spectrum most patients in 
sub-Saharan Africa lie, nor in what proportion the diagnosis may be made 
using existing routine methods alone. Most patients with disseminated TB 
become afebrile within 2 weeks of starting treatment [13]. Where TB is 
suspected in unexplained fever, a therapeutic trial of specific anti-
tuberculosis drugs (isoniazid, pyrazinamide and ethambutol) has been 
suggested [15,16]. We performed a prospective study of BSI in febrile adult 
admissions to our hospital, and investigated all patients for TB using 
methods routinely available in most hospitals in sub-Saharan Africa. We 
measured the prevalence and outcome of mycobacteraemia, and the 
proportion of mycobacteraemic cases who could be identified using routine 
methods. We assessed the clinical indicators of mycobacteraemia, and the 
usefulness of a diagnostic trial of tuberculosis treatment. 
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Methods 
Queen Elizabeth Central Hospital is the main provider of secondary care 
to Blantyre, the largest city in Malawi, and its district. Hospital care, 
including TB treatment, is free. The study took place between 15 February 
2000 and 2 May 2000. Patients were recruited on 23 weekdays of 24 
hours, randomly chosen in advance. All patients admitted to the adult 
medical wards on the specified days (excluding direct admissions to the TB 
ward) were assessed. Patients were eligible for the study if they had an 
axillary temperature ≥37.4°C, or were in shock (pulse ≥120 beats/minute 
and systolic blood pressure <100 mmHg), or if they gave a history of a high 
fever within the last 4 days, and if they gave consent. Afebrile patients with 
a recent history of fever were included because mycobacterial blood 
cultures are often positive even if they are not taken at the time of fever 
[17]. Approval for the study was obtained from the Research Committee of 
the College of Medicine, University of Malawi. A study clinician conducted a 
standardised history and clinical examination. The optic fundi were 
examined by an ophthalmologist. Blood was drawn aseptically for bacterial 
and mycobacterial culture, full blood count, film for malaria parasites and 
HIV tests. Each patient was given three containers for sputum production. 
CXR was performed within 24 hours, and other investigations were 
performed when appropriate. Patients were managed according to 
standard protocols, using facilities normally available to all patients. All 
patients were reviewed by a physician within 24 hours (DKL, JK, EEZ, JGK 
or MEM), and the physical examination was repeated. They were reviewed 
daily while on the wards. On the fourth day bacterial blood culture and 
blood film were repeated if fever was present. Patients whose 
mycobacterial culture became positive after discharge were followed up at 
home if they were not already receiving TB treatment, and outcome one 
month after admission was established for all those with mycobacteraemia.  
For the purposes of clinical management, tuberculosis was diagnosed by 
finding any of the following: acid-fast bacilli (AFB) in sputum or lymph node 
aspirate; caseous lymph node aspirate; ‘classical’ CXR changes (cavities, 
pulmonary fibrosis, upper lobe or bilateral infiltrates, or pleural effusion not 
otherwise explained); ‘non-classical’ CXR changes (other infiltrates or 
intrathoracic adenopathy) together with chronic (≥1 month) cough or 
chronic fever; miliary pattern on CXR; pericardial effusion confirmed by 
ultrasound; or TB meningitis (chronic headache plus cerebrospinal fluid 
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leukocyte count >200/mL with lymphocytes ≥80%). CXRs were reviewed by 
an experienced radiologist (SK) who was blind to the clinical details. 
 
Trial of TB treatment 
Patients with an identifiable clinical diagnosis, a positive blood film for 
malaria or a bacterial growth from blood culture were treated accordingly. 
Patients with a clinical or bacteriological diagnosis of TB were treated 
according to national policy. Disseminated TB was considered a possible 
diagnosis in patients with unexplained persistent fever. Those with negative 
bacterial blood culture, negative blood film and sputum smear, and a CXR 
not suggestive of TB, were given broad-spectrum antibiotics (gentamicin 
plus penicillin or chloramphenicol) for 5 days. Any patient still febrile after 5 
days received a diagnostic trial of specific anti-tuberculosis drugs (daily 
isoniazid, pyrazinamide and ethambutol). If the clinical condition had 
improved after 3 weeks the patient was assumed to have TB and was given 
short-course chemotherapy.  
 
Laboratory methods 
Full blood count was performed with a Coulter Counter. HIV testing was 
performed with Abbot Determine (Dainabot Company, Tokyo, Japan) and 
Unigold (Trinity Biotech, Bray, Ireland); patients with a positive result in 
both tests were regarded as HIV-positive. Sputum smears were stained 
with Ziehl-Neelsen. For the routine culture, 5 ml blood in a single blood 
culture bottle (50 mL Brain Heart Infusion Broth containing sodium 
polyanethol sulphonate, E&O Laboratories, Glasgow, UK) was incubated 
overnight at 37°C before venting. Cultures were examined macroscopically 
every day, followed by Gram staining if turbid or haemolysed. Isolates were 
identified according to standard techniques, including sero-agglutination 
and biochemical tests. Mycobacterial blood cultures were performed using 
Bactec 13A blood culture bottles (Becton Dickinson, Oxford, UK), examined 
manually. Smears were prepared and stained with auramine-phenol once a 
week for a maximum of 8 weeks. Positive cultures showing typical cording 
were reported as presumptive M. tuberculosis, while those that did not cord 
were reported as Mycobacterium species. Positive mycobacterial cultures 
underwent DNA extraction, and then polymerase chain reaction (PCR) for 
Mycobacterium-specific DNA and M. tuberculosis specific DNA. 
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Statistical methods 
Data were double-entered into Epi-Info version 6.04b (CDC, GA; WHO, 
Geneva), validated, and analysed with Stata 6.0 (Stata Corporation, 
College Station, TX). Categorical variables were compared with chi-square 
or Fisher’s exact test. Continuous data were compared with Mann-Whitney 
rank sum test, if skewed. Odds ratios were calculated and adjusted with 
logistic regression. 
Results 
There were 637 admissions on study days, of whom 367 (58%) were 
eligible for the study. Twelve patients declined, two were transferred to 
another hospital, and one was missed by the study team. Eight patients 
who were on TB treatment at the time of admission were excluded. In all, 
344 patients entered the study, 151 men and 193 women, with a mean age 
of 31.5 years (range 15–64); all except 17, with a history of recent fever, 
were febrile on admission. Two hundred and eighty-five (83%) patients 
were HIV seropositive, of whom 156 (46%) met the expanded WHO case 
definition for AIDS surveillance on the day of admission [18]. Table 13 
shows the blood culture results. The commonest infecting organism was M. 
tuberculosis, affecting 17% of all study patients, followed by non-typhi 
salmonellae. Of admitted patients who were afebrile, the proportion with 
bacteraemia (18%) and mycobacteraemia (12%) was similar to that among 
patients who were febrile on admission.  
 
‘Recognised mycobacteraemia’ and reliability of diagnosis 
TB was diagnosed by routine methods in 103 (30%) study patients, of 
whom 97 (94%) were HIV-positive. Of all those diagnosed with TB, 44 
(43%) had mycobacteraemia, while among the 241 not diagnosed with TB, 
M. tuberculosis BSI was identified in 13 (5.4%), and non-tuberculous 
mycobacteraemia in two (0.8%). We shall use ‘mycobacteraemia’ to mean 
M. tuberculosis BSI. Of the 57 patients with mycobacteraemia, 44 (77%) 
had TB diagnosed with routine methods (table 14); one-third (41% of those 
clinically diagnosed) were sputum-positive, and all of those who had TB 
diagnosed clinically had CXR suggestive of TB.  
  
Table 13. Microbial causes of bloodstream infections in HIV-positive and -negative patients 
 
 
Organism isolated 
HIV-negative 
patients (n = 59) 
Number (%) 
HIV-positive 
patients (n = 285) 
Number (%) 
Total patients        
(n = 344)     
Number (%) 
 
Percent of pathogenic 
organisms 
 
 
P-value 
      
Mycobacteria (all)† 2 (3) 57 (20) 59 (17) 46 0.001 
 
M. tuberculosis 2 (3) 55 (19) 57 (17) 44 0.001 
 Mycobacterium species‡ 0 2 (0.7) 2 (0.7) 2 - 
Non-typhi salmonellae§ 1 (2) 41 (14) 42 (12) 33 0.004 
Streptococcus pneumoniae 3 (5) 12 (4.2)¶ 15 (4.4) 12 0.73 
Escherichia coli 0 4 (1.4) 4 (1.2) 3 0.47 
Salmonella typhi 0 1 (0.4) 1 (0.3) 1 - 
Other** 3 (5) 5 (1.8) 8 (2.3) 6 - 
Contaminants 6 (10) 18 (6.3) 24 (7.0) - - 
Nil 44 (75) 155 (54) 199 (58) - - 
Total pathogens (n) 9 120 129 - - 
Malarial parasites 10 (17) 53 (19) 63 (18) - 0.77 
      
NOTE. Five patients had dual infections: 1 Streptococcus pneumoniae and Salmonella enteritidis, 5 with mycobacteria and bacteria (2 
pneumococcus, 1 Salmonella species, 1 Pseudomonas aeruginosa and 1 Klebsiella pneumoniae).  
*P-value for difference between HIV-positive and -negative patients. 
†M. tuberculosis cultures showed cording. Of these, 48 were confirmed with PCR; five were confirmed as mycobacteria by their resistance to 
decolourisation by 20% in Ziehl-Neelsen staining (2 PCR not done, 3 PCR negative); one was positive for mycobacterial PCR (sputum-
positive, cavities on CXR); three others were negative, or showed inhibition on PCR but had clinical TB (including one with PCR-confirmed 
pericardial TB). 
‡Mycobacterium species cultures did not show cording. Both were confirmed by PCR. 
§Non-typhi salmonellae: 25 S. typhimurium, 15 S. enteritidis, 2 salmonella species. 
¶In addition, one sample showed Gram-positive diplococci which failed to grow on subculture. 
**Other: 1 Cryptococcus neoformans, 1 Proteus mirabilis, 1 Group A Streptococcus, 1 Staphylococcus aureus, 1 Pseudomonas aeruginosa, 2 
Klebsiella pneumoniae, 1 Flavobacterium species. 
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Of the 103 patients diagnosed with TB, 61 (59%) had bacteriologically 
proven TB (sputum or lymph node aspirate AFB-positive, pleural fluid 
culture-positive or subsequent blood culture-positive). This rose to 66 
(64%) if those with pericardial effusion on ultrasound or a miliary pattern on 
CXR were included. Only 12 (12%) patients were diagnosed solely on the 
basis of a non-classical CXR plus symptoms.  
 
Table 14. Routine methods of diagnosing TB 
 
 
Diagnostic method 
Patients diagnosed 
with TB (n = 103) 
Number (%) 
Patients with M. 
tuberculosis BSI (n = 57)  
Number (%) 
   
Confirmed   
 Sputum AFB-positive 28 (27) 18 (32) 
 Lymph node aspirate caseous 13 (13) 5 (9) 
Total bacteriologically confirmed  
(not including blood culture)* 
38 (37) 21 (37) 
Classical CXR† 47 (46) 17 (30) 
Non-classical CXR† 35 (34) 18 (32) 
Miliary CXR 11 (11) 9 (16) 
 Total CXR 93 (90) 44 (77) 
Pericardial effusion on ultrasound 4 (4) 1 (2) 
TB meningitis 3 (3) 1 (2) 
   
NOTE. Some patients were diagnosed by more than one method. TB, tuberculosis; BSI, 
bloodstream infection; AFB, acid-fast bacilli; CXR, chest X-ray. 
*Bacteriological confirmation includes sputum AFB-positive, lymph node aspirate and pleural 
fluid culture positive. 
†CXRs suggestive of TB were classified as ‘classical’ (showing cavities, pulmonary fibrosis, 
upper lobe or bilateral infiltrates, or pleural effusion not explained by another disease), 
‘miliary’, or ‘non-classical’ (other infiltrates or intrathoracic adenopathy together with chronic 
cough or fever). Fifteen patients had their pleural effusion aspirated, of which eight were TB 
culture-positive (3 mycobacteraemic). All except one patient (with TB meningitis) had CXR. 
All had sputum examination except 7 with mycobacteraemia and 3 without. Lymph node 
aspirates were from: 6 axilla, 5 neck, 1 inguinal, 1 abdominal; 5 of these were confirmed 
AFB-positive. 
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‘Unrecognised mycobacteraemia’ 
Thirteen patients (23%) with mycobacteraemia were not recognised as 
having TB until blood culture became positive. Of these, four had been 
started on a therapeutic trial of TB treatment, three had clinical pneumonia 
(one died within a few days, two improved), three gave a history of chronic 
fever but improved on the ward, one absconded while still febrile, one 
started antibiotics for chronic cough but did not return for follow-up, and one 
gave a 3-day history of cough, which improved on the ward. Thus seven 
were strongly suspected of TB (four trial of treatment, one died, two did not 
attend for review), and six (11% of those with mycobacteraemia) were truly 
undetectable using routine methods. Two of these were found alive and 
treated with short-course chemotherapy. Two patients had Mycobacterium 
species BSI, both of whom had a short history of cough and a clinical 
picture of pneumonia: one died on day 5, and one improved with antibiotics. 
 
‘Trial of TB treatment’ 
Nine patients were started on a trial of TB treatment. Six were 
subsequently shown to have mycobacteraemia (positive predictive value of 
starting a trial 67%; odds ratio 50.2, 95% confidence interval 10–234, 
compared with all other patients not clinically diagnosed with TB). Five had 
an abnormal CXR not suggestive of TB. Five died during the trial (3 weeks), 
and the sixth died after 5 weeks, having failed to return for review. Of four 
mycobacteraemic patients given a trial as in-patients, only one became 
afebrile, but died 4 days later. Of the non-mycobacteraemic patients given 
a trial, two died within 6 days of starting treatment, and the third requested 
discharge and was not traced. 
 
Mortality 
Mortality on the medical wards was 19% in patients with 
mycobacteraemia compared with 21% in those with other (bacterial) BSI, 
whereas in patients with no BSI, mortality was 8% (p=0.003). Patients with 
mycobacteraemia who received short-course chemotherapy on the TB 
ward were less likely to die during the first month than non-
mycobacteraemic patients on the same treatment, but this was not 
statistically significant (21% vs. 32%, p=0.42).  
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Table 15 shows deaths within one month of admission in patients with 
mycobacteraemia, according to type of treatment given. Some individuals 
died before treatment and some died within a few days of starting 
treatment. Overall, 24 (42%) died within one month of admission. Eleven 
people with (unrecognised) mycobacteraemia went home with no TB 
treatment. They were followed up when culture became positive. Six had 
died, two were alive and three could not be found. 
 
Table 15. Mortality one month after admission in relation to type of TB treatment in 
patients with M. tuberculosis BSI 
Type of treatment 
(number of patients) 
Died within 1 month of 
admission. Number (%) 
Mortality (%) assuming 
those not found had died 
   
No treatment (14) 7 (50) 
(3 not found) 
71 
Short-course 
chemotherapy (28)* 
8 (29) 
(1 left ward and not found) 
32 
Standard 
chemotherapy (9) 
3 (33) 33 
Therapeutic trial of TB 
treatment (6) 
5 (83) 83 
All with M. tuberculosis 
BSI (57) 
23 (40) 
(4 not found) 
64 
   
*Mortality in the 24 patients who were treated on the TB ward was 21%. Four died within a 
few days of starting treatment. 
†All had died within 6 weeks of admission. 
 
Clinical indicators of mycobacteraemia 
Table 16 shows indicators of mycobacteraemia. The strongest indicators 
(other than a clinical diagnosis of TB) were anaemia (Hb <10 g/dL), HIV 
seropositivity, cough, chronic fever and diagnosis of AIDS on the day of 
admission. Three hundred and seven patients underwent an ocular 
examination. Four had clinically suspected choroidal TB granulomas, three 
of whom were mycobacteraemic with clinically disseminated TB. The fourth 
got a trial of treatment, although mycobacterial culture was subsequently 
negative. He became afebrile with treatment but died after 5 days. 
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Table 16. Indicators of mycobacteraemia 
 
Clinical indicator 
Odds ratio 
(95% CI) 
 
P-value 
Adjusted OR 
(95% CI)† 
 
P-value 
     
Anaemia (Hb<10 g/dL) 9.5 (4.0–22.9) <0.001 11.8 (4.5–31) <0.001 
HIV-positive 6.8 (1.6–28.8) 0.009 4.3 (0.93–19) 0.061 
Cough 3.8 (1.6–8.6) 0.002 2.8 (1.2–6.7) 0.020 
Chronic fever (>1 month) 3.3 (1.8–5.9) <0.001 2.2 (1.0–4.8) 0.046 
AIDS on day of admission 3.1 (1.7–5.8) <0.001 3.2 (1.7–6.0) <0.001 
BMI <17 kg/m2 2.4 (1.3–4.4) 0.003 1.8 (1.0–3.5) 0.065 
Pleuritic chest pain 2.3 (1.2–4.1) 0.007 1.8 (0.94–3.3) 0.078 
Orthopnoea 2.0 (1.1–3.6) 0.028 1.5 (0.82–2.9) 0.179 
Breathless on exertion 2.0 (1.1–3.8) 0.029 1.5 (0.76–3.0) 0.246 
Night sweats 2.0 (1.1–3.6) 0.018 1.5 (0.81–2.8) 0.189 
Oral thrush 2.0 (1.1–3.7) 0.028 1.2 (0.59–2.4) 0.632 
Hepatomegaly 1.6 (0.9–3.1) 0.123 1.5 (0.77–2.8) 0.241 
Hepatomegaly (excluding 
bacteraemia) 
1.9 (1.1–3.3) 0.049 1.6 (0.83–3.3) 0.156 
Given trial of TB treatment 
(and not already on TB 
treatment)* 
50.2 (10.8–234) <0.001 52.5 (9.0–303) <0.001 
Sputum AFB-positive 13.3 (5.8–31) <0.001 11.2 (4.5–28.0) <0.001 
Miliary pattern on CXR 24.7 (5.2–118) <0.001 25.8 (5.2–128) <0.001 
Non-classical CXR 6.7 (3.2–14.2) <0.001 5.8 (2.6–13.1) <0.001 
Classical CXR 3.0 (1.5–5.9) 0.001 2.1 (1.0–4.4) 0.045 
Any CXR suggestive of TB 13.9 (7.0–27.6) <0.001 13.0 (6.1–27.8) <0.001 
     
Abbreviations: OR, odds ratio; CI, confidence interval; HIV, human immunodeficiency virus; 
AIDS, acquired immunodeficiency syndrome; BMI, body mass index; TB, tuberculosis; AFB, 
acid-fast bacilli; CXR, chest X-ray. 
*Patients were given a therapeutic trial of TB treatment if they had persistent fever, negative 
bacterial blood culture, sputum and malaria slide, a CXR not suggestive of TB, and no 
response to broad-spectrum antibiotics. 
†Adjusted for age, sex, urban/rural dweller, education level reached, and diagnosis of AIDS 
on day of admission [18]. 
 
Differences between TB patients with and without mycobacteraemia 
Patients with mycobacteraemia were similar to nonmycobacteraemic 
patients who were diagnosed with TB using routine methods, in terms of 
age, sex, HIV status, number with AIDS on admission, body mass index, 
thrush, and a history of previous TB, cough, chronic fever, weight loss, 
night sweats or recent antibiotics. Table 17 shows the main differences 
between TB patients with and without mycobacteraemia. Among patients 
with an eventual diagnosis of TB, those with mycobacteraemia had a 
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shorter length of cough than those without (median 2 weeks versus 1 
month, rank sum p=0.004). Those with mycobacteraemia were less likely to 
have haemoptysis or a pleural effusion, and more likely to be anaemic, 
sputum-positive or to have miliary TB. 
 
Table 17. Differences between TB patients with and without mycobacteraemia 
 
 
Clinical finding 
Mycobacteraemia 
present (n = 57)  
Number (%) 
Mycobacteraemia 
absent (n = 59)  
Number (%) 
 
 
P-value 
OR for myco-
bacteraemia 
(95% CI) 
     
Severe anaemia 
(Hb< 7 g/dL) 18 (32) 9 (15) 0.038 2.6 (1.0–6.3) 
Anaemia 
(Hb<10 g/dL) 50 (89) 38 (66) 0.002 4.4 (1.6–12) 
Sputum-smear 
positive 
18  
(36% of 50 patients) 
10 
(18% of 56 patients) 0.034 2.6 (1.1–6.3) 
Cough >1 month 
 
26 (46) 41 (69) 0.009 0.37 (0.17–0.79) 
Haemoptysis 
 
4 (7) 11 (19) 0.057 0.32 (0.1–1.1) 
Classical CXR 
 
17 (30) 31 (53) 0.010 0.37 (0.01–0.8) 
Pleural effusion 
on CXR 7 (12) 19 (33) 0.009 0.43 (0.2–0.93) 
Cavitation on 
CXR 9 (16) 10 (17) 0.834 0.9 (0.3–2.4) 
     
Abbreviations: OR, odds ratio; CI, confidence interval; CXR, chest X-ray; AFB, acid-fast 
bacilli. 
 
Discussion 
We found M. tuberculosis to be the commonest cause of BSI among 
febrile adults admitted to a medical ward in an area endemic for HIV and 
TB, and identified the clinical indicators of mycobacteraemia. The 
prevalence of mycobacteraemia was much higher than in other African 
studies perhaps due to the higher rate of HIV infection in this study [5,6,8]. 
In common with others, non-tuberculous mycobacteraemia was rare 
[19,20]. Most (77%) patients with mycobacteraemia were identified using 
routinely available diagnostic methods. Only 11% of those with 
mycobacteraemia (1.7% of all study patients) were neither detected by 
routine methods nor entered into a therapeutic trial. In only two people 
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(0.6% of the study patients) did mycobacterial blood culture result in 
treatment of TB that had not previously been diagnosed. Given the 
enormous difficulties in following up patients in this setting, mycobacterial 
blood cultures are unlikely to contribute greatly to routine care. One 
potential bias is that clinicians involved in the study may have been more 
likely to start TB treatment than in routine practice. However, we worked to 
protocols, and 59% of the diagnoses were confirmed microbiologically. 
Only 12 diagnoses were based solely on a ‘non-classical’ X-ray plus 
symptoms (the most subjective category). If TB is diagnosed less often in 
routine practice, our results suggest that many cases are missed. 
Mycobacteraemic patients admitted to the TB ward for short-course 
chemotherapy had a short-term survival that was at least as good as non-
mycobacteraemic TB patients given the same treatment. Their mortality 
after one month (21%) is similar to that in other series of TB patients and 
compares well with that of patients with miliary TB in the pre-AIDS era, of 
whom 20% died within 2 weeks [13,21,22]. We only have data for the first 
month, but this is the period when most deaths occur [13,22]. Although in 
some patients mycobacteraemia may occur as an acute agonal event, in 
many it is a treatable condition [19]. Patients selected for a diagnostic trial 
of TB treatment on the basis of persistent unexplained fever were 
extremely likely to have mycobacteraemia. However, five of six died during 
the treatment trial (the sixth died 2 weeks later), so the diagnostic value 
was in the indications for a trial, not the trial itself. Rifampicin may reduce 
mortality in such patients, although its broad anti-bacterial spectrum means 
that a response does not confirm TB [19]. Given that the clinical picture 
correlated so well with mycobacteraemia it seems reasonable to treat these 
patients promptly with rifampicin-based short-course chemotherapy. In this 
study, 11% of patients diagnosed with TB had a miliary pattern on chest X-
ray, compared with only 1% in another series of TB patients in Malawi [22]. 
We investigated fever rather than chronic cough, but it suggests that 
disseminated TB is often missed. We believe that a high index of suspicion 
and a low threshold for investigating for TB with chest X-ray and sputum 
smear would improve detection, even without facilities for mycobacterial 
blood culture. This would allow prompt treatment and a reduction in 
mortality. M. tuberculosis is the commonest bloodstream infection in febrile 
adults admitted to our hospital. In most, TB is clinically detectable using 
routinely available investigations, and outcome if treated with rifampicin-
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based chemotherapy is as good as that in other bacteraemias or in TB 
without mycobacteraemia. Strengthening of the basic facilities (radiology, 
AFB microscopy and clinical care) would be likely to improve the detection 
and treatment of mycobacterial disease. 
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Abstract 
Bloodstream infection (BSI) in febrile patients is associated with high 
mortality. Clinical and laboratory variables, such as procalcitonin (PCT), 
may predict BSI and help decision-making concerning empirical treatment. 
This study compared two models for prediction of BSI, and evaluated the 
role of PCT vs. clinical variables, collected daily in 300 consecutive febrile 
inpatients, for 48 hours after onset of fever. Multiple logistic regression 
(MLR) and classification and regression tree (CART) models were 
compared for discriminatory power and diagnostic performance. BSI was 
present in 17% of cases. MLR identified the presence of intravascular 
devices, nadir albumin and thrombocyte counts, and peak temperature, 
respiratory rate and leukocyte counts, but not PCT, as independent 
predictors of BSI. In contrast, a peak PCT level of >2.45 ng/mL was the 
principal discriminator in the decision tree based on CART. The latter was 
more accurate (94%) than the model based on MLR (72%; p<0.01). Hence, 
the presence of BSI in febrile patients is predicted more accurately and by 
different variables, e.g., PCT, in CART analysis, as compared with MLR 
models. This underlines the value of PCT plus CART analysis in the 
diagnosis of a febrile patient. 
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Introduction 
Fever is a frequent symptom in patients admitted to medical wards and 
raises suspicion of sepsis [1]. Bloodstream infection (BSI) is present in a 
minority of cases with new-onset fever in the hospital [1–3], but early 
recognition of BSI is important, since mortality is higher than in localised 
infection, and this is especially the case when initial empirical treatment is 
inadequate or delayed [4–6]. Various studies using multiple logistic 
regression (MLR) have evaluated clinical risk factors and laboratory 
variables for the prediction of BSI, including the presence of intravascular 
devices, peak temperature and white cell counts, and nadir albumin levels 
[7–14]. In this respect, the predictive value of procalcitonin (PCT) as a 
marker of BSI is still controversial for conditions such as respiratory tract 
and pulmonary disease, pancreatitis, and after trauma, burns and major 
surgery, partly because of a sensitivity that is too high and a low specificity 
for non-viral microbial infection [15–28]. Few studies have assessed the 
predictive value of PCT in relation to clinical and laboratory variables in 
MLR models, with diverse results [29–33]. Classification and regression 
tree (CART) analysis provides an alternative approach to MLR models, and 
may be more practical for prediction of BSI [34]. Recently, the use of a 
prediction algorithm was evaluated for classification of febrile patients into 
three risk groups for BSI, with sensitivity and specificity of 93% and 67%, 
respectively [34]. Decision trees that result from CART analysis have also 
been shown to predict, reasonably accurately, tuberculous meningitis, 
outcome following Staphylococcus aureus and enterococcal bacteraemia, 
and serious bacterial infection (bacteraemia and/or meningitis) in infants, 
although the latter application varies in accuracy [11,35–38]. The current 
study hypothesised that predictors of BSI depend on the model used, and 
that CART is superior to MLR in this respect. Thus, CART analysis was 
investigated in comparison with MLR for the prediction of BSI in febrile 
adults admitted to medical wards, and the role of PCT was evaluated in 
comparison with clinical and laboratory variables in these models. 
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Patients and methods 
Study design 
During a 1-year period, 300 consecutive patients with new onset fever 
(axillary temperature ≥38.0°C or rectal temperature ≥38.3°C) admitted to 
the Department of Internal Medicine at VU University Medical Centre, 
Amsterdam were included in the study. Demographical characteristics of 
the study population have been published separately [2,3]. The local ethics 
committee approved the study. Informed consent was obtained from each 
patient, or from the next of kin, before inclusion. Exclusion criteria were 
pregnancy, shock or a life expectancy of <24 h. Patients who received 
treatment with cytokines (e.g., interferon-γ or interleukin-2) or cytostatic 
drugs for solid tumours or malignant haematological disease were 
excluded. Demographical variables recorded at inclusion were age, gender 
and ethnicity, and factors that predispose to infections (e.g., the presence 
of intravascular devices and use of immunosuppressive drugs). Clinical 
variables recorded at inclusion, and daily thereafter for 2 days, were 
temperature, respiratory rate and heart rate. Blood samples were collected 
for routine laboratory analyses, including white blood cell count, platelet 
count, and haemoglobin, aspartate aminotransferase (ASAT), alanine 
aminotransferase, bilirubin, lactate dehydrogenase, creatinine, lactate and 
albumin levels. Laboratory variables were analysed using an SE 9000 
analyser (Sysmec, Kolbe, Japan) and a 747 automatic analyser (Hitachi, 
Tokyo Japan). PCT was measured using an immunoluminometric assay 
(BRAHMS Diagnostica, Berlin, Germany) with a lower detection limit of 
0.08 ng/mL; the normal upper limit of PCT is 0.5 ng/mL. Blood cultures 
were processed in BACTEC 9120/9240 automated blood culture machines 
(Becton Dickinson, Franklin Lakes, NJ, USA), and this was followed by 
culture identification using routine microbiological methods if growth was 
positive. Patients were diagnosed as having BSI after isolation of a known 
pathogen from the blood culture. Infection was presumed on the basis of 
history, physical examination and imaging techniques performed by 
attending physicians not involved in the present study, and was proven 
microbiologically when positive results of cultures of local specimens were 
returned. 
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Statistical analysis 
Statistical analysis was performed using SPSS v.10.1.0 (SPSS Inc., 
Chicago, IL, USA). Comparison among patient groups was performed with 
Fisher’s exact test for dichotomous variables, and the Mann–Whitney U-
test for continuous variables. Among the three determinations of each 
continuous clinical and laboratory variable, the peak or nadir values were 
selected for further analysis. Univariate analysis was performed for clinical 
and laboratory variables, and the same variables were included in forward 
MLR analysis to obtain a set of variables, each contributing significantly to 
prediction of BSI. The goodness-of-fit of the model was evaluated with the 
Hosmer and Lemeshow statistic, with an adequate calibration indicated by 
p>0.05. ORs and 95% CIs were calculated from regression coefficients and 
standard errors. CART analysis was performed using the computer 
program S-PLUS 2000 Professional v.1 (MathSoft, Seattle, WA USA). The 
same variables evaluated by MLR were entered as potential predictors in 
CART analysis. The methodology of CART analysis is based on binary 
recursive partitioning [39,40]. The principal idea is to select splits in which 
the data in the descendant subsets are less variable with respect to the 
classification problem. Thus, each subset should contain as many as 
possible cases belonging to a specified outcome (i.e., BSI present), and as 
few as possible to the other outcome (no BSI). Binary refers to the fact that 
all decisions involve a parent node that is broken into two child nodes. 
Recursive refers to the fact that each child node can then become a parent 
node, and in a repetitive pattern, a decision tree with expanding branches is 
created. Splitting rules are developed in a stepwise fashion by analysing 
each potential predictor and all possible cut-off points. The partitioning is 
repeated until a subgroup has a similar endpoint for all cases, or the 
subgroups are too small for further analysis. The present study used a 
minimum node size of five and a group size (the branch of two nodes 
together) of at least ten cases; minimum node deviance was set at 0.010. 
Cases with missing data were excluded from analysis. The discriminatory 
power of the MLR and CART analyses was evaluated in terms of 
sensitivity, specificity, positive predictive value, negative predictive value 
and accuracy, calculated according to standard formulae and compared 
between both models with the chi-square test. Exact p values are given 
until p was <0.01, with p<0.05 denoting statistical significance. Data were 
summarised as median (range). 
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Results 
BSI was significantly more frequent among women than among men (24 
vs. 11%; p<0.01). BSI and non-BSI groups were identical for other 
demographical variables, except that gastrointestinal and endocrinological 
diseases were more common among the BSI group (table 18). Clinically 
presumed infection was microbiologically proven in 133 cases (44%), with 
the respiratory tract (30%) being the most common site of infection, 
followed by the urogenital tract (23%), skin (23%) and the gastrointestinal 
tract (11%). Blood cultures were positive in 52 cases (17%). Escherichia 
coli and S. aureus were the microorganisms encountered most frequently 
(table 19). The most likely source of BSI was the skin (15 cases), followed 
by the gastrointestinal tract (11), urogenital tract (10), respiratory tract (4), 
and the cardiovascular system (4). 
 
Table 18. Demographics of study population in relation to presence of bloodstream 
infection* 
 No BSI BSI p value 
    
Age (years) 59 (17–97) 64 (21–92) 0.36 
Gender (male/female) 136/112 17/35 <0.01 
Karnofsky score (%) 90 (30–100) 80 (40–100) 0.42 
Antibiotics before admission 57 (25) 10 (20) 0.51 
Underlying disease†    
 Cardiovascular disease 59 (25) 13 (26) 0.99 
 Respiratory disease 29 (13) 5 (10) 0.59 
 Gastrointestinal disease 12 (5) 9 (18) <0.01 
 Urogenital disease 25 (11) 6 (12) 0.84 
 Malignancy 51 (22) 14 (28) 0.40 
 Endocrinological disease 46 (20) 17 (33) 0.04 
 Autoimmune disease 18 (8) 8 (16) 0.10 
 Dementia or psychiatric disease 10 (5) 0 0.22 
 Skin disease 11 (5) 2 (4) 0.80 
Immunosuppressive drugs 56 (23) 15 (29) 0.35 
Recent surgery 30 (12) 4 (7.7) 0.31 
    
Abbreviations: BSI, bloodstream infection 
*Data are presented as numbers (%) for dichotomous variables and as medians (range) for 
continuous variables. 
†Including more than one disease per patient. 
Procalcitonin in a decision tree for BSI 
95 
Table 19. Microorganisms isolated from blood cultures 
Microorganism Number 
  
Gram-positive bacteria 25 
 
Staphylococcus aureus 9 
 
Coagulase-negative Staphylococcus 7 
 
Streptococcus pneumoniae 5 
 Viridans streptococci 4 
Gram-negative bacteria 24 
 
Escherichia coli 12 
 
Bacteroides vulgatus 3 
 
Non-typhoid Salmonella spp. 2 
 
Pseudomonas aeruginosa 2 
 
Klebsiella pneumoniae 2 
 
Enterobacter cloacae 1 
 
Morganella morganii 1 
 
Fusobacterium spp. 1 
Polymicrobial infection* 3 
  
*Polymicrobial infection includes cases with: Escherichia coli and Staphylococcus aureus; 
Enterobacter cloacae and Proteus mirabilis; and Staphylococcus aureus and Klebsiella 
oxytoca. 
 
Univariate analysis of clinical and laboratory variables identified nine 
different factors that were predictive of BSI (table 20). The most important 
factor was the peak body temperature. Also, nadir platelet count, nadir 
albumin, and peak ASAT, alanine aminotransferase and peak PCT levels 
were associated strongly with BSI. A complete set of data for MLR and 
CART analysis was available for 262 cases (87%), including 45 cases of 
BSI. MLR identified six factors associated independently with BSI (table 
21). PCT was not independently predictive and was excluded from the MLR 
analysis (p=0.29). The MLR model predicted the presence or absence of 
BSI correctly in 31/45 (69%) and 157/217 (72%) of cases, respectively 
(table 22). A negative prediction using the model was correct in 157/171 
cases (92%). CART analysis yielded the decision tree depicted in figure 6. 
A peak PCT level of >2.45 ng/mL was the principal discriminator, followed 
by nadir haemoglobin ≤6.4 mmol/L, peak body temperature ≥39.0°C, nadir 
albumin ≤18 g/L, peak ASAT level ≥36 U/L and peak lactate levels ≥1.6 
mmol/L.  
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Peak temperature ≥ 39.0ºC
Nadir albumin ≤ 18 g/L
No Yes
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N= 7
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Figure 6. Decision tree analysis with peak procalcitonin (PCT) as the principal discriminator for prediction of bloodstream infection (BSI) in 
patients with fever (n = 262). (a) Branch of the decision tree in cases where peak PCT was >2.45 ng ⁄ mL. (b) Branch with peak PCT levels 
that are lower than the cut-off value. Endpoint boxes include outcome (BSI or No BSI), probability (Pr) of outcome, and number (n) of cases 
included in the node during analysis. ASAT, aspartate aminotransferase; RR, respiratory rate.  
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Table 20. Univariate analysis of clinical and laboratory variables in patients with 
and without bloodstream infection (n = 300)* 
 
No BSI 
(n = 248) 
BSI 
 (n = 52) 
 
P-value 
    
Clinical risk factors    
 Intravascular catheters 9 (3.6) 6 (12) 0.04 
 Devices/procedures 45 (18) 15 (29) 0.08 
 Recent surgery 30 (12) 4 (7.7) 0.31 
 HIV-seropositive 14 (5.6) 1 (1.9) 0.32 
 Immunosuppressive drugs 56 (23) 15 (29) 0.35 
 Underlying malignancy 51 (21) 14 (27) 0.40 
Vital and laboratory variables    
 Peak temperature (°C) 39.3 (38.2–39.3) 39.6 (39.3–39.7) <0.01 
 Peak heart rate (beats/min) 100 (56–160) 100 (60–154) 0.08 
 Peak systolic blood pressure 
(mmHg) 
128 (85–220) 130 (80-190) 0.24 
 Peak respiratory rate 
(breath/min) 
30 (14–56) 28 (12–54) 0.62 
 Peak WBC count (x109/L) 12.8 (11.7–13.8) 15.5 (12.6–18.4) 0.11 
 Nadir platelet count (x109/L) 216 (199–233) 154 (121–187) 0.01 
 Nadir haemoglobin (mmol/L) 6.6 (6.5–6.8) 6.2 (5.8–6.5) 0.02 
 Peak bilirubin (µmol/L) 19 (15–23) 36 (14–58) 0.02 
 Peak ALAT (U/L) 36 (25–47) 52 (14–90) <0.01 
 Peak ASAT (U/L) 39 (28–51) 70 (10–129) <0.01 
 Peak LDH (U/L) 415 (345–485) 476 (303–649) 0.22 
 Peak creatinine (µmol/L) 164 (135–198) 155 (116–191) 0.08 
 Nadir albumin (g/L) 24.5 (23.8–25.2) 21.6 (19.8–23.4) <0.01 
 Peak lactate (mmol/L) 2.0 (1.8–2.2) 2.2 (1.9–2.4) 0.06 
 Peak procalcitonin (ng/mL) 8.1 (1.8–14.4) 37.8 (7.9–67.9) <0.01 
     
Abbreviations: BSI, bloodstream infection; HIV, human immunodeficiency virus; WBC, white 
blood cell; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; LDH, 
lactate dehydrogenase. 
*Data are presented as numbers (%) for dichotomous and medians (range) for continuous 
variables. 
 
BSI was absent in all 67 patients with a PCT level <2.45 ng/mL, a nadir 
haemoglobin >6.4 mmol/L and a peak ASAT level <36 U/L. The probability 
of absence of BSI was 94% if nadir haemoglobin was ≤6.4 mmol/L and the 
peak lactate level was <1.6 mmol/L in patients with a PCT level <2.45 
ng/mL. BSI was present in ten (83%) of twelve patients with a PCT level 
>2.45 ng /mL, a peak temperature ≥39.0°C and a nadir albumin <18 g/L.  
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Table 21. Logistic regression analysis of clinical and laboratory variables predicting 
bloodstream infection in patients with fever (n = 262) 
 OR (95% CI) P-value* 
   
Nadir albumin level 0.90 (0.84–0.97) <0.01 
Nadir platelet count (per 10 units) 0.93 (0.90–0.97) <0.01 
Peak WBC count (per 10 units) 2.59 (1.34–3.39) <0.01 
Intravascular devices 3.7 (1.1–13) 0.04 
Peak temperature 1.9 (1.1–3.5) 0.02 
Peak respiratory rate 0.95 (0.90–0.99) 0.03 
   
Abbreviation: WBC, white blood cell. 
*Hosmer-Lemeshow chi-square = 1.7; p = 0.988. 
 
The probability of predicted outcome in the decision tree was 100% in 12 
endpoints with a total of 194 cases (74%). Only 17 cases were 
misclassified (6.5%, 95% CI 3.5–9.7), resulting in an accuracy of 94% 
(table 21). In 36/45 cases (80%), the presence of BSI was predicted 
correctly; positive prediction of BSI using the model was correct in 82% of 
cases (36/44). The absence of BSI was predicted correctly in 96% of cases 
(209/217). CART analysis was significantly more accurate for prediction of 
BSI than the MLR model (p<0.01), but there was only a trend toward better 
sensitivity of the CART model. 
 
Table 22. Diagnostic value of models for prediction of bloodstream infection 
 MLR analysis CART analysis P-value 
    
Sensitivity (%) 69 80 0.17 
Specificity (%) 72 96 <0.01 
Positive predictive value (%) 34 82 <0.01 
Negative predictive value (%) 92 96 0.06 
Overall accuracy (%) 72 94 <0.01 
    
Abbreviations: MLR, multiple logistic regression; CART, classification and regression tree. 
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Discussion 
This study compared two methods for prediction of BSI among febrile 
hospitalised patients. The performance of the MLR model was similar to 
that of other models described previously [2,3,7,10,14]. However, CART 
analysis, and the resulting decision tree with PCT as the principal 
discriminator, predicted BSI more accurately than the MLR model, to which 
PCT did not contribute. Indeed, the CART prediction model may be more 
useful at the bedside than prediction models based on MLR [34]. The use 
of a decision tree has several advantages over MLR models [39,40]. First, 
CART analysis is an automated method that is relatively easy to interpret, 
with a graphical presentation. The resulting clinical decision rules are easier 
for the clinician to understand than are models based on MLR. Second, 
CART analysis is inherently non-parametric, so that no assumptions are 
made regarding the underlying distribution of variables. Categorical factors 
can thus be used as well as continuous variables. Finally, the workflow of a 
decision tree could be translated easily into a computer program for 
automated calculation. PCT was the primary discriminator for BSI in the 
decision tree, but was not associated independently with BSI in MLR 
analysis. An elevated PCT level of >2.45 ng/mL was able to stratify patients 
into high- and low-risk groups for BSI. Thus, PCT appeared to be the most 
important predictor of BSI in comparison with all the other clinical risk-
factors and laboratory variables included in the study, which is a finding that 
has only been reported previously in patients attending an emergency 
department [29]. However, it has been shown previously that the value of 
PCT for predicting serious bacterial infection in infants is similar to that of 
traditional markers of infection [33]. Rapid tests for PCT that allow bedside 
determinations of PCT levels are available, which enhances the clinical 
applicability of the decision tree considerably. Based on the stratification of 
patients according to PCT and other clinical variables in the decision tree, 
rapid therapeutic interventions will be possible. This may reduce the use of 
antibiotics substantially, as demonstrated recently for PCT-guided 
treatment of lower respiratory tract infections in meningitis [26,27]. In 
addition to the high sensitivity of the decision tree, the high negative 
predictive value of both models is of great importance, as it is equally 
relevant to rule out bacteraemia and to predict its presence.  
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Based on the decision tree, antimicrobial therapy would have been 
initiated correctly in 82% of cases with predicted bacteraemia. However, if 
decisions had been based solely on a positive prediction using the MLR 
model, 60 patients would have been given antimicrobial treatment, even 
though no BSI was present. Eight patients with BSI would have been 
missed with the CART model, in comparison with 14 patients who would 
have been missed with the MLR model. This illustrates the greater 
accuracy of the CART model as a basis for therapeutic decisions in 
comparison with the MLR model. In addition to PCT, nadir haemoglobin, 
peak ASAT and peak lactate levels have a prominent place in the decision 
tree, but are also not included in the MLR model, which demonstrates the 
model-dependency of predictors. However, nadir albumin, peak 
temperature and nadir thrombocyte count were predictors for BSI in both 
MLR and CART analysis. The importance of these factors, together with 
the presence of intravascular devices, identified by MLR, is in agreement 
with previous reports [2,3,10,13,34]. The predictive value of nadir 
thrombocyte counts probably results from disseminated intravascular 
coagulation associated with BSI, whereas reprioritising of acute-phase 
protein over albumin synthesis in the liver as a consequence of the 
liberation of cytokines may result in low nadir albumin levels [1,41]. The 
present study has some potential limitations. From a practical perspective, 
only clinical and laboratory variables that could be determined rapidly were 
included in the study, as the aim was to design a prediction rule to support 
bedside decisions concerning the initiation of antimicrobial therapy directly 
after the onset of fever. Furthermore, cut-offs of a minimal five cases per 
node and ten per group were used in CART analysis to improve 
practicability, but at the cost of accuracy. Only two choices are possible per 
branch for each variable. This improves the clinical use of the tree, but part 
of the predictive value may be lost if there is a linear relationship between a 
continuous variable (e.g., white blood cell count) and the likelihood of the 
outcome (i.e., BSI). Finally, no prospective validation of the decision tree 
was performed. Nevertheless, a decision tree of clinical risk factors and 
laboratory variables should allow a more accurate prediction of BSI in 
febrile patients than an MLR model, partly because different variables, e.g., 
PCT, are used. Based on the high discriminatory power of PCT in the 
decision tree, routine determination of PCT should be considered in the 
diagnostic workup of the febrile patient. 
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Abstract 
Rapid identification of microorganisms in blood cultures is required to 
optimise empirical treatment at an early stage. Fluorescence in situ 
hybridization (FISH) can reduce the time to identification of microorganisms 
in growth-positive blood cultures. In this study, we evaluated the 
performance, time to identification, and potential clinical benefits of FISH 
compared to those of conventional culture methods in routine practice. 
After Gram staining, blood culture fluids were simultaneously further 
identified with FISH and with conventional culture methods. Results and 
points in time of FISH and culture identification (provisional and final 
identifications) were collected and compared. For 91% of microorganisms, 
the genus or family name was identified, and for 79%, the species name 
could be attributed. The sensitivity and specificity of the individual probes 
exceeded 95%, except for the Enterobacteriaceae probe (sensitivity, 89%). 
Cross-hybridisation was obtained with the Klebsiella pneumoniae probe for 
Klebsiella oxytoca. The time gains of FISH and final culture identification 
were more than 18 hours for bacteria and 42 hours for yeasts. With FISH, 
Staphylococcus aureus was differentiated from coagulase-negative 
staphylococci 1.4 hours faster than by provisional identification (p<0.001). 
In conclusion, FISH allows rapid and reliable identification of the majority of 
microorganisms in growth-positive blood cultures. The substantial time gain 
of identification with FISH may allow same-day adjustment of antimicrobial 
therapy, and FISH is especially useful if no provisional identification is 
obtained. With further extension of the number of probes and a reduction in 
turnaround time, FISH will become a very useful diagnostic tool in the 
diagnosis of bloodstream infections. 
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Introduction 
Bloodstream infection by bacteria or fungi is a serious clinical condition, 
associated with increased morbidity and mortality compared to the 
morbidity and mortality associated with localized infections [1]. Empirical 
antimicrobial therapy is usually initiated in ill patients and continued for 
several days before final results of blood cultures are available. Decreasing 
the time to microbiological diagnosis of bloodstream infection is important 
to enable adequate pathogen-based antimicrobial therapy at an early stage 
and to improve outcome [2-4]. For example, a rapid diagnosis of 
candidaemia in a patient with fever in an intensive care unit would imply 
early antifungal therapy. Quick determination at the species level could 
immediately streamline this antifungal treatment to the specific Candida 
species. Also, fast differentiation of Staphylococcus aureus from 
coagulase-negative staphylococci in a blood culture could help the 
microbiologist in consultation with the clinician to discriminate a serious 
infection from a possible contamination. A rapid diagnosis could improve 
prognosis, reduce the length of hospitalisation, and decrease the use of 
inadequate and broad-spectrum antibiotics, thereby reducing the potential 
development of resistance and possible side effects (e.g., less 
hepatotoxicity after streamlining of amoxicillin-clavulanic acid to 
flucloxacillin) [5-7]. Various methods have been assessed to reduce the 
time required for identification of microorganisms in blood cultures, 
including fluorescence in situ hybridization (FISH), PCR algorithms, and 
rRNA probe matrices [8-10]. The use of FISH or rRNA probes is attractive 
because growth-positive blood cultures contain sufficient bacteria to be 
detected by microscopy; therefore no amplification step (as in PCR) is 
required. Another advantage of FISH and probe matrices compared to PCR 
is that a single slide or a microtiter plate is used with an array of probes, 
whereas multiple individual PCRs (one per pathogen) have to be 
performed. This makes PCR more labour-intensive than FISH or probe 
matrices. The FISH technique is based on the hybridisation of probes to 
target rRNA followed by microscopical detection of fluorescence. Probes for 
FISH consist of either an oligonucleotide or a peptide nucleic acid (PNA) 
backbone with a fluorescent label.  
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Evaluation of 115 growth-positive blood cultures showed that FISH with 
oligonucleotide probes is a sensitive method for identification of 
microorganisms in blood cultures [8]. In this study 95% of microorganisms 
were identified at the family level, and 78% and 66% were identified at the 
genus and species level, respectively. The sensitivity and specificity of 
individual probes included in this study were 100%. Similar figures were 
found in another study, except the Staphylococcus aureus probe had a 
much lower sensitivity (67%) [11]. PNA probes have been used in several 
studies for the identification of Staphylococcus aureus, Escherichia coli, 
Pseudomonas aeruginosa, and Candida albicans in blood cultures. The 
sensitivities and specificities of these probes were all more than 98% [12-
16]. Although the sensitivity and specificity of individual probes 
(oligonucleotide and PNA) are very good, the usefulness of FISH as a 
diagnostic test depends on the probes included in the assay and is related 
to the prevalence of microorganisms in a specific setting. The theoretical 
turnaround time of the FISH procedure is 2.5 to 3 hours, depending on the 
Gram stain characteristics of the microorganisms involved. However, the 
time to identification in the routine daily practice of a microbiology 
laboratory is not known. In our laboratory, growth-positive blood culture 
samples are subcultured on solid media directly after Gram staining to try to 
obtain a same-day “provisional identification”. This identification provides a 
clue to the causative microorganism and, in combination with Gram stain 
characteristics and clinical presentation, may lead to adjustment of 
antimicrobial treatment. Provisional identification is always performed in 
parallel to test for a final identification and antibiotic susceptibility 
determination, both of which results are usually available the next morning. 
It is not known whether in this setting FISH is of additional value for routine 
culture-based identification for a faster diagnosis. In the present study we 
evaluated the performance and the times to identification of 
microorganisms in growth-positive blood cultures by routine implementation 
of FISH with oligonucleotide probes compared to those of conventional 
culture methods. 
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Materials and methods 
Study set-up  
Two hundred consecutive growth-positive blood cultures (BACTEC 
Aerobic/F, Anaerobic/F, and Peds/F; Becton Dickinson) were included in 
this study. For practical purposes, only bottles in which growth was 
detected by the automated culture machine between 8.30 a.m. and 2 p.m. 
during week days were included in the study. Only the first growth-positive 
blood culture from a single patient was included, except when the Gram 
stain characteristics of the microorganisms observed in subsequent positive 
blood cultures were different from the first one. Upon detection of growth by 
the automated blood culture machine (BACTEC 9240; Becton Dickinson), 
samples from the blood culture fluid were Gram stained. Three aliquots 
were taken: one was taken for performance of the appropriate subcultures 
for identification and antibiotic susceptibility testing, a second one was 
taken for FISH identification, and a third aliquot was stored at _20°C for 
sequence analysis of the microorganism in case of discrepant results 
between culture identification and FISH. 
 
Conventional microbiological identification 
Final (standard) identification of gram-positive and gram-negative 
bacteria and yeasts was performed with routine microbiological techniques, 
including biochemical characterization, agglutination tests, and automated 
identification of gram-negative microorganisms (VITEK 2; BioMérieux). An 
additional subculture was performed to obtain a “provisional identification”, 
which, in combination with the Gram stain result, aims to provide a same-
day clue for the identity of the causative microorganism. For this purpose, 
subcultures of blood culture fluid were performed on blood agar and 
incubated at 37°C in a CO 2 incubator. If microbial growth was observed on 
the blood agar at the end of the day, the following routine microbiological 
tests were performed: a test for coagulase for differentiation of 
Staphylococcus aureus from coagulase-negative staphylococci when 
staphylococci were observed in the Gram stain, Lancefield grouping when 
beta-haemolysis was observed and streptococci were present in the Gram 
stain, and cytochrome oxidase to differentiate Pseudomonas species from 
other gram-negative rods in case of a Gram stain with gram-negative rods. 
Furthermore, subcultures were performed on blood agar with an optochine 
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disk and in a bile aesculin tube if the microorganisms observed in the 
Gram-stain were suggestive of Streptococcus pneumoniae or Enterococcus 
species. These tests for provisional identification were considered only 
suggestive of certain microorganisms and were always confirmed by final 
identification. 
 
Fluorescence in situ hybridization 
At the time that subcultures were performed, 5 ml of blood culture fluid 
was drawn for FISH. These samples were centrifuged at 1,200 rpm (∼450 
g) for 1 min. The supernatant fraction was inoculated on a glass slide with 
eight square fields; depending on the Gram stain, either six fields were 
inoculated for gram-positive bacteria or four fields were inoculated for 
gram-negative microorganisms or yeasts. The commercial seaFAST sepsis 
kit (SeaPro Theranostics International B.V., Lelystad, The Netherlands) 
was used for FISH according to the manufacturer’s protocol. Briefly, after 
fixation and an extra permeabilisation step with lysosyme/lysostaphine in 
the case of a gram-positive microorganism, cells were permeabilised with 
three consecutive baths of 50%, 80%, and 96% ethanol each for 3 min. 
Oligonucleotide probes (table 23) were applied and slides were incubated 
in a hybridisation chamber in a water bath at 48°C fo r 90 min. After 
hybridisation, unbound probe was washed off. The slides were dried and 
read by fluorescence microscopy (Olympus BX40; magnification, x100) with 
a fluorescein isothiocyanate (absorption wavelength, 494nm; emission 
wavelength, 518nm) and Cy3 (absorption wavelength, 552nm; emission 
wavelength, 570nm) filter. The oligonucleotide probes are complementary 
to portions of the 16S or 23S rRNA of the specific bacteria. Bacteria were 
identified as coagulase-negative staphylococci if fluorescent bacteria were 
seen with the Staphylococcus genus probe and no fluorescence was 
observed with the Staphylococcus aureus probe. A mixed infection was 
identified if fluorescence of the Staphylococcus aureus probe was observed 
for only a proportion of bacteria with fluorescence of the Staphylococcus 
genus probe on the same field. Probes did not differentiate between 
Escherichia coli and Shigella spp. or between Bacteroides spp. and 
Prevotella spp. because of the very high homology of the rRNA sequences 
of these organisms. 
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Table 23. Tandem probes used for identification of microorganisms in blood 
cultures 
 FITC label Cy3 label 
   
Gram-positive probes   
 
Staphylococcus genus Staphylococcus aureus 
 
Streptococcus pyogenes Streptococcus agalactiae 
 
Streptococcus genus Enterococcus genus 
 
Enterococcus faecalis Enterococcus faecium 
 
Clostridium perfringens Streptococcus pneumoniae 
 Eubacteria Enterobacteriaceae 
Gram-negative probes   
 
Escherichia coli/Shigella spp. Haemophilus influenzae 
 
Stenotrophomonas maltophilia Klebsiella pneumoniae 
 
Bacteroides spp./Prevotella spp. Pseudomonas aeruginosa 
 Eubacteria Enterobacteriaceae 
Yeast probes   
 
Candida krusei Candida albicans 
 
Candida dubliensis Candida tropicalis 
 
Glabrata glabrata Candida parapsilosis 
 Eubacteria Pan yeast 
   
 
Sequence analysis 
Sequence analysis was performed on DNA of microorganisms isolated 
from blood culture fluids with discrepant results from culture and FISH. 
DNA was isolated from the stored aliquot of blood culture fluid with 
QIAGEN columns (QIAamp mini kit; QIAGEN), followed by PCR with 16S 
universal primers (466 base pairs) [17]. Sequence determination was done 
with the BigDye Terminator cycle sequencing kit (Applied Biosystems) on 
the ABI Prism 3100 genetic analyzer (Applied Biosystems) by following the 
manufacturer’s instructions. 
 
Statistical analysis 
Data for outcome and points in time were collected for Gram staining and 
conventional culture identification (provisional and final) by a routine 
laboratory technician, and results and points in time of FISH were collected 
by the technician who performed the FISH technique. Data were analysed 
by descriptive statistics, and comparison of times to identification was 
performed with SPSS 10.0.  
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Results 
Two hundred blood cultures that were signalled as growth positive by the 
blood culture machine were included in this study. In 11 cases, no 
microorganisms were detected by Gram-stain or culture or identified by 
FISH. From the remaining 189 blood cultures, a total of 200 
microorganisms were isolated; two different microbial species were present 
in 11 blood cultures. FISH with eubacterial and pan-yeast control probes 
was positive in 100% of samples with bacterial (n=194) and fungal (6) 
growth, respectively, whereas no fluorescence was observed when such 
growth was absent. FISH identification of the genera of Gram-positive 
microorganisms or a family of Gram-negative microorganisms was obtained 
for over 90% (91%; 95% confidence interval [CI], 89 to 93%) of isolates 
(table 24). Genus or species name could be attributed to nearly 84% (95% 
CI, 81 to 87%) and 79% (95% CI, 76 to 82%) of all isolates, respectively. 
With FISH the presence of two pathogens was recognized in all 11 cases of 
mixed infection, including one blood culture with Staphylococcus aureus 
and coagulase-negative staphylococci. In 5/162 cases (3%), identification 
with the species-specific probes included in the assay was not optimal: in 
two isolates of Staphylococcus aureus, no FISH identification was obtained, 
and in one case, S. aureus was misidentified as coagulase-negative 
Staphylococcus. No fluorescence was observed with the species-specific 
probe for two isolates of Escherichia coli. Thus, the sensitivity of the 
available species-specific probes was 97% (95% CI, 96 to 98%) (table 25). 
 
Table 25. Sensitivities and specificities of probes for identification of 
microorganisms in blood cultures* 
Probes Sensitivity Specificity 
   
Species specific 157/162 (97) 36/38 (95) 
Genus specific 129/131 (98) 69/69 (100) 
Enterobacteriaceae 40/45 (89) 155/155 (100) 
Eubacterial control 194/194 (100) 6/6 (100) 
Pan-yeast control 6/6 (100) 194/194 (100) 
   
*Values are numbers of positive samples/numbers of samples tested (percentages).
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Table 24. Identification with FISH of Gram-positive and Gram-negative 
microorganisms in growth-positive blood cultures 
Number of samples  
positive by FISH‡ Microorganism Number of samples positive by culture Genus or 
family 
Genus or 
species 
    
Gram-positive microorganisms    
 Coagulase-negative staphylococci       94 94 94 
 
Staphylococcus aureus 20 18 17 
 
Streptococcus pneumoniae 2 2 2 
 
Streptococcus pyogenes 1 1 1 
 Other streptococci* 9 9 - 
 
Enterococcus faecalis 2 2 2 
 
Enterococcus faecium 2 2 2 
 Other enterococci 1 1 - 
 
Candida albicans  5 5 5 
 
Candida tropicalis 1 1 1 
 Other† 6   
Total 143 135 124 
    
Gram-negative microorganisms    
 
Escherichia coli 23 23 21 
 
Klebsiella pneumoniae 6 6   6 
 
Enterobacter cloacae 6 6 - 
 
Proteus mirabilis 4 - - 
 Non-typhoid salmonellae 3 3 - 
 
Other Enterobacteriaceae§ 3 2 - 
 
Pseudomonas aeruginosa 6 - 6 
 Other¶ 6 - - 
Total 57 46 33 
    
*These include Streptococcus mitis (n=3), Streptococcus oralis (n=2), haemolytic 
Streptococcus group C (n=2), haemolytic Streptococcus group G, and Streptococcus 
sanguis. 
†This group consisted of diphteroid rods (n=2), Propionibacterium acnes (n=2), 
Corynebacterium species, and Bacillus cereus. 
‡Values for Gram-negative microorganisms include identification of the family with the 
Enterobacteriaceae probe and identification of the genus or species. For Gram-positive 
microorganisms, identifications are made only for genus and species. 
§Other Enterobacteriaceae include Serratia marcescens, Klebsiella oxytoca, and Morganella 
morganii. 
¶These include Acinetobacter anitratus (n=2), nonfermenting Gram-negative rods (n=2), 
Fusobacterium nucleatum, and Aeromonas caviae. 
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The specificity of the species-specific probes was 95% (95% CI, 91 to 
98%); one isolate was identified by FISH as Haemophilus influenzae, while 
by conventional techniques, identification of the isolate was not compatible 
with Haemophilus influenzae but was given the description nonfermenting 
gram-negative rods. Sequence analysis of the isolate revealed 
Roseomonas species. Finally, fluorescence was observed with the 
Klebsiella pneumoniae probe for one isolate of Klebsiella oxytoca. The 
fluorescence in this sample was weaker than expected from our experience 
with the Klebsiella pneumoniae probe but sufficiently evident relative to 
background fluorescence to be considered a positive result. Sequence 
analysis of this strain confirmed the conventional identification as Klebsiella 
oxytoca. In two isolates, no fluorescence was observed for Staphylococcus 
aureus, as mentioned before. Thus, the sensitivity of the genus-specific 
probes was 98% (95% CI, 95 to 99.5%) and the specificity 100%. The 
sensitivity and specificity of the Enterobacteriaceae probe were 89% (95% 
CI, 84 to 94%) and 100%, respectively, because no fluorescence was 
obtained in four cases of Proteus mirabilis and one case of Morganella 
morganii. The turnaround time of FISH in routine practice was 3 h 45 min 
(range, 2.3 to 5.7 h) for Gram-negative and 4 h 12 min (range, 2.8 to 5.6 h) 
for Gram-positive microorganisms. Turnaround time data from final and 
provisional identifications were recorded for 178 (89%) samples. 
Provisional identification was made with 167 samples (94%); 11 blood 
cultures were growth positive after 12 a.m., and no growth was observed in 
subcultures the same day. Provisional identification was obtained for 107 
blood cultures with staphylococci (n=81), streptococci (16), enterococci (4), 
and Pseudomonas aeruginosa (6). In the other 60 cases, provisional 
culture identification was not possible, because the specific tests for these 
microorganisms, such as for Escherichia coli, were not included. The time 
gain by FISH compared to final conventional identification of 
microorganisms in blood cultures was quite substantial with a gain of more 
than 18 h (table 26). For yeasts, the time gain to final identification was 
more than 42 h (p<0.001). By FISH, Staphylococcus aureus could be 
differentiated from coagulase-negative staphylococci significantly faster 
than a provisional identification could be obtained (p<0.001). FISH provided 
identification more than 2 h faster than provisional culture identification of 
Pseudomonas aeruginosa.  
  
 
 
 
Table 26. Times to identification of FISH compared to those of culture identification* 
Provisional identification Final identification Microorganism FISH TTI (h) TTI (h) Time gain (h)† TTI (h) Time gain (h) 
      
Staphylococci 4.1 5.5 1.4 ± 1.2 22.9 18.8 ± 1.6 
Streptococci 4.5 5.8 1.3 ± 1.1 23.1 18.6 ± 1.3 
Enterococci 4.7 7.1 2.4 ± 1.3 23.1 18.4 ± 1.7 
Enterobacteriaceae 3.8   23.1 19.3 ± 1.5 
Pseudomonas aeruginosa 3.6 5.7 2.1 ± 0.9 23.7 20.1 ± 1.1 
Yeasts 4.9   47.0 42.1 ± 1.4 
      
*TTI, mean time to identification. 
†Difference in times to identification in hours (means ± standard deviations) between FISH and provisional culture. 
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Discussion 
Blood cultures have been performed for over a century, but little progress 
has been made in conventional culture-based methods to reduce the time 
to diagnosis [18]. Our evaluation of the performance of FISH for the 
identification of microorganisms in blood cultures and the time gain to direct 
identification showed that FISH is a valuable addition to the identification 
techniques available to the clinical microbiologist. In our study, for more 
than 90% of samples, we identified the genus name of gram-positive 
microorganisms or family name of Gram-negative microorganisms, and for 
79%, the species name was attributed to the microorganism. The number 
of microorganisms identified by the assay could be further increased by 
inclusion of probes for viridans streptococci, Enterobacter cloacae, and 
Proteus mirabilis. If these probes had been included, species identification 
of an additional 16 microorganisms (8%) would have been achieved. On 
the other hand, probes for Stenotrophomonas maltophilia and Clostridium 
perfringens, which are relatively uncommon in blood cultures, are included 
in the assay. The spectrum of isolates encountered in a laboratory of 
microbiology is of relevance to the probes that should be included in the 
FISH assay. Factors of influence are a hospital in-patient population, the 
presence of a haemato-oncology ward, reference functions for general 
practitioners, and the number of beds in the intensive care unit. As more 
probes become available, a setting-specific design of the FISH assay will 
be possible. The sensitivity and specificity of individual probes are good. In 
a few samples, the presence of large amounts of protein and blood cells 
hampered the interpretation of slides. The background fluorescence in 
these slides was too strong to be able to distinguish fluorescent bacteria 
from proteins and blood cells. Therefore, no clinically relevant conclusions 
could be drawn with FISH for these samples. This was the case for 4 out of 
200 slides. We did not find a common denominator for these samples, such 
as abnormally high levels of C-reactive protein, extremely high leukocyte 
count, or administration of parenteral nutrition. In one instance, 
Staphylococcus aureus was incorrectly identified as a coagulase-negative 
staphylococcus. This blood culture was obtained from a child with 
osteomyelitis who recovered well with flucloxacillin and who had also 
Staphylococcus aureus cultured from two other blood culture bottles. This 
is a major error, since misidentification of the species of staphylococci may 
greatly influence the decision to start optimal antimicrobial treatment.  
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Probe specificity was not optimal for the Klebsiella pneumoniae probe, 
which is due to cross-hybridisation because of high 23S rRNA homology 
between Klebsiella pneumoniae and Klebsiella oxytoca. In the other case of 
a false-positive FISH result, the possibility of a mixed infection should be 
considered. This blood culture was from a 1-month-old child with 
respiratory failure who had Haemophilus influenzae and Moraxella 
catarrhalis cultured from his sputum. Fluorescent bacteria were observed 
with the Haemophilus influenzae probe in FISH, but Roseomonas species 
were identified by sequence analysis of the microorganisms cultured. 
Roseomonas species are a known cause of bacteraemia, although 
uncommon [19,20]. Haemophilus influenzae and Roseomonas species are 
not closely related, and the Haemophilus influenzae probe is not 
complementary to the Roseomonas species 16S rRNA. Therefore, the 
presence of a mixed infection rather than cross-hybridisation of the probe 
may be the most likely explanation of the FISH result in this blood culture. 
The Enterobacteriaceae probe failed to hybridise in four cases of Proteus 
mirabilis and one case of Morganella morganii. This probe is not 
complementary to the 16S rRNA of both species, as previously described 
for Proteus species [8]. This should be considered when thinking of 
changes in antimicrobial treatment based on the presence or absence of 
fluorescence with the Enterobacteriaceae probe. FISH provides a same-
day identification of the majority of microorganisms in blood cultures, and 
the turnaround time is considerably faster than microbiological culture. This 
can allow a more rapid streamlining of antimicrobial therapy, which 
potentially reduces mortality and length of hospitalisation [5-7]. An 
important example is the time gain to microbiological diagnosis by FISH in 
cases of blood cultures with yeasts. Although the number of cases with 
candidaemia was small in this study, the time gain is very valuable in this 
serious condition of the frequently immunocompromised host, because 
FISH identification allows same-day adjustment of antifungal treatment. 
However, in our setting, the clinical value of identification provided by FISH 
seems limited in those blood cultures for which a provisional identification 
can be obtained. For example, Staphylococcus aureus bacteraemia is 
distinguished from bacteraemia caused by coagulase-negative 
staphylococci only 1 h faster with FISH than by provisional identification. 
The influence on antimicrobial management of FISH seems therefore not 
substantially different from the impact of the somewhat slower provisional 
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identification in these cases. However, a provisional identification can 
frequently not be obtained, because blood cultures are growth positive in 
the afternoon or microorganisms for which no provisional identification is 
possible, such as Enterobacteriaceae, are involved. In these cases, the 
results of same-day identification with FISH are very useful. FISH 
identification requires more than 4 hours after Gram staining before results 
are available. Most therapy interventions with regard to bloodstream 
infections are made at the time of phlebotomy and on the basis of 
notification of Gram-stain characteristics rather than on the basis of 
microbiological identification or susceptibility determination [21,22]. It is 
questionable whether clinicians will routinely wait 4 hours until FISH results 
are available before a start or change of antibiotics. A further reduction in 
the time to diagnosis of microorganisms in blood cultures by FISH therefore 
seems required to extend the potential influence on clinical management of 
FISH identification.  
In conclusion, FISH is a rapid and reliable technique for the identification 
of the vast majority of microorganisms in growth-positive blood cultures and 
provides faster identification than conventional culture. The applicability of 
FISH in routine practice is dependent on the probes included in the assay, 
the epidemiology of microorganisms isolated from blood cultures in an 
individual setting, and the local routine of provisional identification. A 
decrease in the turnaround time to less than 1 h would extend the potential 
use of FISH considerably. With the reduction in the turnaround time of the 
FISH procedure and extension of the panel of probes, FISH will become a 
very useful diagnostic tool in the diagnosis of bloodstream infections. 
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Abstract 
We evaluated a modified fluorescence in situ hybridization (FISH) assay 
for rapid (<1 h) identification of microorganisms in growth-positive blood 
cultures. The results were compared to those of the standard FISH 
technique and conventional culturing. The rapid identification of 
microorganisms with modified FISH can have important effects on clinical 
management of patients with bloodstream infections. 
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Introduction 
Blood culturing is the “gold standard” for diagnosis of bloodstream 
infections (BSI). Results of microbiological culturing can take up to several 
days, which may be too slow for a patient with a quickly deteriorating sepsis 
[1]. Therefore, techniques that speed up the diagnosis of BSI would be 
most useful. Several molecular techniques that permit faster identification 
of microorganisms in growth-positive blood cultures have become 
available, including fluorescent in situ hybridization (FISH) [2-4]. The 
standard FISH technique requires approximately 4 h to identification in 
routine practice [5]. In the present study we evaluated a new, rapid FISH 
procedure, modified to permit the identification of microorganisms in blood 
cultures within 1 h after Gram stain results. 
Materials and Methods 
Study set-up 
We included 100 consecutive growth-positive blood cultures from febrile 
patients admitted to our academic hospital. The present study was carried 
out partially in parallel with another study in which the time to identification 
by standard FISH was evaluated [5]. Ninety-four blood cultures were 
included in both studies; another 6 were included in the present study, 
resulting in a total of 100 samples. Blood cultures were included upon 
detection of growth by the blood culture machine (BACTEC 9240). Gram 
staining of the blood culture fluid was performed, and only the first positive 
blood culture from a single patient was included, except when different 
Gram stain characteristics were observed in subsequent blood cultures. 
Aliquots of blood culture fluid were used for standard and modified FISH 
and for routine identification by standard microbiological techniques. 
 
FISH  
The standard and modified FISH assays were performed with the 
seaFAST Sepsis Kit (SeaPro International B.V., Lelystad, The 
Netherlands), according the manufacturer’s protocols. Blood culture fluid 
was centrifuged at 1,200 rpm (∼450 x g) for 1 min, and the supernatant 
fraction was applied to a glass slide.  
  
Table 27. Tandem probes used for identification of microorganisms in blood cultures 
 
Probe* 
Fluorescein isothiocyanate 
(FITC) label 
 
Cy3 label 
 
Target 
Source or 
reference† 
     
Gram-positive     
 1 Staphylococcus genus‡ Staphylococcus aureus 16S 6 
 2 Streptococcus pyogenes Streptococcus agalactiae 16S 6 
 3 Streptococcus genus Enterococcus genus 16S, 23S 6,7 
 4 Enterococcus faecalis Enterococcus faecium 16S, 23S 7,8 
 5 Clostridium perfringens Streptococcus pneumoniae 16S 3,6 
 6 Eubacteria Enterobacteriaceae§ 16S 3,9 
Gram-negative     
 1 Escherichia coli/Shigella spp. Haemophilus influenzae 16S 10; S 
 2 Stenotrophomonas maltophilia Klebsiella pneumoniae 16S, 23S 3,10 
 3 Bacteroides spp/Prevotella spp. Pseudomonas aeruginosa 16S 6,11 
 4 Eubacteria Enterobacteriaceae§ 16S 3,9 
Yeast     
 1 Candida krusei Candida albicans 18S 3 
 2 Candida dubliensis Candida tropicalis 26S S 
 3 Candida glabrata Candida parapsilosis 18S 3 
 4 Eubacteria Pan-yeast 16S, 26S 9; S 
     
*The panel of probes was chosen on the basis of Gram stain results from blood culture fluid. 
†S, seaFAST Sepsis Kit (in-house development by the manufacturer). 
‡Bacteria were identified clinically as coagulase-negative staphylococci in case fluorescent bacteria were observed with the Staphylococcus 
genus probe but not with the Staphylococcus aureus probe. 
§Except Proteus spp., Morganella spp., and Providentia spp. 
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Slides with Gram-positive microorganisms were incubated in a lysis 
mixture, followed by an ethanol bath for all slides for permeabilisation. 
Tandem oligonucleotide probes were applied and hybridised to target rRNA 
(table 27). Unbound probe was washed off, and the slides were read by 
fluorescence microscopy (Olympus BX40, 100x). The modified FISH assay 
had two modifications from the standard protocol. First, nisin was added to 
the lysis mixture. Nisin is a lantibiotic peptide that forms pores in bacterial 
cell walls [12]. Second, the hybridisation and washing steps were done in a 
microwave oven instead of in a water bath. The hybridisation chamber was 
placed in a plastic box with water preheated to 46°C. This box was then 
placed in the microwave (SHARP R208) and heated to 48°C, after which 
cooling down to 46°C was allowed. This 4.5-min cycle was done four times 
for hybridisation and three times for washing. The turnaround time of this 
modified procedure was less than 1 h. 
 
Sequence analysis 
Sequence analysis of the DNA of microorganisms from all samples with 
results that were discrepant between FISH and microbiological culturing 
was performed. After DNA isolation (QIAamp Mini Kit; QIAGEN), 16S rRNA 
gene amplification was done, followed by sequence determination with an 
ABI Prism 3100 genetic analyzer (Applied Biosystems), according to the 
manufacturer’s instructions. 
Results 
The genus of the Gram-positive microorganisms tested was identified 
correctly by modified FISH in 96% of cases, whereas the family name was 
identified in 69% of Gram-negative microorganisms (table 28). The species 
name could be attributed to 81% of all microorganisms, and eubacterial and 
pan-yeast probes were positive for 100% of the relevant samples. There 
was only one discrepant case between modified and standard FISH. One 
strain of cultured Staphylococcus aureus (as confirmed by sequence 
analysis) was identified correctly with modified FISH, but in standard FISH, 
fluorescence was observed only with the Staphylococcus genus probe.  
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Table 28. Numbers of microorganisms with identification of species, genus, and 
family name by FISH* 
Number of microorganisms identified by 
FISH Microorganism 
Culture 
Genus Species Family† Genus/ 
species 
      
Gram-positive bacteria 
and yeasts 
     
Coagulase-negative 
staphylococci 
45 45 45   
Staphylococcus aureus 7 7 7   
Streptococcus pneumoniae 2 2 2   
Viridans streptococci 3 3 -   
Enterococcus faecalis 2 2 2   
Enterococcus faecium 2 2 2   
Other enterococci 1 1 -   
Candida albicans 4 4 4   
Candida tropicalis 1 1 1   
Other‡ 3 - -   
Totals 70 67 63   
      
Gram-negative bacteria      
Escherichia coli 15   14 14 
Klebsiella pneumoniae 3   3 3 
Enterobacter cloacae 3   3 - 
Other Enterobacteriaceae§ 3   2 - 
Pseudomonas aeruginosa 3   - 3 
Other¶ 5   - - 
Totals 32   22 20 
      
*A mixed infection was present in two cases. 
†Identification of the family was achieved with the Enterobacteriaceae probe. 
‡This group consisted of a diphteroid rod, Propionibacterium acnes, and Bacillus cereus. 
§These include Serratia marcescens, Klebsiella oxytoca, and Proteus mirabilis. 
¶Other Gram-negative microorganisms include Acinetobacter anitratus (2), nonfermenting 
Gram-negative rods (2), and Aeromonas caviae. 
 
The sensitivities of the Enterobacteriaceae- and genus-specific probes 
were 96% and 100%, respectively. Also, the sensitivities of the species-
specific probes for microorganisms encountered in our study were 100%, 
except for the Escherichia coli probe (14 of 15): for one isolate of cultured 
Escherichia coli, the abundance of blood cells and protein made it 
Modified FISH for identification of BSI 
127 
impossible to distinguish background fluorescence from fluorescent 
bacteria with the Escherichia coli and the Enterobacteriaceae probes. 
Identification by FISH was incorrect in two cases: fluorescence was 
observed with the Klebsiella pneumoniae probe for one isolate of cultured 
Klebsiella oxytoca, as confirmed by sequence analysis. Alignment of the 
23S rRNA sequence of Klebsiella oxytoca with the Klebsiella pneumoniae 
probe revealed two mismatches. FISH was not performed on the strain 
isolated in culture. In another sample, fluorescence was observed with the 
Haemophilus influenzae probe, but only nonfermenting gram-negative rods, 
which were identified as Roseomonas species by sequence analysis, were 
cultured [5]. 
Discussion 
We show that a modified FISH assay can identify the vast majority of 
microorganisms in blood cultures within 1 h. The performance of this assay 
was similar to the standard FISH technique and even identified 
Staphylococcus aureus in an extra case. To our knowledge, the use of a 
microwave oven for hybridisation of DNA probes in FISH has been 
described for chromosome analysis but not for identification of bacteria [13, 
14]. We observed a subjectively higher intensity of fluorescence with 
microwave-based FISH, which was also described previously [15]. The 
diagnostic spectrum of the FISH assay should be further enhanced by the 
inclusion of more probes; in particular, extra probes targeting gram-
negative microorganisms would be very useful. The false-positive FISH 
result that we observed with the Klebsiella pneumoniae probe for the 
cultured Klebsiella oxytoca may signal a problem with the specificity of this 
probe [5]. In contrast, in the case of the cultured Roseomonas species and 
its fluorescence with the Haemophilus influenzae probe, a mixed infection 
should be considered because of the lack of rRNA homology and on clinical 
grounds. The turnaround time of the modified FISH assay was less than 60 
min, which is a major time gain compared to standard FISH. This short 
turnaround time can have great impact on the management of patients with 
BSI (figure 7). Most therapeutic interventions occur after phlebotomy and 
upon notification of Gram stain results from blood culture fluids [15]. With 
the identification of microorganisms within 1 hour of Gram staining, it may 
become feasible for microbiologists to wait for FISH identification rather 
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than providing the clinician with only Gram-stain results. In conclusion, the 
modified FISH assay appears to be a promising tool for the early 
optimization of antimicrobial therapy for patients with BSI. 
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Figure 7. Fluorescent microscopy (magnification, x100) of microorganisms from blood culture fluids after modified FISH. Patient A was an 85-
year-old man with a history of relapsing urinary tract infections and chronic prostatitis. He presented with fever, pollakisuria, mental status 
alterations, and a crural wound after collapse. No painful prostate was found upon rectal examination. Leukocyturia was present, but no 
microorganisms were cultured from urine samples. Ceftriaxone treatment was initiated based on suspicion of urosepsis. Gram-negative rods 
seen in the Gram stain of the positive blood culture were identified as Pseudomonas aeruginosa by FISH within 1 hour, whereas final 
identification was obtained only the next morning. The figure shows fluorescence of the eubacterial probe with the Pseudomonas aeruginosa 
strain, which was identical to the fluorescence observed with the Pseudomonas aeruginosa-specific probe. Patient B was a 71-year-old 
woman who was admitted for debulking of a lung tumor because of vascular compression. Postoperatively, she developed fever and dyspnea. 
Empirically, clarithromycin and ceftriaxone therapy was started for possible postobstruction pneumonia. Yeasts seen in a Gram stain of blood 
culture fluid were identified with the species-specific probe as Candida albicans (shown in the figure) within 1 hour  by FISH. Culture 
identification was available late the next day. 
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Abstract 
Direct Etest was performed on growth-positive blood culture fluids after 
selection of antibiotics based on fluorescence in-situ hybridization (FISH) 
identification of the causative microorganisms. In 497 of the 517 bacterium-
antibiotic combinations results were interpreted identically to standard 
microbiological methods. The direct Etest proved to be reliable for rapid 
antibiotic susceptibility testing in positive blood cultures. 
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Introduction 
Bloodstream infections are associated with considerable mortality, which 
may range from 20 to 50% depending on factors like the pathogen involved 
and the underlying condition of the host [1]. Coagulase-negative 
staphylococci (CoNS), Staphylococcus aureus, Enterobacteriaceae, and 
Candida albicans are responsible for the majority of bloodstream infections 
[1]. Early institution of pathogen-directed therapy is of major importance to 
improve treatment outcome and to decrease the use of inadequate and 
broad-spectrum antibiotics [2]. Positive blood cultures are suitable to serve 
as ‘an inoculum’ for further laboratory testing because they usually yield 
only one pathogenic species. Several, mostly successful, approaches to 
speed up pathogen identification and antimicrobial susceptibility testing 
based on positive blood cultures have been described [3-9]. However, 
antibiotics for direct Etest and disk-diffusion have to be selected based on 
Gram-stain results. This still leaves open the final identification of the 
involved microorganism and as a consequence a relatively broad array of 
antibiotics to be tested. The recently described fluorescence in situ 
hybridisation (FISH) provides a rapid identification of bacteria from positive 
blood cultures allowing a more directed choice of antibiotics for 
susceptibility testing [10]. Therefore, in this study we used the FISH results 
for selection of antibiotics to be used in a direct Etest to assess antibiotic 
susceptibility of staphylococci and streptoccoci (both compared with disk 
diffusion on subcultures) and of Enterobacteriaceae (compared to VITEK2 
results on subcultures) from BACTEC 9240 positive blood cultures. 
Methods 
Microorganisms of growth-positive blood cultures (BACTEC aerobic/F, 
anaerobic F and Peds/F bottles) after incubation in BACTEC 9240 (Becton 
Dickinson, USA) were identified by fluorescence in situ hybridization (FISH) 
as described before [10]. Based on this identification antibiotics were 
selected for direct susceptibility testing by Etest (AB-Biodisk, Sweden). For 
staphylococci and Enterobacteriaceae 100 µL of growth-positive blood 
culture fluid was plated on Mueller Hinton agar. Streptococci-containing 
culture fluids were plated (100 µL) on Mueller Hinton agar supplemented 
with 5% sheep blood and incubated in 5% CO2. All plates were incubated at 
37°C. Oxacillin MICs were read after 36-48 h, all oth er MICs after 16-24h. 
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In addition, bacterial identification and antibiotic susceptibility testing was 
done according to standard microbiological procedures on subcultures. In 
our laboratory, this involves disk susceptibility testing for Gram-positive and 
VITEK2 testing for Gram-negative microorganisms. All interpretations 
(resistant, susceptible or intermediate) were according to the criteria of 
Clinical and Laboratory Standards Institute (CLSI) [11]. Erythromycin 
induced clindamycin resistance, as determined by disk-diffusion, was not 
included in our comparisons. Differences between direct Etest versus 
classical methods were classified as minor errors (one test intermediate 
susceptible vs. resistant or susceptible in the other test), major error 
(resistant vs. susceptible) and very major error (susceptible vs. resistant). 
 
 
Table 29. Results of Etests performed on 100µL of growth-positive blood cultures 
after identification of genus or species by FISH 
Microorganism Number of culture 
positive samples 
  
Staphylococci (n = 94) 18 
 
Staphylococcus aureus 76 
 Coagulase-negative staphylococci  
  
Streptococci (n = 10) 
 
 
Beta-haemolytic Streptococcus group A 1 
 
Beta-haemolytic Streptococcus group C 2 
 
Streptococcus mitis 2 
 
Streptococcus oralis 2 
 
Streptococcus pneumoniae 2 
 
Streptococcus sanguis 1 
  
Enterobacteriaceae (n = 38) 
 
 
Enterobacter cloacae 5 
 
Escherichia coli 19 
 
Klebsiella oxytoca 1 
 
Klebsiella pneumoniae 5 
 
Morganella morganii 1 
 
Proteus mirabilis 3 
 
Salmonella enteritidis 1 
 
Salmonella typhimurium 2 
 
Serratia marcescens 1 
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Results and discussion 
In total, 189 growth-positive blood cultures were included in the study 
[10]. Of these, 142 containing one microbial species of staphylococci, 
streptococci or Enterobacteriaceae were analysed for direct antibiotic 
susceptibility (table 29). Comparison of the direct Etest and standard 
methods of antibiotic susceptibility testing according to the classification in 
different categories is shown in table 30. For all evaluable staphylococcal 
strains (both antibiotic susceptibility tests performed), clindamycin and 
penicillin susceptibility were concordant in both the direct Etest and by disk 
diffusion. Ten CoNS strains yielded discrepant results for erythromycin and 
oxacillin. One very major error was observed: the direct Etest reported a 
MIC of 0.094 mg/L for oxacillin, whereas disk diffusion was interpreted as 
resistant (no zone of inhibition). 
For streptococci identical interpretation was observed with both methods 
for penicillin susceptibility. One Streptococcus oralis strain demonstrated 
one minor and one major error for erythromycin and clindamycin, 
respectively. The other major error (clindamycin) was found for a 
Streptococcus mitis strain.  
For all evaluable strains of Enterobacteriaceae the direct Etest and the 
VITEK2 results obtained with cefotaxime were identical. Four E.coli strains 
were responsible for one minor error (amoxicillin) and three major errors 
(one for gentamicin and two for trimethoprimsulfamethoxazole), 
respectively. The other two major errors, both with gentamicin, were 
observed for one Proteus mirabilis strain and one Salmonells enteritidis 
strain. Our data demonstrate that the direct Etest provides reliable antibiotic 
susceptibility interpretation for CoNS, S. aureus , streptococci and 
Enterobacteriaceae, the major groups of microorganisms causing 
bloodstream infections. This is in accordance with the findings of Hong et 
al. for Gram-positive cocci and Chang and colleagues for yeasts [6,12]. In 
combination with identification by FISH [10], which refines the choice of 
empirical antibiotics for therapy in addition to Gram-stain, antibiotics may 
be adjusted based on direct Etest results about 1 day earlier compared to 
standard microbiological methods testing subcultures. For cefotaxime and 
penicillin the Etest provided reliable results for all strains tested with these 
antibiotics. 
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Table 30. Comparison of direct Etest versus standard microbiological methods for 
antibiotic susceptibility testing 
Microorganism 
No. of 
evaluable 
bacterium 
antibiotic 
combinations 
Identical 
(%) 
No. of 
minor 
errors 
(%) 
No. of 
major 
errors 
(%) 
No. of 
very 
major 
errors 
(%) 
      
Staphylococci 358 348 (97) 4 (1.1) 5 (1.5) 1 (0.3) 
 Erythromycin 90 84 (93) 4 (4) 2 (2) 0 
 Clindamycin 91 91 (100) 0 0 0 
 Penicillin 90 90 (100) 0 0 0 
 Oxacillin 87 83 (95) 0 3 (4) 1 (1) 
      
Streptococci 26 23 (88) 1 (3.8) 2 (7.7) 0 
 Erythromycin 9 7 (78) 1 (11) 1 (11) 0 
 Clindamycin 8 7 (88) 0 1 (12) 0 
 Penicillin 9 9 (100) 0 0 0 
      
Enterobacteriaceae 133 126 (95) 2 (1.5) 5 (3.8) 0 
 Amoxicillin 31 29 (94) 2 (6) 0 0 
 Gentamicin 34 31 (91) 0 3 (9) 0 
 Trimethoprim-
sulfamethoxazole 
34 32 (94) 0 2 (6) 0 
 Cefotaxime 34 34 (100) 0 0 0 
      
 
In 5.3% of the cases (n=20) the Etest produced a different result in 
comparison to standard methods. Except for one very major error all Etest 
results were more conservative than obtained by VITEK or disk diffusion, 
which is in agreement with the findings of Hong et al. [6]. From the results 
of our study, it can be concluded that there is hardly any risk of inadequate 
antibiotic treatment of patients by using results of a direct Etest. A 
drawback, however, is that by direct Etest no erythromycin induced 
clindamycin resistance for staphylococci is detected. By disk diffusion 11 
out of 76 CoNS and one out of 18 S. aureus strains showed this inducible 
resistance. Other investigators have studied direct antibiotic susceptibility 
testing of fluid from growth-positive blood cultures on automated systems 
like VITEK2 and BD Phoenix [3-5,7,8].  
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Most studies report excellent data for the direct test [3,5,7,8]. Compared 
to those studies our data demonstrated a relatively high percentage of 
major errors for Enterobacteriacea and streptococci. Probably, this was due 
to the comparison of the direct Etest with different other standard 
microbiological methods for antibiotic susceptibility testing (disk diffusion or 
VITEK), while in other studies the direct method was compared with the 
same method after inoculum adjustment. In conclusion, direct Etest for the 
appropriate antibiotics as selected on basis of FISH results, may be a 
valuable tool for timely adjustment of empirical antimicrobial therapy in 
bloodstream infections. 
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Abstract 
We applied real-time broad-range polymerase chain reaction (PCR) to 
detect bacteraemia in blood from febrile patients. Interpretation of 
amplification results in relation to clinical data and blood culture outcome 
was complex, although the reproducibility of the PCR results was good. 
Sequencing analysis of the PCR products revealed the presence of 
Burkholderia species DNA while no Burkholderia species grew in culture. 
The source of this contamination was shown to be the commercial DNA 
isolation kit used in the automated MagNA Pure Isolation Robot. A high 
degree of suspicion is required when uncommon or unexpected pathogens 
are diagnosed by molecular methods as clinical consequences can be 
serious. 
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Introduction 
Diagnostic techniques for detection of microbial pathogens in human 
samples have developed rapidly over the last two decades. Conventional 
microbiological techniques are more and more supplemented or replaced 
by molecular techniques, such as the (real-time) polymerase chain reaction 
(PCR). A major drawback of the application of PCR is the high risk of 
contamination of samples by exogenous DNA. In recent years, a step 
forward has been made with the introduction of automated ‘closed’ systems 
for DNA isolation and PCR. Compared to manual techniques, these 
systems permit better standardization and reproducibility, and reduce the 
risk of contamination. Real-time PCR with automated detection is an 
example of a ‘closed’ system with the added advantage of quantification of 
the DNA present in the samples [1,2]. This technique has been used to 
detect and quantify blood borne microbial pathogens including HIV and 
HCV, and has led to the application of ‘viral load’ determination as an 
important tool in clinical practice [3,4]. In contrast, detection of bacteria in 
blood by real-time PCR has been described in only a few studies; one is a 
study on meningococcaemia in children [5]. This study showed high 
sensitivity and good correlation of disease severity with quantity of 
meningococcal DNA. In principle, it is possible to detect any bacterial 
species with a real-time broad-range PCR assay based on the 16S rRNA 
gene [6]. This procedure is of course only applicable to clinical samples 
that, in the absence of infection, are sterile. As such, real-time broad-range 
PCR should enable rapid diagnosis of bacteraemia and quantification of a 
‘bacterial load’ as a potential marker for severity of infection. Furthermore, 
quantification of the bacterial load could be useful for monitoring therapy, 
for example for determination of the effect and required duration of 
antibiotic treatment. In this report, we describe the application of a real-time 
PCR assay to detect bacteraemia. We present an unexpected problem 
caused by contamination from an unexpected source and discuss the 
potential clinical consequences. 
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Materials and methods 
Data collection 
After informed consent, those patients were included in the study in whom 
blood cultures were clinically indicated and who were admitted to the 
Department of Internal Medicine or the Department of Haematology, or 
presented at the Emergency Department of our university hospital. Blood 
collection tubes for PCR were routinely added to blood culture sets; blood 
for culture and PCR was drawn simultaneously. Each time an individual 
blood culture was obtained, a sample for PCR was also collected so that 
multiple blood samples from a single patient at multiple points in time could 
be included. 
 
Sample processing 
Blood for culture was collected in Bactec Plus Aerobic/F and Anaerobic/F 
bottles (Becton Dickinson), and routinely processed in the Microbiology 
Laboratory. Blood for PCR was collected in a 3 mL EDTA tube (Becton 
Dickinson) and stored at -20°C. Isolation of DNA was performed using the 
commercially available Total Nucleic Acid Isolation Kit (Roche Diagnostics) 
with the MagNA Pure LC Instrument (Roche Diagnostics). DNA was 
isolated from 200 µL whole blood and eluted in 50 µL according to the 
manufacturer’s instructions. Isolated DNA was amplified the same day 
using universal primers and probe targeting the 16S DNA region of bacteria 
with the real-time TaqMan 7000 System (Applied Biosystems) [6]. PCRs of 
50 µL were performed using the commercial TaqMan Universal PCR 
Mastermix (Applied Biosystems) and included forward and reverse primers 
(900 nM each), a TaqMan probe (200 nM) and 20 µL of template DNA. 
DNA isolation (500 pfu of lambda phage) and PCR inhibition (separate (low 
level) spiking with 50 cfu equivalents Escherichia coli DNA to detect slight 
inhibition) controls were included for each individual sample whereas each 
PCR run included five samples without DNA (no template controls). 
Automated sequencing of the PCR products (466 basepairs) was 
performed with the Dye Terminator Kit on the ABI Prism 310 Genetic 
Analyzer Applied Biosystems). 
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Analysis 
Results of blood cultures and PCR were collected. A quantity of more 
than 200 copies of target DNA per PCR (mean cycle threshold (Ct) value 
32.03) was defined as cut-off value for a positive PCR result to distinguish 
between infection and baseline level of bacterial DNA present in blood of all 
(healthy) individuals [7]. PCR results were evaluated in the context of blood 
culture outcome and clinical data. On basis of interim analysis of PCR 
results, we decided to temporarily stop PCR analysis of more blood 
samples for reasons described in this article. 
Results and discussion 
Ninety-eight blood samples from 65 patients were randomly selected for 
interim-analysis and tested by PCR. In six samples the PCRs showed 
partial inhibition; the DNA isolation control failed for two other samples. The 
DNA isolation probably failed because of clotting of the blood in the pipette 
during DNA isolation as was observed for one sample. All eight samples 
were excluded from further analysis. Thus, 90 PCR results were available 
for further evaluation, 13 of which (14%) were positive in blood cultures. 
The microorganisms isolated from blood cultures were: coagulase-negative 
staphylococci (6), E. coli (2), Enterococcus faecalis (1), Campylobacter 
jejuni (1), Propionibacterium acnes (1), Bacteroides fragilis (1), and 
Streptococus pyogenes (1). Results of PCR compared with blood culture 
outcome are illustrated in figures 8a and 8b, and summarised in figure 9. 
Whole blood PCR was positive in 10/13 samples with positive blood 
cultures, including samples of patients 1 and 2 as illustrated in figure 8a. In 
the three growth-positive samples, for which no positive amplification signal 
was detected by PCR, coagulase-negative staphylococci were identified by 
culture. This may be due to sub-optimal lysis of staphylococci. The addition 
of an extra lysis step before automated DNA isolation may be necessary to 
increase DNA isolation efficiency from gram-positive bacteria, especially 
when the initial load is low.  
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Figures 8a and 8b. Real-time PCR on blood samples. (A) Patients 1 and 2 had blood 
cultures positive for CoNS. Patients 3–5 had no growth in their blood culture: patient 3 had a 
respiratory infection; patient 4 was admitted for persisting unexplained fever. He was on 
antibiotics and received dexamethason for Wegener’s disease; patient 5 was neutropenic 
and receiving antibiotics. Patient 6 had C. jejuni bacteraemia. (B) Sample 6a had a negative 
blood culture and was drawn 17 hours prior to samples 6b and c. Those were taken at 
exactly the same time, but only sample 6b showed growth with C. jejuni in blood culture. 
Patient 7 showed growth of CoNS only in culture 7a that was drawn 1 day prior to sample 
7b. NTC, no template control; CoNS, coagulase-negative staphylococci. 
6a 
6b,c 
7a,b 
B 
NTC 3 5 1 2 4 
A 
Universal PCR for detection of BSI 
145 
Blood cultures were negative in 77 samples, 23 (30%) of which showed 
amplification signals similar to the no template controls, as illustrated by the 
amplification signal of patient 3. These signals were at the level of 
previously described contaminated PCR mix reagents which contain traces 
of E. coli DNA present in the Taq DNA polymerase and UNG enzyme [8]. 
The other 54 samples (70%) yielded a PCR product; these included blood 
samples of patients that were treated with antibiotics (i.e., patients 4 and 5) 
and samples with different blood culture outcome at multiple points in time 
(i.e., patients 6 and 7). In patients 4 and 5 there was a high degree of 
suspicion of bacteraemia as they were immunocompromised hosts with 
central venous catheters. As conventional culture was hampered by use of 
antibiotics in these patients, the positive PCR result was most interesting. 
Patient 6 had C. jejuni bacteraemia, which was only detected by one blood 
culture (6b); another culture (6c) obtained at the same time was negative. 
PCR however showed full reproducibility of amplification for both samples 
as illustrated in figure 8b. In addition, sample 6a, which was collected 17 h 
prior to samples 6b and 6c, suggests that PCR could possibly detect 
bacteraemia in an earlier stage than blood culture. Patient 7 had a first 
positive blood culture with coagulase-negative staphylococci (7a) while a 
second culture (7b), drawn one day later when treated with antibiotics, was 
negative. PCR showed amplification in both samples. This may be 
explained by the detection of bacterial DNA fragments from blood and 
leukocytes under antimicrobial treatment. Intrigued by the amplification 
signal of the blood sample of patient 4, who was still admitted to our 
hospital with persistent unexplained fever under antibiotics, we instantly 
performed sequencing analysis of this PCR product. To our surprise, 
Burkholderia species were identified. We considered the possibility of 
clinical Burkholderia cepacia bacteraemia in this patient. Burkholderia 
species include Burkholderia pseudomallei and B. cepacia which can be 
isolated from water and soil. B. pseudomallei is endemic in South-East Asia 
and Australia and causes melioidosis that is frequently bacteraemic. 
However, melioidosis is very rarely seen in The Netherlands and, if 
encountered, only as imported tropical disease [9]. Our patient had not 
travelled to an endemic area. B. cepacia is most frequently encountered in 
patients with cystic fibrosis, but also in other immunocompromised patients, 
and is usually a nosocomial infection [10]. In the latter, a common source is 
frequently found in the hospital, like contaminated intravenous fluid bags or 
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even contaminated chlorhexidine bottles used for disinfection [11,12]. 
Nevertheless, the likelihood of clinical Burkholderia bacteraemia seemed 
low although our patient was immunocompromised. A few days later, 
sequence analysis of nine out of 12 other blood samples also showed 
Burkholderia species (seven samples) or related bacteria such as Ralstonia 
species and beta Proteobacterium with identical sequences and 98% 
match to the specific organism. These samples were randomly chosen and 
included four growth-positives (Ct values 29.99 30.80); in all of them 
Burkholderia species were identified. The range of Ct values for the nine 
samples was 28.21–31.82 as compared to 33.21–34.78 for the three 
samples in which no organism could be identified. In addition, sequence 
analysis of the amplification product of three no template controls (Ct values 
35.56–37.14) did not identify any bacterial species. This turned the odds 
even more against clinical infection as these samples were obtained from 
different departments, which reduced the likelihood of a nosocomial source. 
The presence of cross-contamination was strongly suspected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Mean cycle threshold values of PCR results in relation to blood culture outcome 
(number of samples). Error bars indicate standard deviation. Abbreviations: pos, positive; 
neg, negative. 
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At the same time, Burkholderia species and related bacteria were found 
using the same DNA extraction kit (i.e., Total Nucleic Acid Isolation kit from 
Roche Diagnostics) on blood products in a research setting at the Sanquin 
Blood Bank, Amsterdam. This study was conducted using different MagNA 
Pure instruments with different batches of reagents. Sequence analysis 
showed that the amplification products obtained at the Blood Bank were 
similar to those obtained in our laboratory. This prompted us to search for a 
common source of cross-contamination. Direct real-time amplification of 
reagents from the DNA extraction kit was performed. Amplification signals 
were obtained from wash buffer-III and elution buffer from multiple batches 
of this kit; PCR amplification of other buffers was inhibited. No bacteria 
could be cultured from the buffers, but sequencing analysis of PCR 
products amplified from the buffers revealed Burkholderia sp. and related 
bacteria. Similar results were obtained for two other DNA isolation kits also 
commercially available from Roche Diagnostics (i.e., Large Volume and the 
DNA Isolation kit III). These data strongly suggest that the cross-
contamination originates somewhere during the production process of 
these three DNA isolation kits. Although cross-contamination of reagents 
used in PCR (i.e., Taq DNA polymerase) is well known, contamination of a 
commercially available DNA isolation kits has been described only twice 
previously [13,14]. Both studies independently showed that Qiagen 
columns were contaminated during the production process with Legionella 
DNA, because these columns were continuously flushed with water. To our 
knowledge, this is the first study describing commercially available isolation 
kits for the MagNA Pure LC Instrument as source of cross-contamination. 
This standardised ‘closed system’ for DNA isolation is a very useful 
improvement for pathogen-specific molecular diagnostics. However, as for 
now, it turns out to have no use for the isolation of DNA for broad-range 
16S rDNA PCR assays. Guaranteed DNA-free kits are needed to make this 
isolation system applicable to broad-range molecular diagnostics. The 
reproducibility of PCR results and concordance between clinical data and 
blood culture results with amplification signals in our study is intriguing. 
Other studies suggest that universal PCR can improve the detection of 
bacteraemia, especially in case of prior antibiotic use [15,16]. These 
studies do not use automated DNA isolation and real-time PCR to detect 
DNA of bacteria.  
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Automated DNA isolation and subsequent real-time PCR may possibly 
detect interfering sources of bacterial DNA, like contaminated mastermixes 
or DNA isolation kits, but also baseline levels of bacterial DNA in blood as a 
result of increased sensitivity. Nevertheless, we think that our results are 
encouraging and more than the effect of cross-contamination only. 
Sequence analysis showed the presence of Burkholderia species in 10 of 
13 samples (including four growth-positives), but in seven of them a 
background sequence was present. Three patients without a background 
sequence had negative results for both PCR and blood culture. 
Unfortunately, the background sequences were not distinct enough to allow 
analysis and identification. Possibly, the presence of contaminating traces 
of DNA in the DNA isolation buffers is concentrated during the DNA 
isolation procedure, so that the amount of contaminating DNA is more after 
elution than the actual DNA of the infectious agent. The fact that the 
amplification reactions are in concordance with the clinical data may be 
related to the presence of blood components during bacteraemia that 
function as PCR enhancer for DNA of both infectious and contaminating 
agents, as is known from bovine serum albumins [17]. The subsequent 
sequencing reaction will show the sequence of the most prominent DNA 
amplification product, being the DNA from Burkholderia. After removal of 
cross-contamination, the value of real-time PCR to detect bacteraemia can 
be evaluated further. Molecular techniques including universal PCR are 
more and more incorporated in routine microbiological diagnostics, but a 
guaranteed contamination free environment is required. Contamination can 
originate from an unexpected source and interfere at any stage in the 
diagnostic process, as we show in this study. Presence of contamination is 
especially worrisome when the DNA appears to be from known pathogens. 
Fortunately, Burkholderia species are rarely isolated in our country and 
therefore we suspected immediately that contamination was at stake. If 
Burkholderia species had been endemic in our setting or if a relevant 
species such as Pseudomonas aeruginosa had been detected, it would 
have put the patient at risk for wrong diagnostic procedures and incorrect 
antimicrobial therapy. A high degree of suspicion is required when 
uncommon or unsuspected pathogens are diagnosed by molecular 
methods, as it is for unexpected findings when using conventional 
techniques. 
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Abstract 
Background: PCR detection of bacterial DNA in blood offers a faster 
alternative to blood culture and is unaffected by prior use of antibiotics. We 
evaluated the performance of real-time PCR assay for quantitative 
detection of Staphylococcus aureus and Enterococcus faecalis 
bacteraemia directly in blood of critically ill patients, without prior cultivation. 
Methods: Whole blood samples for PCR were obtained simultaneously to 
blood samples for culture from patients admitted to the Intensive Care Unit 
of our hospital. After extraction of DNA from 200µL of blood, real-time PCR 
was performed for specific detection and quantification of S. aureus and E. 
faecalis DNA. PCR results were compared to blood culture outcome. 
Results: The sensitivity of the S. aureus PCR was 75% and that of the E. 
faecalis PCR was 73%, both with high specificity (93 and 95%). PCR 
reactions were positive for 10 blood samples with negative blood cultures in 
the S. aureus PCR and 7 with the E. faecalis PCR. The majority of these 
PCR results were likely to represent clinically true positive results for S. 
aureus or E. faecalis infection.  
Conclusion: Quantitative detection of S. aureus and E. faecalis DNA in 
blood by real-time PCR enables the rapid diagnosis of bacteraemia, also 
under antimicrobial treatment.  
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Introduction 
Gram-positive microorganisms, especially Staphylococcus aureus and 
Enterococcus faecalis, account for the majority of episodes of bacteraemia 
in patients admitted to the Intensive Care Unit (ICU) [1,2]. The occurrence 
of bacteraemia may be an ominous prognostic factor in these patients with 
an attributable mortality of 16-25% [3,4]. As such, the early recognition of 
bacteraemia is important to institute adequate antimicrobial therapy [5,6]. At 
present, blood culture is the diagnostic gold standard, but it may take more 
than two days before results are available. Furthermore, the sensitivity of 
blood cultures is markedly reduced if blood samples are obtained after the 
initiation of antimicrobial treatment [7,8]. Therefore, the clinical impact of 
routine blood cultures is often limited [9,10].  
PCR detection of bacteraemia directly in blood samples, without prior 
cultivation, offers a faster alternative to the blood culture and is presumably 
unaffected by the prior use of antibiotics [11-14]. An additional advantage of 
the use of a real-time PCR assays is the possibility to quantify the amount 
of bacterial DNA. The PCR assays can be aimed at universal detection of 
bacterial DNA in blood or target a specific microorganism like Neisseria 
meningitis or Streptococcus pneumoniae [14-16]. 
In this study we evaluated the performance of two real-time PCR assays 
for the direct, quantitative detection of S. aureus and E. faecalis 
bacteraemia in blood samples of patients admitted to the ICU. 
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Methods 
Blood samples 
Blood samples for PCR were collected simultaneously to blood cultures 
from patients admitted to the ICU of our university hospital between 
November 2003 and December 2005. As such, a total of 2000 blood 
samples from 552 patients was collected and stored at –20ºC. From these 
stored samples, two cohorts of blood samples were selected for S. aureus 
PCR (SA cohort) and E. faecalis PCR (EF cohort), each including all blood 
samples from 80 individual patients. For the SA cohort, blood samples from 
all patients (n=16) with S. aureus isolated from simultaneous blood culture 
were selected and combined with blood samples from 64 random patients 
with no growth of S. aureus in their blood cultures. The same principle was 
applied to select blood samples from patients (13 with positive blood 
cultures and 67 with negative cultures) for the EF cohort. This study was 
approved by the Medical Ethical Committee of our hospital. Clinical data of 
this cohort are described elsewhere [17]. 
 
Blood cultures 
Blood was collected for routine culture in blood culture bottles 
(BACTECTM Aerobic/F, Anaerobic/F, Becton Dickinson) and incubated in 
the automated blood culture system (BACTEC 9240, Becton Dickinson). 
After automatic detection of growth, microorganisms were identified with 
standard microbiological techniques. 
 
DNA isolation 
Whole blood samples for PCR were collected in 3mL EDTA tubes 
(Becton Dickinson); bacterial DNA was isolated from 200µL blood. Prior to 
DNA isolation, 250 cfu Escherichia coli (=50 cfu equivalents/PCR; ATCC 
strain 25922) were spiked to each blood sample as extraction control. To 
remove haemoglobin, 1000µL of Triton-Tris-EDTA (TTE: 20mM Tris-HCl of 
pH 8.3, 1mM EDTA, 1% Triton x-100) was added to the blood sample and 
centrifuged at 12000 rpm for 10 minutes. The supernatant fraction was 
removed followed by resuspension of the pellet in 1000µL TTE. This step 
was repeated but with resuspension in 200µL of Tris-EDTA (TE: 10mM 
Tris-HCl of pH 8.3, 1mM EDTA).  
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Bacterial DNA was then extracted from this 200µL with the QIAamp DNA 
Mini Kit (Qiagen, Germany) according to the manufacturer’s instructions. 
The extract was eluted in 100µL of elution buffer. 
 
PCR assays 
DNA amplification and detection was performed on a TaqMan 7000 
System (Applied Biosystems, Foster City, CA, USA). The following reaction 
mixture (50µL) was used in the PCR assay: 25µL TaqMan Universal PCR 
Mastermix (Applied Biosystems), 20µL of extracted DNA and 5µL of 
specific primers and probes as described below. Standard PCR cycling 
conditions were applied: heating at 95°C for 10 minutes followed by 45 
cycles of 95°C for 15 seconds and 60°C for 1 minute. 
We designed a set of primers and probe for specific amplification of the 
16S rRNA gene of S. aureus. The sequences were 5’-CATCGGAAACATT 
GTGTTCTGTAT-3’ and 5’-TTTGGCTGGAAAATATAACTCTCGTA-3’ for 
the forward and reverse primer. The probe sequence was: 5’-FAM-
AAGCCGTCTTGATAATCTTTAGTAGTACCG-3’. The technical specificity 
of this PCR set was evaluated with various related microorganisms 
including multiple strains of coagulase-negative staphylococci, streptococci 
and enterococci. No false-positive reactions were observed ensuring 
adequate specificity of the PCR assay. The primers and probes that were 
used to amplify and detect the 16S rRNA genes of E. faecalis and E. coli 
are described elsewhere [18,19]. A standard curve of S. aureus or E. 
faecalis DNA consisting of four 10-fold dilutions of a stock solution of 
50.000 cfu equivalents/PCR was included in each run for automatic 
calculation of the bacterial DNA load (BDL). This standard curve was 
generated after isolation of pooled culture-negative blood samples spiked 
with the relevant quantity of bacteria. 
 
Analysis of PCR results 
The DNA of each blood sample was tested in three separate reactions: 1) 
diagnostic PCR to detect either S. aureus or E. faecalis DNA, 2) detection 
of E. coli DNA to evaluate extraction efficiency, and 3) detection of 50 cfu 
equivalents of S. aureus DNA or E. faecalis DNA added to the PCR mixture 
to test possible specific template inhibition.  
Chapter 9 
156 
Blood samples with discrepant results between blood culture and PCR 
were retested (including DNA isolation and PCR). Also, if a blood sample 
did not pass the process or inhibition control, the sample was retested. In 
case these control reactions failed twice, the sample was considered 
inhibited or not isolated with sufficient efficacy and excluded from further 
analysis.  
 
Definitions 
Bacteraemia was defined as the isolation of a known pathogen from 
blood cultures. Blood samples were considered to be drawn under 
antimicrobial treatment if antibiotics had been administered less than 48 
hours ago. PCR results were defined as positive when amplification signals 
were observed, and negative if such a signal was absent with control 
reactions. Positive PCR reactions for samples with negative simultaneous 
blood cultures were considered to be ‘likely’, ‘possible’ or ‘unlikely’ to 
represent a clinical true positive result. PCR results were defined clinically 
‘likely’ if S. aureus or E. faecalis was isolated from any microbial culture 
within 24 hours around the time point of blood sampling; ‘unlikely’ if other 
microorganisms were isolated from those cultures; and ‘possible’ if no 
microorganisms were isolated from any microbial culture and S. aureus or 
E. faecalis infection was possible on clinical grounds. 
 
Statistical analysis 
Data are described as numbers (%) for dichotomous and median (range) 
for continuous variables. PCR results were compared to blood culture 
outcome in 2x2 tables and sensitivity, specificity and predictive values were 
calculated. The χ2 test or Fisher’s Exact test if appropriate were used to 
compare categorical variables; the Mann-Whitney U test for continuous 
variables. A p-value of less than 0.05 was considered statistically 
significant. 
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Results 
Blood samples 
A total of 175 blood samples were included in the SA cohort and 180 in 
the EF cohort. The clinical characteristics of the study population have 
been described elsewhere [17]. S. aureus was isolated from 30 (17%) 
simultaneous blood cultures in the SA cohort, including a methicillin-
resistant strain in two blood samples from one patient, and E. faecalis was 
present in 16 (9%) of the blood cultures in the EF cohort.  
 
Table 31. Microorganisms isolated from blood cultures in the Staphylococcus 
aureus and Enterococcus faecalis cohorts 
Microorganism 
Cohort SA 
(n = 175) 
Cohort EF 
(n = 180) 
   
Coagulase-negative Staphylococcus 8 9 
Staphyococcus aureus 30 0 
Enterococcus faecalis 1 16 
Enterococcus faecium 2 4 
Bacillus species 1 1 
Candida species 1 1 
Other Gram-positive* 1 0 
   
Escherichia coli 1 0 
Pseudomonas aeruginosa 2 1 
Proteus mirabilis 0 2 
Enterobacter cloacae 0 1 
Serratie marcescens 0 1 
Other Gram-negative† 2 2 
   
No microorganisms isolated 129 147 
   
NOTE. Data are numbers of microorganisms. Polymicrobial infection was present in 3 
respectively 5 blood cultures in the SA and EF cohorts. SA, Staphylococcus aureus; EF, 
Enterococcus faecalis. 
*Streptococcus sanguis was cultured from this blood culture bottle. 
†Acinetobacter species and Hafnia species were isolated from these blood cultures. 
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PCR assays 
The analytical sensitivity of all three PCR assays, as determined in 
spiked, culture-negative, whole blood samples, was below 5 cfu 
equivalents/PCR. Analytical specificity was evaluated against a wide variety 
of related strains and no aspecific amplification reactions were observed. In 
addition, no false-positive amplification reactions were observed when 
another microorganism than the target microorganism was isolated from 
the blood culture (table 31). This provides evidence that the specificity of 
the S. aureus and E. faecalis PCR assays was adequate.  
 
PCR results 
PCR amplification results for detection of S. aureus and E. faecalis DNA 
in blood were available for 163 (93%) and 177 (98%) blood samples. This 
includes 49 (14%) blood samples that were tested twice because the 
control reactions failed the first time. Fifteen (4%) blood samples were 
excluded from further analysis because of repeated inadequate extraction 
(n=10) or inhibition (n=5) controls. Two of these excluded blood samples 
grew S. aureus in simultaneous conventional culture, and one grew E. 
faecalis. PCR amplifications were positive for 75% and 73% of blood 
samples with S. aureus or E. faecalis isolated from simultaneous blood 
cultures (table 32).  
 
Table 32. Detection of Staphylococcus aureus (A), and Enterococcus faecalis (B) 
bacteraemia by PCR versus blood culture 
A. Staphylococcus aureus 
 Blood culture result  
PCR result Positive Negative Total 
 
   
Positive 21  10  31 
Negative  
 7  125 132 
Total 28 135 163 
   
NOTE. Data are numbers of blood samples. The sensitivity of PCR compared to blood 
culture outcome was 75%, the specificity was 93%, the positive predictive value was 68% 
and the negative predictive value was 95%. 
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B. Enterococcus faecalis 
 Blood culture result  
PCR result Positive Negative Total 
 
   
Positive 11 7 18 
Negative 4 155 159 
Total 15 162 177 
 
   
NOTE. Data are numbers of blood samples. The sensitivity of PCR compared to blood 
culture outcome was 73%, the specificity was 96%, the positive predictive value was 61% 
and the negative predictive value was 97%. 
 
This includes the results of the blood samples that were tested twice 
because of a negative PCR and positive blood culture result in the first 
PCR. This second test was positive in 3/10 samples that were initially 
negative with the S. aureus PCR and in 3/7 samples retested with the E. 
faecalis PCR. As such, sensitivity increased from 64 and 53% to 75 and 
73% by repeated testing of blood samples by S. aureus and E. faecalis 
PCR, respectively. S. aureus PCR was positive in 10/135 (7%) and the E. 
faecalis PCR in 7/162 (4%) of blood samples with no growth in blood 
culture. Although simultaneous blood cultures were negative, the detection 
of bacterial DNA by PCR was considered clinically likely in 50% of these 
blood samples, possible in 42% and unlikely in one patient (table 33). The 
origin of the positive PCR result in the latter patient remains unclear, 
because the S. aureus PCR was repeatedly positive for this blood sample, 
while no amplification reaction was observed when the cultured strain of S. 
marcescens was tested. This makes a technical failure (cross-reaction of S. 
marcescens DNA in the S. aureus PCR) unlikely. 
 
Determination of BDL 
Quantification of the amount of DNA was possible for 27 (87%) samples 
with positive S. aureus and 17/18 with positive E. faecalis PCR 
amplifications. The BDL could not be calculated for the other samples with 
positive amplification results due to the presence of (partial) inhibition; 
these samples were excluded from analysis of BDL. The median S. aureus 
BDL in PCR positive samples was 10.6 (range 0.3–84) and the median E. 
faecalis BDL was 2.7 (0.3–165) x103 cfu equivalents/mL. 
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NOTE to table 33. Number of samples is the number of blood samples that were PCR 
positive and blood culture negative. The clinical focus was the suspected focus of infection 
by the clinician at the moment blood was drawn for culture. Culture results represent a 
positive isolation of S. aureus or E. faecalis in any microbiological culture.  
Abbrevations: RF, respiratory failure; CABG, coronary artery bypass grafting; PTCA, 
percutaneous transluminal coronary angioplasty; CXR, chest X-ray; VAP, ventilator-
associated pneumonia; BAL, bronchoalveolair lavage. 
*The two blood samples of these patients were obtained with an interval of more than 3 
weeks between them. One patient had a CXR showing pulmonary infiltrates and a positive 
culture of tracheal aspirate with S. aureus in both episodes. 
 
  
Table 33. Clinical characteristics of patients with positive PCR result and no growth in simultaneous blood cultures 
 
Patient 
Micro- 
organism 
No. of 
samples 
Reason of 
admission 
Clinical 
focus 
Microbial 
culture 
Antibiotics 
<48h 
Miscellaneous PCR  
result 
 
 
       
A S. aureus 2 VAP Respiratory tract BAL Yes 
CXR: pulmonary 
infiltrates Likely 
B S. aureus 2* RF after CABG Respiratory tract 
Tracheal 
aspirate Yes 
CXR: pulmonary 
infiltrates Likely 
C S. aureus 2* Septic pneumonia Cardiac ischaemia Arterial line - Yes 
No growth in culture 
of catheter tip Possible 
D S. aureus 1 RF after CABG Wound 
sternum - Yes 
No growth in culture 
of pus from wound Possible 
E S. aureus 1 Cardiogenic shock 
after PTCA Arterial line - No 
No growth in culture 
of catheter tip Possible 
F S. aureus 1 RF after near-drowning 
Respiratory 
tract - Yes 
Alcohol abuse, 
CXR: interstitial 
infiltrates 
Possible 
G S. aureus 1 Cardiogenic shock 
after CABG Arterial line - Yes 
Serratia marcescens 
in pus / catheter tip Unlikely 
H E. faecalis 3 Multitrauma with 
open cruris fracture Wound Blood Yes 
E. faecalis in blood 
culture 1 day earlier Likely 
I E. faecalis 1 Multitrauma with 
open cruris fracture Wound Pus Yes 
Extensive wounds of 
the leg Likely 
J E. faecalis 1 Pneumonia in pancytopenia Arterial line - Yes 
Chemotherapy for 
multiple myeloma Possible 
K E. faecalis 1 RF after resection of 
sigmoid 
Peritoneal 
fluid 
Peritoneal 
fluid Yes 
CXR: 
no abnormalities Possible 
L E. faecalis 1 
Sepsis after 
pancreas tail 
resection 
Peritoneal 
fluid 
Peritoneal 
fluid / pus 
wound 
Yes Underlying 
malignancy Likely 
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Measurement of BDL over time 
Ten patients had more than one blood sample with positive amplification 
reactions for S. aureus (n=7) or E. faecalis (n=3). This involved two blood 
samples that had been obtained simultaneously but from different body 
sites for 9 patients. For one patient with S. aureus bacteraemia follow-up of 
blood samples over time was available. This patient was a 46-years old 
man who was admitted to the ICU of our hospital with cardiogenic shock 
after placement of a coronary stent because of acute myocardial infarction. 
He developed fever on day 6 after admission and intravascular lines and 
devices (including a subclavian line and intra-aortic balloon pump) were 
either replaced or removed because an intravascular source of infection 
was suspected. Flucloxacillin therapy was initiated when S. aureus growth 
was detected from the first blood culture, which was 30 hours after it had 
been obtained. Subsequent blood cultures and culture of the subclavian 
line also grew S. aureus resistant to penicillin only. Although the fever 
initially subsided, it soon rose again and despite the addition of ceftriaxone 
to the treatment regimen, the patient died of septic shock without apparent 
focus. Figure 10 shows the course of BDL and evolution of temperature 
over time for this patient. Results of PCR reactions and cultures were 
negative during a short febrile episode on day two, which settled rapidly 
without obvious clinical cause. For all subsequent blood samples positive 
PCR reactions were obtained corresponding to the isolation of S. aureus 
from blood cultures. The BDL appeared to mirror the evolution of fever 
during this episode be it that S. aureus DNA was still circulating in the blood 
during the temporary resolution of fever on day 8. 
Discussion 
In this study we show that the majority of blood culture proven cases of S. 
aureus and E. faecalis bacteraemia can be diagnosed by detection of 
bacterial DNA directly from blood samples by real-time PCR, without prior 
cultivation. With the current PCR techniques, results can be available within 
a few hours and thus provide a faster alternative to the blood culture. The 
possible early adjustment of antimicrobial therapy based on these PCR 
results might improve prognosis [6,20]. 
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Figure 10. Courses of temperature and Staphylococcus aureus BDL in a patient with 
Staphylococcus aureus bacteraemia. Staphylococcus aureus was isolated from all 
corresponding blood cultures except from those obtained on day 2. Mean BDL was 
calculated in case BDL was available for two simultaneously obtained blood cultures. 
Antimicrobial treatment was administered as indicated. 
Abbreviations: BDL, bacterial DNA load; cfu eq = colony forming units equivalents. 
  
The sensitivities of our PCR assays were comparable to those found in 
other studies of specific detection of N. meningitidis and S. pneumoniae 
DNA in blood samples [12,14, 21-23]. However, sensitivity may still be too 
low to warrant implementation of these assays in routine practice. The main 
issue in this regard is probably the small volume of 200µL of blood that is 
used in DNA isolation (which results in an equivalent of 40µL of blood that 
is tested in PCR) as compared to the much larger volume of blood (10mL) 
in blood cultures. The use of a small volume of blood could cause a 
sampling error or be too small to detect (low-grade) bacteraemia. A 
possible solution would be the processing of a larger volume of blood for 
PCR. The clear increase in sensitivity after a second DNA isolation and 
PCR supports this hypothesis. The current developments are aimed at 
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increasing the input volume of blood possible in DNA isolation. This has to 
overcome an increasing risk of inhibition in the PCR associated with 
concurrent larger amounts of human DNA and immunoglobulins [24-26]. 
The presence of inhibitive components in blood may also explain the 
relatively high number of blood samples that was tested twice because of 
failing control reactions in the first test. An alternative option for the 
increase in input volume of blood would be to test multiple samples from 
one patient, which might also have the advantage of a better detection of 
intermittent bacteraemia. PCR reactions were positive for several blood 
samples while simultaneous culture did not yield growth. The detection of 
extra cases of bacteraemia by PCR has been recognised previously, 
especially when blood samples are obtained after the initiation of 
antimicrobial treatment [15,27]. In our study, the detection of S. aureus and 
E. faecalis DNA by PCR may have been related to infection with these 
microorganisms in the majority of cases. A proportion of these episodes of 
‘DNAemia’ can probably be attributed to the presence of bacteria in the 
bloodstream that did no grow in culture because of the use of antibiotics, 
while other episodes may be the result of leakage of bacterial DNA into the 
bloodstream from a localised infection, or even from colonization. Although 
we did not discriminate between infection and colonization in our cohort, 
the role of colonization in false-positive PCR reactions is suggested to be 
limited in adults [28]. The clinical interpretation of the origin of a positive 
‘DNAemia’ maybe unclear but is different from that of culture-positive 
bacteraemia. For example, the amount of living bacteria is substantially 
reduced within hours after the administration of antibiotics, while bacterial 
DNA persists in blood under antimicrobial treatment and may still be 
detected during several days [29,30].  
The S. aureus and E. faecalis BDL in our study were comparable to the 
amount of DNA that was reported during S. pneumoniae bacteraemia, but 
lower than in invasive Salmonella typhi or N. meningitidis infection [11, 
21,29,31]. This suggests that the BDL in blood during bacteraemia may 
vary between microorganisms as is also known from studies with 
quantitative blood cultures [32]. Also, the S. aureus BDL was a 10-100 fold 
higher than the number of circulating bacteria reported during S. aureus 
endocarditis, underlining the possibility of the presence of bacterial DNA 
fragments in addition to viable bacteria in PCR [33-34]. Nevertheless, a 
systemic or localised infection with S. aureus or E. faecalis should strongly 
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be suspected when positive PCR results are obtained in combination with a 
suggestive clinical presentation. In such case, the initiation of specific 
treatment for that microorganism seems justified. 
A major advantage of PCR is the short turnaround time of 4-6 hours 
under the present conditions. As a result, PCR determination of the BDL 
could lead to a same-day initiation or optimalisation of antimicrobial 
treatment. For example, flucloxacillin therapy could have been started more 
than 24 hours earlier in the patient that we reported. Also, the increase of 
bacterial DNA in this patient on day 9 after admission might have led to the 
decision to add an aminoglycoside to the therapeutic regimen and to 
extend diagnostic procedures. Possibly, BDL provides a quantitative 
measure of bacteraemia that could be used to classify patients into 
prognostic risk groups, to distinguish between infection and colonization, or 
as a surrogate marker for comparison of different antimicrobial agents for 
conditions such as endocarditis in future clinical trials [29-31].  
In conclusion, quantitative detection of S. aureus and E. faecalis DNA in 
blood by real-time PCR enables the rapid the diagnosis of bacteraemia, 
also under antimicrobial treatment.  
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Abstract 
Background: The clinical value of determination of Staphylococcus aureus 
and Enterococcus faecalis bacterial DNA load (BDL) in blood of critically ill 
patients was studied. 
Methods: Blood samples for PCR were obtained simultaneously when 
blood cultures were taken on clinical grounds from patients admitted to the 
intensive care unit. Real-time PCR amplification with primers and probes 
specific for S. aureus and E. faecalis was performed to determine BDL.  
Results: S. aureus BDL was determined in blood samples from 80 patients 
with 98 episodes of suspected infection and E. faecalis BDL during 100 
episodes in another 80 patients. Sensitivity of S. aureus and E. faecalis 
BDL for positive blood cultures was 67% and 75%, respectively; specificity 
was 90% and 94%. Episodes with positive BDL and negative blood culture 
results occurred more frequently under antimicrobial treatment than blood 
culture positive episodes (p<0.05), which on the other hand were more 
frequently related to a microbiological focus (p<0.01). The area under the 
receiver operating characteristics (ROC) curve for prediction of 
bacteraemia was 0.81 (p<0.001) for S. aureus BDL and 0.85 (p<0.001) for 
E. faecalis BDL, while white blood cell count (WBC) and C-reactive protein 
(CRP) did not have discriminative power. Higher BDL was associated with 
microbiological invasiveness and clinical severity of infection (p<0.01). 
Conclusions: In critically ill patients, S. aureus and E. faecalis BDL in 
blood may be used as a better marker for bacteraemia than WBC and 
CRP, and relates to the microbiological invasiveness and clinical severity of 
bacterial infection. 
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Introduction 
Early recognition of bacteraemia facilitates adequate antimicrobial 
therapy [1,2]. However, estimation of the likelihood of bacteraemia is 
difficult because of the diversity of symptoms that are associated with this 
condition. Unfortunately, blood cultures may take up to two days or more to 
yield results and more rapid microbiological tests for bacteraemia are not 
yet available [3]. Decision models based on clinical and laboratory variables 
have been designed to support the bedside prediction of bacteraemia and 
microbial infection [4-6]. These models are based on clinical and routine 
laboratory variables such as underlying disease, recent surgery, peak 
temperature, heart rate, white blood cell count (WBC) and C-reactive 
protein (CRP) level. The performance of these prediction models is specific 
for the patient population in which they were derived, e.g. patients with 
febrile neutropenia or patients admitted to an intensive care unit (ICU), 
which may hamper widescale implementation. Furthermore, WBC and 
CRP, the classical host predictors of infection, may also be elevated during 
other, non-infectious conditions [7-10]. As opposed to these host 
inflammatory factors, the determination of microbial factors such as 
bacterial DNA or endotoxins might prove a more specific marker of 
bacteraemia and could be applicable more widely.  
The amount of DNA from living and dead bacteria that circulates in blood, 
the bacterial DNA load (BDL), can be measured by real-time PCR. 
Determination of the universal BDL, based on detection of the 16S rRNA 
gene that is present in all bacteria, has shown to be a sensitive but not very 
specific tool to diagnose bacteraemia in critically ill patients [11,12]. A more 
specific alternative is the microorganism-specific BDL which has been 
determined for various microorganisms including Streptococcus 
pneumoniae, but, to our knowledge, not for Staphylococcus aureus and 
Enterococcus faecalis, the two most prevalent causes of Gram-positive 
infections in the ICU [13-15]. BDL not only provides a diagnostic tool, but 
may also be used as a quantitative measure of bacteraemia with certain 
prognostic value, as shown for invasive meningococcal disease and 
Brucella melitensis infection [16,17]. However, these studies did not assess 
the relationship between BDL and the clinical indicators elaborated above.  
In this study we aimed to evaluate the clinical value of the S. aureus and 
E. faecalis BDL in relation to clinical, laboratory and microbiological 
features in critically ill patients. 
Chapter 10 
172 
Methods 
Patients and blood samples 
The study was conducted at the ICU of our university hospital and was 
approved by the local Medical Ethical Committee. Whenever blood cultures 
where clinically indicated, an additional whole blood sample was obtained 
for PCR and stored at –20ºC. As such, a total of 2000 blood samples from 
552 patients were collected during the study period. From this collection, 
blood samples were selected for determination of S. aureus BDL (SA 
cohort) or E. faecalis BDL (EF cohort). Both cohorts included all blood 
samples from 80 patients: all patients with S. aureus (n=16) or E. Faecalis 
(n=13) isolated from at least one blood culture supplemented with all blood 
samples from randomly selected patients (64 and 67, respectively). Clinical 
and laboratory data of these patients were collected retrospectively from 
the patient charts and were only included if they had been obtained within 
24 hours from the time point of sampling blood for culture and BDL.  
 
Clinical definitions 
Distinct episodes of suspected infection were defined if more there was 
more than 48 hours between blood cultures and resolution of fever (if 
present) had occurred in that period. Episodes of suspected infection were 
classified as hospital-acquired if blood samples had been obtained more 
than 48 hours after admission. Blood samples were considered to be drawn 
under antimicrobial treatment when antibiotics had been administered less 
than 48 hours prior to blood sampling. Bacteraemia was defined as the 
isolation of a known pathogen from blood culture. A microbiological focus of 
S. aureus or E. faecalis was considered present if the pathogen was 
isolated from cultures other than blood. Infection was defined as the 
isolation of S. aureus or E. faecalis from any microbial culture plus the 
presence of an inflammatory reaction as determined by a raised WBC (>12 
x109/L) or CRP (>50mg/L) level. The infection was considered severe if 
levels of both inflammatory markers were elevated. The absence of 
infection was defined as negative cultures for S. aureus and E. faecalis and 
normal WBC and CRP levels. The microbiological focus was considered to 
be the respiratory tract when cultures of tracheal or sinus aspirates, or 
bronchoalveolar lavage yielded growth, the skin and/or soft-tissue in case 
of positive cultures of pus or wound swabs, and the intravascular catheter 
when culture of the tip was positive. Patients were diagnosed as having 
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endocarditis when cardiac valve vegetations were observed by 
transoesophageal echocardiography and bacteraemia was present. The 
Simplified Acute Physiology Score (SAPS II) was calculated to assess 
severity of disease at admission while the Sequential Organ Failure 
Assessment (SOFA) score was used to score organ dysfunction [18,19]. 
Systemic Inflammatory Response Syndrome (SIRS) criteria were used as 
defined by Bone et al [20].  
 
Blood cultures 
Blood was collected for routine culture in blood culture bottles 
(BACTECTM Aerobic/F, Anaerobic/F, Becton Dickinson) and incubated in 
the automated blood culture system (BACTEC 9240, Becton Dickinson). 
After automatic detection of growth, microorganisms were identified with 
standard microbiological techniques. 
 
DNA isolation and real-time PCR 
The technical details of DNA isolation and PCR are described elsewhere 
[Peters RP, van Agtmael MA, Gierveld S, Danner SA, Groeneveld AB, 
Vandenbroucke-Grauls CM, Savelkoul PH, submitted]. In brief, bacterial 
DNA was isolated from 200µL of blood with the QIAamp DNA Mini Kit 
(Qiagen, Germany) according to the manufacturer’s instructions. Bacterial 
DNA was amplified under standard PCR cycling conditions on a TaqMan 
7000 System (Applied Biosystems, Foster City, CA, USA) with specific 
primers and probes targeting the 16S rRNA gene of S. aureus, E. faecalis 
or E. coli. The analytical detection limit of these three PCR assays was less 
than 5 cfu equivalents/PCR which equals 125 cfu equivalents/mL blood. 
The DNA of each blood sample was tested three times: 1) the diagnostic 
PCR to determine S. aureus or E. faecalis BDL, 2) detection of E. coli DNA 
which was spiked to the blood sample prior to DNA isolation to evaluate 
extraction efficiency, and 3) detection of 50 cfu equivalents of S. aureus 
DNA or E. faecalis DNA added to the PCR mixture as inhibition control. 
Blood samples with discrepant results between culture and PCR and 
samples that failed the control reactions were retested. In case the controls 
failed twice, the sample was excluded from further analysis. 
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Calculation of BDL 
A standard curve of S. aureus or E. faecalis DNA consisting of four 10-
fold dilutions of a stock solution of 5.000 cfu equivalents/PCR was included 
in each PCR run to calculate BDL. This standard curve was generated after 
isolation of pooled culture-negative blood samples spiked with the relevant 
quantity of bacteria. BDL results were defined as positive when more than 
125 cfu equivalents/mL blood were detected and negative if no 
amplification signal was observed and control PCR reactions were 
adequate. In case two blood samples had been drawn simultaneously, the 
average BDL was calculated. If multiple blood samples were available from 
different time points, we used only the BDL of the first blood sample to 
study the relation between BDL and clinical variables. 
 
Statistical analysis 
Values are described as numbers (%) for dichotomous and median 
(range) for continuous variables. Sensitivity, specificity and predictive 
values were calculated. The χ2 test or Fisher’s Exact test if appropriate 
were used to compare categorical variables, and the Mann-Whitney test to 
compare continuous variables. Clinical variables were compared between 
four groups defined by blood culture and BDL results using the Kruskal-
Wallis test for continuous and the χ2 test with Yates’ correction for 
binominal variables. In addition, differences between these groups were 
calculated after Bonferroni correction. The Spearman rank correlation 
coefficient (rs) (if above 0.35 or below 0.35) was used to describe relations 
between continuous variables. Receivers operating characteristic (ROC) 
curves were used to evaluate BDL, WBC and CRP for prediction of 
bacteraemia and the areas under the curves (AUC) were compared by 
Mann Whitney analysis using MedCalc Software (Mariakerke, Belgium). An 
AUC closer to 1 indicates greater diagnostic power, while an AUC of 
0.5 denotes no diagnostic potential. The Youden’s index was used for 
determination of the optimal cut-off values in ROC curves. P-values of less 
than 0.05 were considered to be statistically significant. 
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Results 
Patient characteristics 
A total of 103, respectively 102 episodes of suspected infection were 
included in the SA and EF cohorts. Table 34 describes the patient 
characteristics of both cohorts. S. aureus bacteraemia was observed during 
16 (16%) episodes in 16 (20%) patients, including two patients with 
endocarditis. A microbiological focus of S. aureus was present in 27 (26%) 
episodes, with the respiratory tract (n=16) as the most common focus 
followed by intravascular catheters (n=7). A methicillin-resistant strain was 
isolated from two blood samples from one patient. Bacteraemia by E. 
faecalis was present during 14 (14%) episodes of suspected infection in 13 
(16%) patients. A microbiological focus of E. faecalis was observed during 
20 (20%) of the episodes in the EF cohort, with positive cultures from 
samples of the respiratory tract (n=7), intravascular catheters (6) and skin 
and soft tissue (5). A microbiological focus was present in all except one 
(94%) of the episodes of S. aureus bacteraemia and in 12/14 of the 
episodes (86%) of E. faecalis bacteraemia.  
 
Determination of BDL 
The BDL could be determined for 98/103 (95%) of the episodes of 
suspected infection in the SA cohort and for 100/102 (98%) in the EF 
cohort. The process controls failed for the other samples and these were 
excluded from further analysis. The S. aureus BDL was positive in 18 of the 
episodes (18%); E. faecalis BDL was positive in 14 (14%). The median S. 
aureus BDL (8.1; range 0.3–84 x103 cfu equivalents/mL) did not differ 
significantly from the median E. faecalis BDL (3.9; range 0.3–165 x103 cfu 
equivalents/mL) during BDL positive episodes. 
 
BDL and blood culture results  
S. aureus BDL was positive in 10/15 and E. faecalis BDL in 9/12 of the 
bacteraemia cases, resulting in sensitivities of 67 and 75%. In addition, 
determination of S. aureus or E. faecalis BDL yielded positive results in 
8/83 respectively 5/88 of the episodes with no growth in concurrent blood 
cultures. Therefore, specificities were 90% and 94%. 
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Table 34. Demographics of patients included in the Staphylococcus aureus and 
Enterococcus faecalis cohorts 
 SA cohort (n = 80) EF cohort (n = 80) 
   
Male/female 46/34 45/35 
Age 61 (15–95) 64 (15–87) 
Episodes of suspected infection 103 102 
Hospital-acquired 86 (84) 90 (88) 
SIRS 74 (72) 75 (74) 
SAPS II score 45 (26–78) 47 (22–71) 
SOFA score 8 (0–17) 7 (0–17) 
Length of stay 19 (1–77) 17 (1–141) 
Mortality 22 (28) 22 (28) 
   
Reason for admission   
 Cardiovascular disease 24 (30) 23 (19) 
 Respiratory disease 14 (18) 11 (14) 
 Gastrointestinal disease 8 (10) 5 (6) 
 Sepsis 13 (16) 12 (15) 
 Neurological disease 9 (11) 11 (14) 
 Trauma 5 (6) 8 (10) 
 Other 7 (9) 10 (13) 
   
Underlying condition   
 Diabetes mellitus 18 (23) 13 (16) 
 Malignancy 9 (11) 13 (16) 
 Substance abuse 4 (5) 5 (6) 
 Chronic infection* 2 (3) 2 (3) 
Recent surgery 43 (54) 48 (60) 
Procedures† 8 (10) 5 (6) 
   
NOTE. Data are presented as numbers (%) for dichotomous variables and as medians 
(range) for continuous variables. SA, Staphylococcus aureus; EF, Enterococcus faecalis; 
SIRS, systemic inflammatory response syndrome; SAPS, simplified acute physiology score; 
SOFA, sequential organ failure assessment; CABG, coronary artery bypass grafting. 
*Including human immunodeficiency virus and hepatitis B or C virus infection. 
†These include: percutaneous transluminal coronary angioplasty and endoscopic retrograde 
cholangiopancreatography. 
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Table 35 describes clinical and microbiological variables in relation to blood 
culture and BDL results. Blood samples from episodes with positive BDL 
and negative culture results had been obtained more frequently under 
antimicrobial treatment than blood culture positive episodes (p<0.05). On 
the other hand, a microbiological focus of S. aureus was more frequently 
present in blood culture and BDL positive episodes (p<0.05); especially 
intravascular catheters as focus were associated with blood culture positive 
episodes (p=0.03).  
 
Predictive value of BDL for bacteraemia  
The AUC for the ROC curve for S. aureus BDL prediction of bacteraemia 
was 0.81 (p<0.001), while the AUCs for WBC (0.64) and CRP (0.53) did not 
have any discriminative power. Similarly, the AUC for the ROC curve for E. 
faecalis BDL had strong discriminative power for bacteraemia (0.85; 
p<0.001), but not WBC (0.66; p=0.21) and CRP (0.51; p=0.99). The AUCs 
for the ROC curves for S. aureus BDL and CRP were significantly different 
(p=0.02), while this was only a trend for E. faecalis BDL and CRP (p=0.09). 
Based on the optimal cut-off values for BDL in the ROC curves, the 
presence of S. aureus and E. faecalis bacteraemia was predicted correctly 
in 10/14 (71%) and 9/14 (64%) of the episodes (table 36). Bacteraemia was 
predicted to be absent in 79/84 (94%) and 83/86 (97%) of the episodes, 
respectively. 
 
Table 36. Diagnostic accuracy of BDL for the prediction of Staphylococcus aureus 
and Enterococcus faecalis bacteraemia 
Data S. aureus bacteraemia E. faecalis bacteraemia 
   
Cut-off value  0.46 0.13 
Sensitivity (%) 67 75 
Specificity (%) 95 94 
Positive predictive value (%) 71 64 
Negative predictive value (%) 94 97 
LR of positive result 13.83 13.20 
LR of negative results 0.35 0.27 
   
NOTE. Data represent the diagnostic characteristics of BDL with the optimal cut-off value 
(x103 cfu equivalents/mL) as determined by Youden’s index. BDL, bacterial DNA load; CFU, 
colony forming unit; LR, likelihood ratio. 
  
Table 35a. Clinical characteristics of patients in relation to PCR and blood culture results for Staphylococcus aureus  
 BC +/ BDL + BC +/ BDL – BC –/ BDL + BC –/ BDL – 
P-value 
(KW / χ2) 
 
Patients 10 5 6 54  
Male/female 6/4 3/2 2/4 33/21 NS 
Age (years) 60 (33-86) 71 (49-81) 75 (61-80) 63 (19-95) NS 
Length of stay (days) 17 (1-41) 21 (9-51) 18 (8-62) 14 (1-77) NS 
Mortality in ICU 4 (40) 1 (20) 1 (17) 14 (26) NS 
      
Episodes of suspected infection 10 5 8 75  
Hospital-acquired 7 (70) 3 (60) 6 (75) 67 (89) NS 
SIRS 8 (80) 4 (80) 6 (75) 53 (72) NS 
Antimicrobial treatment <48h ago 1 (10)* 3 (60) 7 (88) 38 (51) <0.05 
SAPS II score 43 (27-78) 51 (43-59) 53 (34-71) 47 (40-51) NS 
SOFA score 9 (3-12) 6 (2-9) 9 (2-11) 8 (0-17) NS 
White blood cell count (x109/L) 14.0 (9.8-37.2) 15.5 (3.7-25.6) 10.7 (6.6-20.6) 12.4 (0.1-26.8) NS 
C-Reactive Protein (mg/L) 116 (28-250) 167 (38-339) 99 (30-195) 96 (3-357) NS 
BDL (x 103cfu equivalents/mL) 16.8 (1.5-84.3)* <0.12 2.53 (0.27-25.4) <0.12† <0.001 
      
Presumed clinical focus of infection      
  Intravascular catheters 7 (70) 2 (40) 2 (25) 21 (28) NS 
  Respiratory tract  1 (10) 2 (40) 5 (63) 37 (49) NS 
  Skin and soft tissue 2 (20) 2 (40) 2 (25) 6 (8) NS 
  Other 1 (10) 2 (40) - 19 (25) NS 
Microbial focus of S. aureus 10 (100)* 4 (80) 4 (50) 8 (11)‡ <0.001 
  Intravascular catheters 6 (60) - - 1 (13) <0.05 
  Respiratory tract 4 (40) 2 (50) 4 (100) 6 (75) NS 
  Skin and soft tissue - 1 (25) - 1 (13) NS 
  Other 2 (18) 2 (50) - - NS 
*P<0.05 vs. episodes of positive BDL and negative blood culture results. 
†P<0.01 vs. both groups of BDL positive episodes. 
‡P<0.01 vs. both groups of episodes with positive blood culture results. 
  
Table 35b. Clinical characteristics of patients in relation to PCR and blood culture results for Enterococcus faecalis  
 
BC +/ BDL + BC +/ BDL – BC –/ BDL + BC –/ BDL – 
P-value 
(KW / χ2) 
Patients 8 3 5 62  
Male/female 6/2 2/1 2/3 35/27 NS 
Age (years)  73 (39-84) 63 (54-68) 53 (44-74) 64 (15-87) NS 
Length of stay (days) 36 (4-105) 11 (8-97) 31 (2-84) 17 (1-141) NS 
Mortality in ICU 4 (50) 1 (33) 1 (20) 15 (24) NS 
      
Episodes of suspected infection 9 3 5 83  
Hospital-acquired 9 (100) 2 (67) 5 (100) 72 (87) NS 
SIRS 8 (89) 2 (67) 3 (60) 62 (76) NS 
Antimicrobial treatment <48h ago 2 (22) 2 (67) 5 (100)* 36 (43) <0.05 
SAPS II score - 51 - 44 (22-71) NS 
SOFA score 9 (1-12) 6 3 (1-7) 7 (0-17) NS 
White blood cell count (x109/L) 12.3 (1.5-47.8) 9.1 (8.7-16.5) 14.0 (8.2-26.2) 12.2 (0.2-46.3) NS 
C-Reactive Protein (mg/L) 134 (32-357) 347 71 (3-166) 94 (3-473) NS 
BDL (x103 cfu equivalents/mL) 10.4 (0.3-16.5)† <0.12 3.3 (0.5-19.2) <0.12 <0.001 
 
     
Presumed clinical focus of infection      
  Intravascular catheters 4 (44) - 1 (20) 21 (25) NS 
  Respiratory tract  3 (33) 2 (67) - 36 (43) NS 
  Skin and soft tissue 3 (33) 1 (33) 2 (40) 9 (11) NS 
  Other - - 2 (40) 19 (23) NS 
Microbial focus of E. faecalis 8 (89) 2 (67) 3 (60) 5 (6)‡ <0.001 
  Intravascular catheters 4 (50) - - 1 (20) NS 
  Respiratory tract 4 (50) 1 (50) - - NS 
  Skin and soft tissue - 1 (50) 2 (67) 2 (40) NS 
  Other 1 (13) - 2 (67) 2 (40) NS 
*P<0.05 vs. episodes with positive BDL and blood culture results. 
†P<0.01 vs. episodes of negative BDL and blood culture results and P <0.05 vs. BDL negative and blood culture positive episodes. 
‡P<0.01 vs. BDL and blood culture positive episodes and P <0.05 vs. episodes of BDL positive and blood culture negative results. 
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Association of BDL with clinical and laboratory variables 
There were no significant correlations for clinical variables, SAPS II or 
SOFA score vs. S. aureus or E. faecalis BDL, or between the BDL and 
WBC or CRP. When only episodes with a positive BDL result were 
considered, the E. faecalis BDL positively correlated to the CRP level 
(figure 11). BDL related to the microbiological extent and clinical severity of 
infection (tables 37a and 37b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Correlation between bacterial DNA load (BDL) and C-reactive protein (CRP) in 
BDL positive episodes. Correlation was positive for E. faecalis BDL and CRP (p=0.01), but 
not for S. aureus BDL and CRP (p=0.4).  
 
Discussion 
In the present study we show that BDL can be used as a marker of 
bacteraemia in critically ill patients. With the current PCR assays, the BDL 
can be available within a few hours after blood is obtained. This allows the 
early institution of antimicrobial therapy, which may benefit the patient 
[2,21]. The performance of our PCR assays used for determination of S. 
aureus and E. faecalis BDL is comparable to that of other quantitative 
assays for detection of bacteraemia [13,22-24].  
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Table 37a. Laboratory variables in relation to microbiological extent of infection 
 
Bacteraemia Microbial focus only No focus P-value 
Staphylococcus aureus 
    
Number of episodes 15 12 71  
BDL (x103 cfu equivalents/mL) 8.2 (<0.12-84.3)* <0.12 (<0.12-7.4) <0.12 (<0.12-25.4)† <0.001 
WBC (x109/L) 15.3 (3.7-37.2) 13.2 (8.8-25.7) 12.2 (0.1-26.8) NS 
CRP (mg/L) 116 (28-339) 122 (49-339) 81 (3-357) NS 
     
Enterococcus faecalis 
    
Number of episodes 12 8 80  
BDL (x103 equivalents/mL) 2.4 (<0.12-165) <0.12 (<0.12-19.2) <0.12 (<0.12-4.6)† <0.001 
WBC (x109/L) 11.8 (1.5-47.8) 12.5 (8.2-16.2) 12.3 (0.2-46.3) NS 
CRP (mg/L) 142 (32-357) 62 (36-166) 93 (3-473) NS 
 
Table 37b. Laboratory variables in relation to severity of infection 
 
Serious infection Infection No infection/colonization P-value  
Staphylococcus aureus 
    
Number of episodes 7 3 6  
BDL (x103 cfu equivalents/mL) 7.7 (1.5-84.3)* 15.5 (0.27-25.5) <0.12† <0.01 
WBC (x109/L) 19.0 (12.7-37.2) 11.5 (10.8-25.9) 10.2 (8.0-11.4)† <0.01 
CRP (mg/L) 119 (81-250) 99 (30-121) 21 (3-49)† <0.01 
     
Enterococcus faecalis 
    
Number of episodes 7 6 4  
BDL (x103 equivalents/mL) 9.8 (<0.12-164.6)* 3.0 (<0.12-127.9) <0.12† <0.05 
WBC (x109/L) 15.3 (12.3-27) 10.2 (8.2-47.8) 8.5 (6.5-11.3)† <0.05 
CRP (mg/L) 158 (134-347) 77 (33-257) 23 (4-42)† <0.01 
NOTE. Data are presented as median (range). P-values are provided of Kruskal-Wallis analysis of variance vs. patients in other groups of the 
same category. BDL, bacterial DNA load; WBC, white blood cell count; NS, not significant; CRP, C-reactive protein. 
*P <0.05 vs. microbial focus only. 
†P <0.01 vs. both other groups. 
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Also, BDL was positive during several episodes of suspected infection with 
negative blood culture results in our study. In these episodes antimicrobial 
therapy had often been administered prior to blood sampling which 
considerably reduces the diagnostic yield of blood cultures, but does not 
seem to affect PCR [25-27]. On the other hand, blood culture positive 
episodes were more likely to present with a microbiological focus of S. 
aureus. Possibly, the number of bacteria during primary S. aureus 
bacteraemia is lower than in S. aureus bacteraemia with a clear primary or 
metastatic focus, which would result in a lower BDL [28]. Indeed, the S. 
aureus BDL was lower in blood samples obtained during blood culture 
negative than in blood culture positive episodes. This suggests that the 
main diagnostic value of BDL may lie in the identification of bacteraemia in 
patients with a low number of viable bacteria, i.e. in case of prior 
antimicrobial treatment or in patients without an overt microbiological focus. 
The BDL can be used as a marker of S. aureus and E. faecalis 
bacteraemia and may be more accurate than the traditionally used WBC 
and CRP in critically ill patients. In fact, the predictive value of BDL was 
superior to that of CRP and better than WBC. This may be explained by the 
direct detection of bacterial DNA instead of mediators of the response to 
this bacterial infection. As such, changes in levels of CRP and WBC not 
only require more time, but are also subject to many patient characteristics 
and may be mimicked by other, non-infectious, inflammatory conditions 
[29,30]. For example, CRP levels may also be elevated as a result of 
surgery or trauma, while WBC may be normal in elderly patients despite the 
presence of infection [31]. The BDL on the other hand may originate from 
bacteraemia, a localized infection, or colonization. Although the value of 
BDL during infection is obvious, positive BDL results due to colonization 
may result in unnecessary treatment with antibiotics. We did not 
discriminate between infection and colonization in our study, but the 
contribution of colonization to positive BDL results has been suggested to 
be minor in adult patients [32]. Possibly, the height of BDL might be used in 
future studies to discriminate between infection and colonization. If BDL 
instead of blood culture results had been used to guide antimicrobial 
therapy, 68% of the predicted episodes of bacteraemia would have been 
treated correctly while the absence of bacteraemia was correctly predicted 
in more than 95% of the episodes of suspected infection.  
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BDL may provide a marker for the severity and invasiveness of bacterial 
infection. This hypothesis is supported by the positive correlation between 
E. faecalis BDL and CRP in BDL positive patients, which has also been 
observed for Legionella pneumophila DNA in patients with pneumonia [33]. 
However, we did not observe a relationship between BDL and severity of 
disease as determined by SAPS-II, SOFA score, SIRS or mortality, unlike 
studies on meningococcal BDL [17,34]. This may be explained by the 
relatively small number of patients with a positive BDL result and the 
diverse spectrum of underlying disease in our ICU patients. 
Our study has several limitations. First, the technical detection limit or our 
PCR assay should be improved. Technical developments are aimed at 
increasing the input volume of blood and have to overcome the subsequent 
increased presence of PCR inhibitory components in blood [35,36]. 
Secondly, we only included S. aureus and E. faecalis BDL in our study. For 
a more general prediction of bacteraemia, PCR assays targeting other 
microorganisms should also be included. Alternatively, broad-range PCR 
assays can be used, but these assays are relatively prone to contamination 
and do not provide a specific identification of the involved species [37,38]. 
Thirdly, we did not measure the course of BDL over time. The kinetics of 
bacterial DNA in blood is largely unknown, but DNA may persist for many 
days [17,34]. Possibly, the monitoring rather than a single determination of 
BDL has a stronger prognostic value, like for CRP [39]. Finally, the number 
of patients in our study is small; larger studies are warranted to evaluate 
the use of BDL in clinical practice.  
In conclusion, the determination of the S. aureus and E. faecalis BDL in 
critically ill patients provides a better marker of bacteraemia than WBC and 
CRP and relates to the microbiological invasiveness and clinical severity of 
bacterial infection. 
Chapter 10 
184 
References 
1. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez 
FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on 
the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 
2003; 31: 2742–51. 
2. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate 
antimicrobial treatment of bloodstream infections on patient outcomes in the ICU 
setting. Chest 2000; 118: 146–55. 
3. Peters RP, van Agtmael MA, Danner SA, Savelkoul PH, Vandenbroucke-Grauls CM. 
New developments in the diagnosis of bloodstream infections. Lancet Infect Dis 2004; 
4: 751–60. 
4. Jaimes F, Arango C, Ruiz G, et al. Predicting bacteremia at the bedside. Clin Infect Dis 
2004; 38: 357–62. 
5. Bossink AW, Groeneveld AB, Hack CE, Thijs LG. The clinical host response to 
microbial infection in medical patients with fever. Chest 1999; 116: 380–90. 
6. Peters RP, Twisk JW, van Agtmael MA, Groeneveld AB. The role of procalcitonin in a 
decision tree for prediction of bloodstream infection in febrile patients. Clin Microbiol 
Infect 2006; 12: 1207–13. 
7. Bogar L, Molnar Z, Kenyeres P, Tarsoly P. Sedimentation characteristics of leukocytes 
can predict bacteraemia in critical care patients. J Clin Pathol 2006; 59: 523–5. 
8. Caterino JM, Scheatzle MD, Forbes ML, D’Antonio JA. Bacteremic elder emergency 
department patients: procalcitonin and white count. Acad Emerg Med 2004; 11: 393–6. 
9. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, et al. Markers of bacteremia in febrile 
neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more 
reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004; 23: 539–44. 
10. Chirouze C, Schuhmacher H, Rabaud C, et al. Low serum procalcitonin level accurately 
predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis 
2002; 35: 156–61. 
11. Cursons RT, Jeyerajah E, Sleigh JW. The use of polymerase chain reaction to detect 
septicemia in critically ill patients. Crit Care Med 1999; 27: 937–40. 
12. Sleigh J, Cursons R, La Pine M. Detection of bacteraemia in critically ill patients using 
16S rDNA polymerase chain reaction and DNA sequencing. Intensive Care Med 2001; 
27: 1269–73. 
13. van Haeften R, Palladino S, Kay I, Keil T, Heath C, Waterer GW. A quantitative 
LightCycler PCR to detect Streptococcus pneumoniae in blood and CSF. Diagn 
Microbiol Infect Dis 2003; 47: 407–14. 
14. Laupland KB, Kirkpatrick AW, Church DL, Ross T, Gregson DB. Intensive-care-unit-
acquired bloodstream infections in a regional critically ill population. J Hosp Infect 2004; 
58: 137–45. 
15. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical 
intensive care units in the United States. National Nosocomial Infections Surveillance 
System. Crit Care Med 1999; 27: 887–92. 
BDL as marker of bacteraemia 
185 
16. Navarro E, Segura JC, Castano MJ, Solera J. Use of real-time quantitative polymerase 
chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy 
and post-therapy follow-up in patients with brucellosis. Clin Infect Dis 2006; 42: 1266–
73. 
17. Hackett SJ, Guiver M, Marsh J, et al. Meningococcal bacterial DNA load at presentation 
correlates with disease severity. Arch Dis Child 2002; 86: 44–46. 
18. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the 
incidence of organ dysfunction/failure in intensive care units: results of a multicenter, 
prospective study. Working group on “sepsis-related problems” of the European Society 
of Intensive Care Medicine. Crit Care Med 1998; 26: 1793–800.  
19. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS 
II) based on a European/North American multicenter study. JAMA 1993; 270: 2957–63. 
20. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and 
guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus 
Conference Committee. American College of Chest Physicians/Society of Critical Care 
Medicine. Chest 1992; 101: 1644–55. 
21. Fraser A, Paul M, Almanasreh N, et al. Benefit of appropriate empirical antibiotic 
treatment: thirty-day mortality and duration of hospital stay. Am J Med 2006; 119: 970–
6. 
22. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB. 
Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and 
Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-
time PCR. J Clin Microbiol 2001; 39: 1553–8. 
23. Hackett SJ, Carrol ED, Guiver M, et al. Improved case confirmation in meningococcal 
disease with whole blood Taqman PCR. Arch Dis Child 2002; 86: 449–52. 
24. Makhoul IR, Smolkin T, Sujov P, et al. PCR-based diagnosis of neonatal staphylococcal 
bactermias. J Clin Microbiol 2005; 43: 4823–5. 
25. McKenzie R, Reimer LG. Effect of antimicrobials on blood cultures in endocarditis. 
Diagn Microbiol Infect Dis 1987; 8: 165–72. 
26. Grace CJ, Lieberman J, Pierce K, Littenberg B. Usefulness of blood culture for 
hospitalized patients who are receiving antibiotic therapy. Clin Infect Dis 2001; 32: 
1651–5. 
27. Heininger A, Binder M, Schmidt S, Unertl K, Botzenhart K, Doring G. PCR and blood 
culture for detection of Escherichia coli bacteremia in rats. J Clin Microbiol 1999; 37: 
2479–82. 
28. Whimbey E, Kiehn TE, Brannon P, Benezra D, Armstrong D. Clinical significance of 
colony counts in immunocompromised patients with Staphylococcus aureus 
bacteremia. J Infect Dis 1987; 155: 1328–30. 
29. Povoa P, Coelho L, Almeida E, et al. C-reactive protein as a marker of infection in 
critically ill patients. Clin Microbiol Infect 2005; 11: 101–8. 
30.  Reny JL, Vuagnat A, Ract C, Benoit MO, Safar M, Fagon JY. Diagnosis and follow-up 
of infections in intensive care patients: value of C-reactive protein compared with other 
clinical and biological variables. Crit Care Med 2002; 30: 529–35. 
Chapter 10 
186 
31. Fontanarosa PB, Kaeberlein FJ, Gerson JW, Thomson RB. Difficulty in predicting 
bacteremia in elderly emergency patients. Ann Emerg Med 1992; 21: 842–8. 
32. Dagan R, Shriker O, Hazan I, et al. Prospective study to determine clinical relevance of 
detection of pneumococcal DNA in sera of children by PCR. J Clin Microbiol 1998; 36: 
669–73. 
33. Diederen BM, de Jong CM, Marmouk F, Kluytmans JA, Peeters MF, van der Zee A. 
Evaluation of real-time PCR for the early detection of Legionella pneumophila DNA in 
serum samples. J Med Microbiol 2007; 56: 94–101. 
34. Ovstebo R, Brandtzaeg P, Brusletto B, et al. Use of robotized DNA isolation and real-
time PCR to quantify and identify close correlation between levels of Neisseria 
meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from 
patients with systemic meningococcal disease. J Clin Microbiol 2004; 42: 2980–7. 
35. Al-Soud WA, Radstrom P. Purification and characterization of PCR-inhibitory 
components in blood cells. J Clin Microbiol 2001; 39: 485–93. 
36. Al-Soud WA, Jonsson LJ, Radstrom P. Identification and characterization of 
immunoglobulin G in blood as a major inhibitor of diagnostic PCR. J Clin Microbiol 
2000; 38: 345–50. 
37. Peters RP, Mohammadi T, Vandenbroucke-Grauls CM, Danner SA, van Agtmael MA, 
Savelkoul PH. Detection of bacterial DNA in blood samples from febrile patients: 
underestimated infection or emerging contamination? FEMS Immunol Med Microbiol 
2004; 42: 249–-53. 
38. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Kaczmarski EB, Fox AJ. 
Contamination and sensitivity issues with a real-time universal 16S rRNA PCR. J Clin 
Microbiol 2000; 38: 1747–53. 
39. Povoa P, Coelho L, Almeida E, et al. Pilot study evaluating C-reactive protein levels in 
the assessment of response to treatment of severe bloodstream infections. Clin Infect 
Dis 2005; 40: 1855–7. 
  
 
 
 
 
Chapter 11 
 
 
 
 
The clinical value of quantification of Streptococcus 
pneumoniae DNA in blood of patients suspected of 
community-acquired pneumonia or meningitis 
 
 
 
Remco P.H. Peters1,2, Richard F. de Boer3, Tim Schuurman3, Sonja 
Gierveld2, Mirjam Kooistra-Smid3, Michiel A. van Agtmael1, Christina M.J.E. 
Vandenbroucke-Grauls2, Maike C.J. Persoons4 and Paul H.M. Savelkoul2 
 
 
Departments of 1Internal Medicine and 2Medical Microbiology & Infection Control, 
VU University Medical Center, Amsterdam, 3Department of Research and 
Development, Laboratory for Infectious Diseases, Groningen, and Department of 
Medical Microbiology, Scheper Hospital Emmen, Laboratory for Infectious 
Diseases, Groningen, The Netherlands 
 
 
Submitted for publication 
Chapter 11 
188 
Abstract 
Background: Real-time PCR can be used to detect and quantify the 
bacterial DNA load (BDL) in blood during bacteraemia, without prior 
cultivation. We studied the clinical relevance of determination of 
Streptococcus pneumoniae BDL in blood samples from patients suspected 
of community-acquired pneumonia or meningitis. 
Methods: Blood samples for PCR were collected simultaneously with 
samples for blood culture. After DNA extraction from 200µL of blood, real-
time PCR was done with primers and probe for specific detection of the S. 
pneumoniae autolysin (lytA) gene, and BDL was calculated.  
Results: PCR amplification results were available for blood samples from 
62 patients. PCR was positive in 11/14 (79% sensitivity) patients with 
positive simultaneous blood cultures. Four patients had a positive PCR 
result but no growth in blood cultures: three of them were likely to have a S. 
pneumoniae infection, while this was possible in the fourth. The 
discriminative power of BDL was comparable to that of the white blood cell 
count (WBC) and C-reactive protein (CRP) for prediction of S. pneumoniae 
bacteraemia as determined by receiver operating characteristics curves. 
The optimal cut-off of BDL for prediction of bacteraemia was 223 cfu 
equivalents/mL. BDL was higher in patients who fulfilled the systemic 
inflammatory response syndrome criteria on presentation (p=0.04), and 
correlated with WBC (p<0.01) and CRP levels (p<0.001).  
Conclusions: Determination of the BDL in blood by real-time PCR aids in 
the diagnosis of invasive pneumococcal disease and might provide a novel 
tool in the management of patients with S. pneumoniae infection. 
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Introduction 
Streptococcus pneumoniae is the most prevalent cause of community-
acquired pneumonia and meningitis in adults [1,2]. The presence of 
bacteraemia in these patients is an independent predictor of mortality and 
early recognition is thus essential [3]. At present, the blood culture is the 
gold standard to diagnose invasive pneumococcal disease. However, blood 
cultures may require more than two days before results are available and 
their sensitivity is considerably reduced if blood samples are obtained 
under antimicrobial treatment [4,5]. As such, blood cultures have limited 
impact on the initial choice of antimicrobial treatment, especially if no 
underlying risk factors are present [5-7]. 
The PCR technique enables the detection of S. pneumoniae DNA directly 
in blood, without prior cultivation. PCR may provide a diagnosis faster than 
blood culture and is presumably not affected by prior use of antibiotics [8-
13]. In addition, the real-time PCR system offers the opportunity to quantify 
the initial amount of DNA in the sample. Several authors have studied the 
use of real-time PCR assays for the detection of S. pneumoniae 
bacteraemia directly in blood samples, with variable results [14-17]. 
However, to our knowledge, quantification of the S. pneumoniae bacterial 
DNA load (BDL) in blood was only described in one study [17]. The data in 
that study suggest that the S. pneumoniae BDL may provide a quantitative 
measure of bacteraemia, but the association between BDL and clinical 
characteristics was not evaluated. To determine the clinical relevance of 
the S. pneumoniae BDL, we quantified the amount of S. pneumoniae DNA 
in blood from patients suspected of invasive pneumococcal disease, and 
related the BDL to clinical and laboratory variables. 
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Materials and Methods 
Patients and blood samples 
This study was carried out at the Scheper hospital which has 380 beds 
and serves a regional function. The study was approved by the local 
Medical Ethical Committee. Whenever blood was drawn for culture on 
clinical indications, an additional blood sample was obtained for PCR from 
all patients in the emergency department, the medical ward and the 
intensive care unit (ICU). In total, 1139 blood samples were obtained from 
476 patients during a 16 months inclusion period. Retrospectively, patients 
were selected from this cohort for the current study. Patients were eligible if 
they were adults (>18 years of age) who had been admitted for respiratory 
tract infection (RTI) or meningitis, and had blood cultures drawn within 24 
hours after admission. Clinical and laboratory data were collected 
retrospectively from patient’s charts. Laboratory data were only included if 
they had been determined within 12 hours around the time point of 
sampling blood for culture and PCR. 
 
Clinical definitions 
RTI was defined as the presence of two or more respiratory symptoms 
and either abnormalities on clinical chest examination characteristic of RTI, 
or a pulmonary infiltrate on chest X-ray. Pneumonia was diagnosed if a 
pulmonary infiltrate was observed on the chest X-ray and at least two of the 
following symptoms were present: cough, dyspnoea, chest pain or fever 
(temperature >38.5ºC). Patients were included with suspicion of meningitis 
in case of suggestive symptoms (headache, neckstiffness, fever); 
meningitis was definite after the isolation of a known pathogen from 
cerebrospinal fluid (CSF). Bacteraemia was defined as the isolation of a 
known pathogen from blood cultures. A focus of pneumococcal infection 
was considered to be present if S. pneumoniae was isolated from any other 
body site than blood, including CSF, sputum and throat swab samples. The 
systemic inflammatory response syndrome (SIRS) and sepsis criteria were 
used as defined by Bone et al [18]. The pneumonia severity index (PSI) 
was calculated as described by Fine et al while the CURB-65 score was 
used according to Lim and colleagues [19,20]. 
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Blood cultures 
Blood was collected for routine culture in blood culture bottles (Bact/Alert 
FAN®) and incubated in an automated blood culture system (Bact/Alert 
240, Organon, Technika). Microorganisms were identified with standard 
microbiological techniques after automatic detection of growth. 
 
DNA extraction 
Whole blood samples were collected for PCR in 3mL EDTA tubes 
(Beckton Dickinson) and stored at –20°C. For DNA extraction 200µL of 
blood was used after spiking of 3000 copies of phocine herpesvirus-1 
(PhHV) as extraction and inhibition control (equal to 300 copies/PCR) [21]. 
To remove haemoglobin, 1000µL of Triton-Tris-EDTA (20mM Tris-HCl of 
pH 8.3, 1mM EDTA, 1% Triton x-100) was first added to the sample 
followed by centrifugation at 12000 rpm for 10 minutes. The supernatant 
fraction was removed and the pellet resuspended in 1000µL TTE. This step 
was repeated, but with resuspension of the pellet in 200µL of Tris-EDTA 
(10mM Tris-HCl of pH 8.3, 1mM EDTA). DNA was then extracted with the 
QIAamp DNA Mini Kit (Qiagen, Germany) according to the manufacturer’s 
instructions, and eluted in 100µL of elution buffer. 
 
Real-time PCR assays 
The oligonucleotide primers and probes used for specific amplification of 
S. pneumoniae and PhHV-1 DNA are summarized in table 38. The 
analytical sensitivity of the S. pneumoniae PCR assay was less than 5 cfu 
equivalents/PCR as determined by a dilution series of S. pneumoniae 
(ATCC strain 6306) spiked to pooled culture-negative whole blood samples. 
Specificity was evaluated against a wide variety of related species and no 
aspecific signals were observed with these strains. The PhHV assay has 
been published elsewhere [21], but we modified the probe to a minor grove 
binding probe to avoid the use of a fluorescent quencher. DNA amplification 
was done on a TaqMan 7000 System (Applied Biosystems, Foster City, 
CA, USA) with standard PCR cycling conditions. We used the following 
reaction mixture (50µL) for PCR analysis: 25µL TaqMan Universal PCR 
Mastermix (Applied Biosystems), 20µL of extracted DNA and 5µL of 
specific primers (300nM) and probes (100nM). 
  
Table 38. Sequences of oligonucleotide primers and probes used for real-time PCR 
 Gene  Sequence (5’ to 3’)  
Microorganism target Forward primer Reverse primer Dye-labelled probe 
     
S. pneumoniae lytA ACCGCTGGAGGAAGCACA GCCTGTAGCCATTTCGCCT FAM-AGACGGCAACTGGTACT-NFQMGB 
  
 AGCGATTTTCTTCCAGCCTGT  
PhHV* gB polymerase GGGCGAATCACAGATTGAATC GCGGTTCCAAACGTACCAA NED-CGCCACCATCTGGAT-NFQMGB 
     
Abbreviations: lytA, autolysin A; FAM, 6-carboxyfluorescein; NFQ, no fluorescent quencher; MGB, minor grove binding; PhHV, phocine 
herpesvirus-1; gB, glycoprotein B; NED, 2,7',8'-benzo-5'-fluoro-2',4,7-trichloro-5-carboxyfluorescein. 
*As published by van Doornum et al [21]. 
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PCR results were defined as positive when amplification signals were 
observed, and negative if such a signal was absent in the presence of an 
adequate amplification of the PhHV control reaction. If a PhHV control 
failed, DNA of that sample was diluted 1:1 with PBS and amplified again. If 
the PhHV amplification signal was then still insufficient or in case a 
discrepancy was observed between PCR and blood culture result, blood 
samples were retested. If the PhHV control reactions failed twice, the 
sample was excluded from further analysis. 
 
Determination of BDL 
BDL was calculated with a standard curve of S. pneumoniae DNA 
consisting of four 10-fold dilutions of a stock solution of 5.000 cfu 
equivalents/PCR (ATCC strain 6306). This standard curve had been 
generated after isolation of DNA from pooled culture-negative blood 
samples spiked with the relevant amount of bacteria. If PCR amplifications 
were positive for two simultaneously obtained blood samples, the average 
BDL for these samples was computed. The detection limit for BDL in blood 
was 5 cfu equivalents/PCR which equals 125 cfu equivalents/mL blood. 
 
Statistical analysis 
Sensitivity, specificity and predictive values were calculated by standard 
2x2 tables. The χ2 test, or Fisher’s Exact test if appropriate, were used to 
compare categorical variables, and the Mann-Whitney U test to compare 
continuous variables. Clinical variables were compared between groups 
defined by blood culture and BDL results with the Kruskal-Wallis test for 
variance for continuous variables and with the χ2 test with Yates’ correction 
for binominal variables. Spearman rank correlations (rs) were used to 
describe relations between continuous variables. Receiver operating 
characteristic (ROC) curves were used to evaluate the discriminative power 
of BDL, white blood cell count (WBC) and C-reactive protein (CRP) for 
bacteraemia at various cut-off points and the area under the curve (AUC) 
was calculated. An AUC closer to 1 indicates greater diagnostic power, 
while an AUC of 0.5 denotes no diagnostic potential. The Youden’s index 
was used to determine the optimal cut-off values of the ROC curves. P-
values of less than 0.05 were considered to be statistically significant. 
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Results 
Patient population 
A total of 130 blood samples from 63 patients were included in this study. 
Blood samples for culture and PCR were obtained from patients on the 
medical ward (30 patients), the emergency department (27) and the ICU 
(6). Fifty-nine patients had RTI and four meningitis. Demographics of the 
study population are described in table 39. Forty patients with RTI (65%) 
fulfilled the criteria for pneumonia, meningitis was microbiologically 
confirmed in all four patients admitted for meningitis. 
 
Table 39. Clinical characteristics of the study population at inclusion 
Variable Patients (n = 63) 
  
Gender (male/female) 42/21 
Age (years) 71 (24-91) 
Length of stay (days) 10 (1-60) 
Mortality 8 (13) 
  
COPD 30 (48) 
Recent pneumonia (<5 years) 16 (25) 
Cough 48 (76) 
Dyspnoea 39 (62) 
Chest pain 13 (21) 
Cold chills reported 23 (37) 
On corticosteroid treatment 9 (14) 
Antibiotics before admission 15 (24) 
  
Fever (temperature >38.5°C) 47 (75) 
Altered mental status 16 (25) 
Abnormalities on chest examination 41 (65) 
Sepsis 29 (46) 
SIRS 48 (76) 
  
Erythrocyte sedimentation rate (mm/h) 38 (6-93) 
White blood cell count (x109/L) 14.2 (7.0-43.2) 
C-reactive protein (mg/L) 129 (6-578) 
  
NOTE. Data are presented as numbers (%) for dichotomous variables and as median 
(range) for continuous variables. COPD, chronic obstructive pulmonary disease; SIRS, 
systemic inflammatory response syndrome. 
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Culture results 
Fourteen patients (22%) had positive blood cultures with S. pneumoniae 
(n=21); 13 of them had RTI and one had meningitis. Five of the fourteen 
patients with bacteraemia had positive microbial cultures with S. 
pneumoniae of sputum (4), throat swab (1) or CSF (1). In addition, 9 
patients without bacteraemia had S. pneumoniae isolated from sputum (7), 
throat swab (1) and CSF (1) samples. Five of these nonbacteraemic 
patients were diagnosed with pneumonia and one with meningitis. Urinary 
antigen tests for Legionella pneumophila were done on clinical indication 
for 9 patients and all were negative. 
 
Table 40. Detection of Streptococcus pneumoniae bacteraemia by PCR versus 
blood culture 
 Blood culture result  
PCR result Positive Negative Total 
 
   
Positive 11 4 15 
Negative 3 44 47 
Total 14 48 62 
 
   
NOTE. Data are numbers of patients. The sensitivity of PCR compared to blood culture 
outcome was 79%, the specificity was 92%, the positive predictive value was 73% and the 
negative predictive value was 92%. 
 
Real-time PCR detection of S. pneumoniae bacteraemia 
PCR amplification results were available for 127 (98%) blood samples 
from 62 patients. Three blood samples, including two blood samples from 
one patient, were excluded from further analysis because they failed the 
PhHV control reactions. The sensitivity of PCR compared to blood culture 
for detection of S. pneumoniae bacteraemia was 79% (table 40). Patient 
characteristics in relation to blood culture and PCR results are depicted in 
table 41. S. pneumoniae infection was very likely in three of the four 
patients with positive PCR and negative blood culture results and possible 
in the fourth. Two of these four patients had S. pneumoniae isolated from 
sputum or throat swab and fulfilled the criteria for pneumonia; in one of 
these patients S. pneumoniae meningitis was confirmed by a positive 
cerebrospinal fluid culture.  
  
Table 41. Clinical characteristics in relation to PCR and blood culture results 
 BC +/ PCR + 
(n = 11) 
BC +/ PCR – 
(n = 3) 
BC –/ PCR + 
(n = 4) 
BC –/ PCR – 
(n = 44) 
P-value 
(Kruskal-Wallis/ χ2) 
 
     
Demographics 
     
Sex (male) 6 (55) 2 (67) 3 (75) 31 (71) NS 
Age (years) 70 (24-84) 67 (27-77) 59 (39-89) 74 (31-91) NS 
Length of stay (days) 12 (1-60) 7 (7-13) 12 (9-21) 9 (2-52) NS 
Mortality 3 (27) - - 5 (11) NS 
      
Clinical signs and symptoms 
     
Cold chills reported 5 (46) 1 (33) 1 (25) 16 (36) NS 
Antibiotics before admission - - 2 (50) 13 (30) NS 
On corticosteroid treatment - 1 (33) - 8 (18) NS 
Fever (temperature >38.5°C) 8 (80) 3 (100) 3 (100) 33 (83) NS 
Chest examination suggestive of RTI 11 (100) 3 (100) 2 (50) 29 (74) NS 
SIRS 11 (100) 3 (100) 3 (100) 31 (76) NS 
Diagnosis of pneumonia 9 (82) 3 (100) 2 (50) 25 (57) NS 
Pneumonia severity index class 3 (1-4) 3 (2-4) 3 (2-3) 4 (1-5) NS 
CURB-65 score 2 (0-3) 2 (1-3) 1 (0-2) 1 (0-5) NS 
 
     
Laboratory variables      
WBC (x109/L) 20.4 (10.8-34.9)* 20.4 (14.9-21.9) 18.9 (15.9-43.2) 12.4 (7.0-38.4) <0.01 
CRP (mg/L) 357 (170-538)† 188 (22-341) 67 (53-578) 86 (6-451) <0.01 
BDL (cfu equivalents/mL) 650 (<125-17075) <125 690 (223-900) <125‡ <0.001 
      
Other investigations      
Radiological abnormalities 10 (91) 3 (100) 2 (50) 25 (57) NS 
Focus of S. pneumoniae 4 (36) 1 (33) 4 (100)* 5 (11) <0.001 
      
*P <0.01 vs. patients with negative blood culture and PCR results. 
†P <0.001 vs. patients with negative results for PCR and blood culture.  
‡P <0.01 vs. both groups with positive PCR results. 
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The fourth patient was an 89-years old woman with a history of chronic 
obstructive pulmonary disease (COPD). She presented with cough, 
dyspnoea, chest pain, dysuria and chills since one day. On examination 
she was febrile (39.1ºC), had a respiratory rate of 32/minute and extensive 
rhonchi on left basal side of the chest. The WBC was 15.9 x 109/L; CRP 
was 67 mg/L. No abnormalities were observed on her chest X-ray. S. 
pneumoniae was isolated from a sputum sample, and Escherichia coli and 
Proteus mirabilis were isolated from her urine. She recovered after 
treatment with amoxicillin/clavulanic acid and was discharged after 10 days. 
PCR reactions were negative in blood samples from three patients with 
bacteraemia. All three had pneumonia; S. pneumoniae was cultured from 
sputum of one patient. 
 
Determination of BDL 
The BDL could be calculated for 61/62 patients because the PhHV 
process control failed in two blood samples from one patient due to partial 
inhibition, despite a positive DNA amplification result. The median BDL was 
475 cfu equivalents/mL (range <125–17075) during bacteraemia episodes 
and <125 cfu equivalents/mL blood (range <125–900) for blood samples 
with negative simultaneous blood cultures. No significant difference was 
observed for BDL between patients included for pneumonia or meningitis 
(p=0.13). 
 
BDL for prediction of invasive S. pneumoniae infection 
ROC curves for BDL, WBC and CRP were generated for prediction of S. 
pneumoniae bacteraemia (figure 12). The AUCs were not statistically 
different between these ROC curves. The optimal cut-off point for BDL was 
223 cfu equivalents/mL as determined by Youden’s index, which results in 
a sensitivity of 71%, specificity of 94%, positive likelihood ratio of 11.4 and 
negative likelihood ratio of 0.3. 
 
Association of BDL with clinical, laboratory and microbiological 
variables 
BDL was higher in patients presenting with SIRS (p=0.04), but no 
associations were observed for BDL with other clinical variables. 
Correlations were positive for BDL and WBC (rs=0.39; p<0.01) and for BDL 
and CRP (rs=0.47; p<0.001). Also, BDL was higher in patients with 
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bacteraemia compared to patients with a pneumococcal focus of infection 
and negative blood cultures, or compared to patients without S. 
pneumoniae infection (table 42). Finally, no association was noted between 
BDL and radiographic abnormalities, PSI, or CURB-65 score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Receiver operating characteristic (ROC) curves for BDL, WBC and CRP for 
prediction of Streptococcus pneumoniae bacteraemia. The area under the ROC curve for 
BDL was 0.82 (p<0.001), for WBC 0.81 (p<0.001) and for CRP 0.85 (p<0.001). 
 
Discussion 
In the present study we show that determination of the BDL of S. 
pneumoniae in blood can be used to diagnose S. pneumoniae 
bacteraemia, and provides a marker of bacteraemia that has similar 
discriminative power as WBC and CRP in our patient population. Detection 
of S. pneumoniae DNA in blood by PCR had a sensitivity of 79% compared 
to blood culture. This sensitivity is higher than reported in three other 
studies in which real-time PCR was used for detection of S. pneumoniae 
DNA in blood samples from patients with culture-proven pneumococcal 
bacteraemia (43-69%) [14-16]. In one study performed on samples from 
patients suspected of 
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Table 42. Laboratory variables in relation to type of Streptococcus pneumoniae infection 
 Bacteraemia 
(n = 14) 
Focal infection 
only (n = 9) 
No S. pneumoniae 
infection (n = 39)  
P-value 
(KW) 
     
BDL (cfu equivalents/mL) 475 (<125-17075)* <125 (<125-900) <125 <0.001 
WBC (x109/L) 15.3 (3.7-37.2)* 13.2 (8.8-25.7) 12.2 (0.1-26.8) 0.001 
CRP (mg/L) 315 (22-538)*† 66 (12-578) 86 (6-451) 0.001 
     
NOTE. Data are presented as median (range). P-values are provided of Kruskal-Wallis analysis of variance vs. patients in other groups of the 
same category, and as footnotes between groups after Bonferroni correction.  
Abbreviations: KW, Kruskal-Wallis; BDL, bacterial DNA load; WBC, white blood cell count; CRP, C-reactive protein. 
*P <0.01 vs. patients with no S. pneumoniae infection. 
†P <0.05 vs. patients with only a focus of S. pneumoniae infection. 
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meningitis and/or septicaemia a higher sensitivity (92%) was obtained 
[17]. The assay used in that study was based on detection of the 
pneumolysin gene instead of the autolysin gene used as the PCR 
target in our study, but it is not plausible that that accredits for the 
observed difference in sensitivity [15]. More likely, the pneumococcal 
DNA load in blood is higher in patients with meningitis than in patients 
with bacteraemic pneumonia and thus results in a higher detection 
rate [22,23]. Nevertheless, the PCR assays have to be further 
improved to ensure clinical applicability. One of the main issues is the 
volume of blood that is tested: we used only 200µL of blood for DNA 
isolation. This is fifty times less blood than the volume that is tested in 
blood culture. As such, a sampling error may account, at least partly, 
for the difference in sensitivity between PCR and blood culture. 
Current technical developments are aimed at increasing the volume 
of blood that can be processed. A problem in this respect is the 
inhibitory effect of larger amounts of immunoglobulins and human 
leukocytic DNA on the PCR [24-26]. 
An important observation in our study is the identification by PCR of 
four cases of S. pneumoniae infection with negative blood cultures 
[27]. On clinical grounds, a S. pneumoniae infection was very likely in 
three of these patients, suggesting that the PCR result identified a 
true pneumococcal bacteraemia. In the fourth patient it was unclear 
whether the detection of S. pneumoniae in blood was related to 
clinical infection or the result of colonization. It has been shown 
previously that nasopharyngeal colonization with S. pneumoniae may 
result in positive PCR signals in healthy children, but the presence of 
pneumococcal DNA in blood of adult patients with mere 
nasopharyngeal colonization and no bacteraemia was not observed 
[28,29]. A plausible hypothesis is that the BDL is higher in patients 
with true pneumococcal infection than in patients with colonization; 
this possibility merits further exploration.  
The range of S. pneumoniae BDL that we observed is in 
concordance with the results from a previous study.14 S. pneumoniae 
BDL has a strong discriminative power for prediction of S. 
pneumoniae bacteraemia, similar to that of WBC and CRP. However, 
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the S. pneumoniae BDL is a specific marker of S. pneumoniae 
infection whereas WBC and CRP levels are elevated in any bacterial 
infection. As such, a positive pneumococcal BDL would justify 
antibiotic therapy specifically aimed at pneumococci. In The 
Netherlands, where resistance is very low, this would mean treatment 
with penicillin [30]. 
BDL was higher in patients presenting with SIRS, which suggests a 
relation between BDL and the extent of the host inflammatory 
response. This hypothesis is supported by the positive correlation of 
BDL with WBC and CRP which was also described for the BDL of 
Enterococcus faecalis and L. pneumophila and CRP [31,32]. As such, 
BDL, like CRP, is related to the degree of inflammatory reaction and 
might provide a measure of severity of disease [33,34]. S. 
pneumoniae BDL was higher in patients with bacteraemia than in 
those with local S. pneumoniae infection or no S. pneumoniae 
infection, which may reflect an association with the invasiveness of 
infection. However, unlike in meningococcal infection, we did not 
observe any association between height of BDL on admission and 
severity of pneumonia, length of stay, or mortality [35]. This may be 
due to the relatively small number of patients with bacteraemic S. 
pneumoniae pneumonia in our cohort and should be subject of future 
studies.  
In conclusion, determination of the S. pneumoniae BDL in blood by 
real-time PCR aids in the diagnosis of patients suspected of invasive 
pneumococcal disease and might provide a novel tool in the 
management of patients with S. pneumoniae infection. 
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Summary and general discussion 
Bacteraemia, the presence of bacteria in the bloodstream, was 
recognised more than a century ago [1]. At that time, 25mL of blood was 
cultured in liquid media and on agar plates [2]. If growth was observed, 
identification of the bacteria was achieved by determination of the 
phenotypic characteristics of the strain, including the presence or absence 
of haemolysis and the result of Gram-staining. Ever since, both the insight 
in clinical presentations that are associated with bacteraemia and the 
optimization of laboratory methods for detection of microorganisms from 
blood have evolved [3-5]. The ultimate goal of these developments is to 
permit the early institution of adequate treatment of the patient, which is 
important to improve prognosis, to reduce length of hospital stay and costs, 
and to prevent the development of antimicrobial resistance [6-13]. The aim 
of this thesis was to study strategies for improvement of diagnosis and 
management of bloodstream infections (BSI) at different stages of the 
clinical and diagnostic process (figure 13). These include the design of 
models for bedside prediction of bacteraemia, the speed-up of time to 
identification and susceptibility testing of microorganisms in growth-positive 
blood cultures by fluorescence in situ hybridisation (FISH) and direct E-test, 
and the use of quantitative polymerase chain reaction (PCR) assays for the 
direct detection of bacterial DNA in blood, without prior cultivation. In 
general, clinical assessment of the patient on presentation will result in 
initial therapeutic decisions. The combination of risk factors, presenting 
signs and symptoms, and results of laboratory tests will lead to an 
estimation of the likelihood of BSI. Dependent on this, empirical 
antimicrobial treatment will be initiated, and the choice of and mode of 
administration of antibiotic may be different when BSI is suspected than in 
case a localised infection is more likely, e.g. the use of broad spectrum 
antibiotics or intravenous rather than oral administration of antimicrobial 
agents may be more opportune. The impact of identifying clinical predictors 
of BSI to support these therapeutic decisions is high in settings where 
resources for laboratory and radiological tests are low. The Queen 
Elizabeth Central Hospital (QECH) in Malawi, a country in sub-Saharan 
Africa, is a good example of a setting that would benefit from good clinical 
predictors of BSI. Almost one million people in this country are infected with 
the human immunodeficiency virus (HIV), an important risk factor for BSI 
[14-16]. Microbiological and radiological facilities are limited and patients  
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Figure 13. Flow-chart with the strategies that are evaluated in this thesis for diagnosis and 
management of bloodstream infection. The different strategies are marked with a double 
bar. PCR, polymerase chain reaction; FISH, fluorescence in situ hybridization. 
 
are usually treated empirically. Therefore, a study was carried out at QECH 
to determine clinical predictors of BSI as described in chapters 2 and 3.  
BSI was present in approximately one third of the febrile adult patients on 
admission to the medical wards. The most prevalent microorganisms 
isolated from blood cultures were non-typhoid salmonellae (NTS), 
Streptococcus pneumoniae and Mycobacterium tuberculosis. The majority 
of patients with NTS bacteraemia did not have a clear clinical focus of 
infection, whereas S. pneumoniae bacteraemia usually presented 
secondary to a local infection. The strong predictive value of splenomegaly 
and body temperature higher than 39°C for NTS bacteraemia is an 
important observation that could aid in the management of HIV-infected 
febrile patients in a resource-poor setting. We found a high prevalence of 
M. tuberculosis bacteraemia in our study. Several authors have previously 
advocated the routine use of mycobacterial blood cultures to diagnose M. 
tuberculosis bacteraemia in countries with a high prevalence of HIV 
infection and tuberculosis (TB), including Malawi, because of the high 
mortality associated with untreated mycobacteraemia [17,18]. However, 
mycobacterial blood cultures are expensive and their clinical impact may be 
limited because patients might be dead or discharged from hospital by the 
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time the results are available [19-22]. In this context, clinical predictors and 
routinely microbiological methods for detection of TB can be most helpful to 
establish the diagnosis of M. tuberculosis bacteraemia, as described in 
chapter 3. Clinical indicators of M. tuberculosis bacteraemia were cough, 
chronic fever, severe anaemia and HIV seropositivity. TB was diagnosed 
with routinely available investigations (sputum-smear, chest X-ray, fine 
needle aspiration) in the vast majority of patients with M. tuberculosis 
bacteraemia. Thus, M. tuberculosis bacteraemia in this setting usually 
presents with a detectable focus of infection rather than that it is primarily 
an intravascular infection, as suggested by others [18,19,23]. However, 
additional studies are warranted to further characterise those patients 
without a clear focus of TB but with M. tuberculosis bacteraemia. An 
important observation in this regard was the high prevalence of M. 
tuberculosis bacteraemia in patients that were eligible for a diagnostic trial 
of TB treatment. This suggests that the diagnostic value of this trial lies 
more in its indications than in the trial itself. Therefore, although only a 
small number of patients were included in our study, a trial of TB treatment 
does not seem to add to the diagnosis of TB. Instead, it seems reasonable 
to treat these patients directly with short-course chemotherapy, and clinical 
validation of this approach in a larger cohort is warranted.  
The routine availability of blood cultures to detect bacteraemia or 
mycobacteraemia does not seem feasible in a resource-poor setting like 
QECH in Malawi. Instead of putting money and effort in creating such 
services, it would be better to focus on the improvement of clinical 
education and strengthening of basic laboratory facilities. Nevertheless, the 
intermittent evaluation of blood culture isolates at a few hospital settings is 
important to provide and monitor the epidemiological spectrum of 
microorganisms causing BSI. These epidemiological data will help to 
determine the choice of empirical antimicrobial treatment in settings without 
blood culture facilities. At present, various programmes have emerged to 
supply highly active antiretroviral therapy (HAART) to HIV infected patients 
in Malawi [24]. HAART was not yet routinely available at the time our study 
was performed. The widespread treatment of HIV-infection may change the 
incidence, spectrum and presentation of severe bacterial infections, 
including BSI [25,26]. This necessitates a re-evaluation of clinical predictors 
of BSI once the majority of HIV-infected patients have been enrolled in the 
antiretroviral therapy (ART) programmes. 
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We used multiple logistic regression (MLR) analysis to identify clinical 
predictors of BSI in adult patients admitted to QECH. However, although 
these models provide insight in the predictive value of individual factors for 
BSI, translation into clinical practice may be difficult. An alternative 
approach is the use of risk stratification models or the design of a decision 
tree with classification and regression tree (CART) analysis as described in 
chapter 4 [27-29]. The decision tree that we designed for prediction of BSI 
in febrile medical patients had a reasonable accuracy and better 
performance than the MLR model. Peak temperature, nadir albumin and 
nadir thrombocyte count were predictors in both models, but procalcitonin 
(PCT) concentration was only included in the decision tree. In fact, PCT 
was the principal discriminator in the decision tree, which shows the model-
dependency of predictors. The observed strong discriminative value of PCT 
is in accordance with other studies that show that PCT may be a more 
specific marker of BSI than C-reactive protein (CRP) or white blood cell 
count (WBC) [30-34].  
At the time the data from the Malawi cohort were analysed, the 
programme for CART analysis was not available to us. If CART analysis 
had been performed on those data, body temperature and splenomegaly 
would have been the main discriminators between patients with and without 
bacteraemia (RPH Peters, personal observation). Also, no prospective 
validation was performed of the prediction models described in chapters 2, 
3 and 4 due to the low number of patients with BSI. Other studies show 
that the reproducibility of models may be different in other settings or 
patient populations [35,36]. As such, prospective confirmation of the MLR 
and CART models for prediction of BSI is crucial to define their potential 
clinical applicability. An important facilitator in this regard is the emerging 
use of handhold computers and electronic patient files. Decision models 
can be installed on these computers and might be used for an automatically 
calculation of risk of BSI in the individual patient. Although the use of such 
programmes may be highly supportive when making decisions on empirical 
treatment, computer-calculated predictions should never be used as a 
substitute for critical thinking or responsibility by the clinician. 
 
The blood culture is the gold diagnostic standard for the diagnosis of BSI. 
However, the impact of blood culture results on clinical management may 
be limited due to the relatively long turnaround time, a low sensitivity for 
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fastidious microorganisms, and the reduced yield when cultures are 
obtained under antimicrobial treatment [37-40]. As a result, the majority of 
therapeutic decisions related to BSI are taken at the moment that blood is 
drawn for culture and when Gram-stain characteristics of growth-positive 
blood cultures become available [41]. Molecular assays including FISH and 
PCR can be used to speed-up time to identification of microorganisms from 
growth-positive blood cultures [42,43]. In chapter 5, the routine use of 
FISH for identification of microorganisms from growth-positive blood 
cultures is evaluated, with emphasis on time to diagnosis by FISH 
compared to the routine identification methods. The majority of 
microorganisms, especially Gram-positives, could be identified with FISH 
within 3-4 hours. This number could be further increased with the inclusion 
of extra probes in the assay, for example probes targeting rRNA of 
Enterobacter cloacae or Proteus mirabilis. Although the time-gain to 
identification by FISH compared to preliminary and final culture 
identification was quite significant, it is questionable whether FISH will be 
used in routine practice, especially in settings where preliminary culture 
identification is performed. The main reason is that clinicians might not 
await FISH results for another 3-4 hours after notification of Gram-stain 
results before initiation or adjustment of empirical antimicrobial treatment. 
Therefore, the standard FISH procedure was modified as described in 
chapter 6 to reduce turnaround time to less than one hour. This modified 
FISH assay had a similar performance as the standard FISH assay. With 
FISH results available within one hour after Gram-stain, clinicians may 
await FISH results before initiation or adjustment of antimicrobial therapy.  
As shown in figure 7, identification of microorganisms with FISH can 
have clear implications for the antimicrobial management of the patient. 
Recently, it was demonstrated that therapeutic interventions based on 
identification of microorganisms in growth-positive blood cultures by FISH 
reduce antibiotic usage, length of stay and hospital costs [44-46]. In these 
studies, FISH is used to discriminate between Candida albicans and non-
albicans Candida species and to differentiate between S. aureus and 
coagulase-negative staphylococci. However, these studies were carried out 
at settings in the United States where no preliminary identification is 
performed. It is unclear whether the observed reduction in antibiotic usage 
after FISH identification could also have been achieved by implementation 
of preliminary culture identification, but at a lower cost. Furthermore, the 
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studies involve two clinical conditions where clear therapeutic 
consequences are associated with the FISH result. Although they provide a 
first step in the assessment of cost-effectiveness of FISH for identification 
of microorganisms in growth-positive blood cultures, a randomised 
prospective study, preferably in multi-center format, is highly warranted to 
assess the clinical impact, feasibility and cost-effectiveness of FISH in 
routine practice. 
Identification of microorganisms in growth-positive blood cultures by FISH 
or PCR can lead to the adjustment of antimicrobial treatment. The choice 
for a change of antibiotics is based on the epidemiologically most likely 
susceptibility pattern of the microorganism that was identified by FISH or 
PCR. Determination of the antimicrobial susceptibility of the isolates is 
routinely done with disk-diffusion tests or with the automated VITEK 
system. An E-test performed directly on positive blood cultures, prior to 
species identification, may provide an alternative approach for standard 
susceptibility testing; the timely availability of the test result might also 
decrease antibiotic consumption [47]. As shown in chapter 7, direct E-test 
guided by FISH results can be used to obtain antimicrobial susceptibility 
data of microorganisms from growth-positive blood cultures within 24 hours. 
Direct E-test in general provides a similar classification of antimicrobial 
resistance as disk-diffusion or VITEK, although a more conservative result 
was generated in a few cases. As a result, only a few patients would have 
been treated with other antibiotics on basis of direct E-test than based upon 
the results of disk diffusion or VITEK, but always with antibiotics for which 
the microorganism is susceptible. However, the cost-effectiveness of direct 
E-test is highly questionable and needs to be investigated. 
Although FISH offers faster identification of microorgansims from growth-
positive blood cultures than routine identification techniques, the initial, 
time-consuming step of culturing blood has still to be performed. This can 
be overcome by the direct detection of microoganisms in blood by PCR, 
without prior cultivation. The use of PCR assays for detection of 
bacteraemia offers a faster alternative to culturing blood and is presumably 
not affected by the prior use of antibiotics [48,49]. Chapters 9 and 10 are 
confined to the detection of Staphylococcus aureus and Enterococcus 
faecalis DNA in blood by quantitative PCR (QPCR) during bacteraemia in 
critically ill patients, while chapter 11 describes the clinical relevance of 
detection of Streptococcus pneumoniae DNA in blood samples from 
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patients suspected of community-acquired pneumonia or meningitis. The 
sensitivity of these three QPCR assays compared to blood culture outcome 
lies in the range of 70-80%. This apparently low sensitivity may be 
explained, at least in part, by the small volume of blood (200µL) that was 
tested compared to the larger volume of blood inoculated into blood culture 
bottles (10mL), which may result in a sampling error. As such, the current 
technical developments are aimed at increasing the volume of blood that 
can be processed in DNA isolation, but the consequent inhibitory effects on 
PCR have to be overcome [50-52].  
The specificity of the QPCR assays for detection of BSI in whole blood 
samples ranged from 92-96%. However, it is highly questionable whether 
positive PCR results in the absence of growth-positive blood cultures 
clinically should be considered ‘false-positive’. The majority of patients with 
positive PCR reactions for S. aureus, E. faecalis and S. pneumoniae and 
not growth in simultaneous blood cultures had a clinically manifest focus of 
infection with the respective microorganism, as demonstrated by the 
isolation of the pathogen from other body sites than blood. In addition, a 
considerable number of those blood samples had been obtained after the 
initiation of antimicrobial therapy which reduces the yield of blood cultures 
considerably, but presumably has no effect on PCR [39,49]. It is not 
possible to determine whether these positive PCR reactions are related to 
true, undetected bacteraemia, represent circulating dead bacteria, or 
merely originate from DNA leakage from a local infection into the 
bloodstream, or even from colonization. Instead of ‘bacteraemia’, it might 
be better to use the term ‘DNAemia’ in the context of QPCRs on blood, 
because this does not commit to the origin of DNA or viability of bacteria in 
the bloodstream. Future studies should be focused on increasing our 
understanding of the clinical relevance of such a ‘DNAemia’. Possible 
approaches are the determination of the bacterial DNA load (BDL) in blood 
as a quantitative marker of DNAemia to distinguish infection from 
colonization, or the comparison between DNA and RNA content as a 
measure of viability [53]. 
Results of PCR assays directly on blood samples may be available a few 
hours after the blood sample was obtained and might influence the 
institution of antimicrobial therapy. For example, a positive S. aureus PCR 
in blood from a patient suspected of endocarditis would establish the 
diagnosis and result in a more directed treatment at an early stage. 
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However, in clinical practice, many microorganism-specific PCR assays 
have to be performed to cover all possible microorganisms involved in the 
patient’s condition. Instead, PCR algorithms may be used, if possible 
guided by the panel of microorganisms involved in the patient’s condition, 
which has become more and more feasible with the decreasing turnaround 
time of PCR amplification systems [43].  
Instead of using microorganism-specific PCR assays, a broad-range, 
universal PCR assay may be used that theoretically detects all bacterial or 
fungal DNA in one reaction. These assays are usually based on the 
detection of the highly conserved 16S gene of bacteria (eubacterial) or the 
18S gene or internal transcribed spacer (ITS) regions of fungi (panfungal) 
[54-56]. These assays have been used for rapid prediction of BSI in 
patients presenting to the emergency department, neutropenic patients and 
neonates [57-59]. The performance of these broad-range PCR assays is 
variable, but may be better in blood samples from neonates (sensitivity 96-
100% and specificity 58 to 98%) than in blood samples from adult patients 
(54-100% and 93-99%) [57-64]. Although there is no obvious reason for the 
difference in performance of these assays, a possible explanation could be 
that the concentration of microorganisms in blood of neonates is higher 
than in adults. A positive PCR amplification signal with the broad-range 
PCR does not specify from which specific microorganism DNA is present in 
the bloodstream. For that purpose, sequence-analysis of the broad-range 
amplification product is required [65]. However, the routine performance of 
sequence analysis is not feasible because of the high costs and relatively 
long turnaround time. Another disadvantage of these broad-range PCR 
assays is that not only clinically relevant, but also contaminating DNA is 
detected. This contaminating DNA can originate from many sources, 
including the commercially available kits that are used for DNA isolation 
[66,67]. Misinterpretation of false-positive results due to contamination 
potentially has adverse clinical consequences, as described in chapter 8. 
Therefore, efforts should be made to reduce contamination in diagnostic 
kits, especially for DNA isolation. While much progress has been made with 
the introduction of ‘closed’, real-time systems for PCR amplification 
detection, the developments to reduce contamination during DNA isolation 
have been scarce. Improvement of this situation is critical for future 
application of the broad-range assays in routine diagnostic practice. All 
taken together, the clinical role of broad-range PCR assays in the diagnosis 
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of BSI may be limited to establishing a diagnosis in patients with ongoing 
unknown illness despite other microbiological tests, e.g. persisting 
unexplained fever. When there is overt clinical infection, the direct use of an 
algorithm or panel of species-specific PCR assays seems to offer a better 
alternative. 
 
The BDL in blood offers a quantitative measure of bacteraemia and is 
discussed in chapters 10 and 11. The receiver operating characteristic 
(ROC) curves generated for S. aureus, E. faecalis and S. pneumoniae BDL 
suggest that prediction BDL may be a better and certainly more specific 
marker of bacteraemia than the routinely used inflammatory markers CRP 
and WBC. With a further decreasing turnaround time of PCR assays, it will 
be feasible to obtain blood samples for determination of BDL 
simultaneously to full blood count and chemistry, and use the results at the 
same point in time of the diagnostic process. 
BDL correlated positively with levels of CRP in critically ill patients with 
positive PCR amplification results, while the correlation of S. pneumoniae 
BDL with CRP was manifest for the entire cohort of patients suspected of 
community-acquired pneumonia or meningitis. The different correlations in 
these cohorts may be explained by the much more prominent role of S. 
pneumoniae as a pathogen involved in bacterial respiratory tract infections, 
as compared to the diverse aetiology of illnesses for which blood cultures 
are indicated in the intensive care unit (ICU). As such, the increase of CRP 
levels may be the result of other illnesses in a higher proportion of critically 
ill patients than in patients with community-acquired respiratory tract 
infections. On the other hand, due to the strict monitoring of patients in the 
ICU, blood samples may have been obtained at a different stage of the 
illness than those from patients with community-acquired episodes. As 
such CRP levels may be low despite the presence of BSI, because of the 
relatively slow response of CRP to infection. Both explanations are also 
reflected in the low discriminatory value of WBC and CRP that was 
observed in the ICU cohort compared to the strong discriminative value of 
those variables in the other cohort suggesting a more heterogeneous 
patient population in the ICU. Nevertheless, the observed positive 
association of BDL with CRP suggests that BDL is related to the degree of 
inflammation, with a higher BDL evoking a stronger inflammatory response. 
This idea is supported by associations that were observed for BDL and 
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microbiological invasiveness and clinical severity of infection, and the 
higher S. pneumoniae BDL in patients who fulfilled the systemic 
inflammatory response syndrome (SIRS) criteria on admission. Despite 
these associations, the relation of BDL with clinical symptoms, severity of 
illness and prognosis has yet to be elucidated. The anecdotic data from one 
patient as depicted in figure 10 suggest that the course of S. aureus BDL 
may mimic the course of temperature during bacteraemia, although no 
general conclusions should be drawn from this case report. In contrast to 
our data, BDL on admission correlated with disease severity and short-term 
outcome in patients with systemic meningococcal disease [68,69]. 
However, the average values of meningococcal BDL in blood during 
meningococcaemia are much higher and more diverse than the BDLs 
observed in our cohorts, possibly associated with the more fulminant nature 
of that condition. Therefore, the numbers of patients with BSI in our cohorts 
may have been too low to detect associations between BDL and disease 
severity or prognosis.  
 
The strategies to diagnose and manage BSI have gradually improved 
during the last century. With the recent emergence of molecular tests, the 
first steps are made towards a rigorous change in diagnostics of BSI which 
will have even more effect on clinical practice than the introduction of 
automated detection systems in the 1960s. The short-term developments to 
improve the diagnosis of BSI are aimed at the rapid identification of 
microorganisms in growth-positive blood cultures by FISH assays or PCR 
algorithms. Although these are promising tools to speed-up the 
identification of the causative microorganism in BSI, it is still essential to 
perform a time-consuming culture step prior to FISH or PCR. Therefore, for 
the long term, it is to be expected that the direct quantitative molecular 
detection of circulating bacteria and bacterial DNA fragments in blood will 
become the standard for diagnosing BSI. To achieve this goal, the 
sensitivity and specificity of the current QPCR assays have to be further 
improved, the risk of contamination reduced, and the turnaround time 
should even be further decreased. In addition, with the increasing 
understanding and opening up of the bacterial genomes and in combination 
with the mounting knowledge of antimicrobial resistance genes and 
mechanisms, molecular assays for determination of antimicrobial 
susceptibility will be more and more incorporated in the routine diagnostic 
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process. For example, a recent study shows that DNA microarray can be 
used for simultaneous identification and testing of genotypic antimicrobial 
resistance of S. aureus, Escherichia coli and Pseudomonas aeruginosa 
[70]. The integration of molecular assays for identification and 
determination of antimicrobial resistance will be important spearheads in 
the future technical developments. The clinical interpretation of the 
DNAemia detected by these molecular assays will evolve with the 
increasing knowledge of the relationship between BDL and clinical and 
microbiological characteristics. The potential theoretical value of monitoring 
BDL is appealing and warrants further investigation of the kinetics of DNA 
in blood. Possibly, the course of BDL can be used to predict prognosis, to 
monitor response to treatment, or as a surrogate marker in clinical trials to 
evaluate efficacy and duration of antimicrobial treatment in bacteraemic 
conditions such as endocarditis. 
The individual patient is eventually the one who has to benefit from all 
these technical developments, ultimately by receiving adequate 
antimicrobial treatment at the earliest possible moment. BDL provides 
another piece of the clinical jigsaw that lays out to the clinician when 
making bedside decisions about empirical therapy. As such, the clinical 
management of patients suspected of BSI will always remain an integrated 
assessment of risk factors, clinical symptoms and laboratory factors, which 
can only be supported but never replaced by high-tech laboratory facilities. 
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Samenvatting en discussie 
Bacteriëmie, de aanwezigheid van bacteriën in de bloedbaan, werd meer 
dan een eeuw geleden voor het eerst beschreven [1]. In die tijd bestond de  
diagnostiek uit het kweken van 25mL in verschillende vloeibare media en 
op agar platen [2]. Als er bacteriële groei optrad, werd de betreffende 
bacterie geïdentificeerd op grond van fenotypische karakteristieken, 
waaronder de aan- of afwezigheid van hemolyse, en op basis van de 
Gram-kleuring. Sinds die tijd is het inzicht in de klinische presentatie van 
patiënten met bloedbaan infectie toegenomen en zijn de laboratorium 
technieken voor detectie van micro-organismen in bloed verder ontwikkeld 
[3-5]. Het ultieme doel van deze ontwikkelingen is om de patiënt vroegtijdig 
adequaat te behandelen, hetgeen leidt tot een betere prognose, de 
opnameduur verkort en ziekenhuiskosten verminderd. Daarnaast wordt de 
ontwikkeling van antimicrobiële resistentie tegengegaan [6-13]. Deze thesis 
heeft tot doel nieuwe klinische en technische methoden te ontwikkelen die 
kunnen leiden tot verbetering van de diagnostiek en behandeling van 
bloedbaan infecties, onder andere door het ontwerpen van modellen voor 
de klinische voorspelling van bacteriëmie, het verkorten van de tijd die 
nodig is voor de identificatie en gevoeligheidsbepaling van micro-
organismen in positieve bloedweken door implementatie van fluorescentie 
in situ hybridisatie (FISH) en directe Etest, en het gebruik van een PCR 
voor de directe detectie van bacterieel DNA in bloed, zonder voorafgaand 
een kweek te maken (figuur 14).  
In de dagelijkse praktijk worden de initiële therapeutische beslissingen 
genomen op grond van de klinische presentatie van de patiënt. De arts 
maakt een inschatting van de kans op een (bloedbaan) infectie op basis 
van de combinatie van risicofactoren, klinische symptomen en resultaten 
van eenvoudig laboratorium onderzoek. Afhankelijk van deze inschatting 
zal empirisch gestart worden met antibiotica. De keuze van het antibioticum 
en de wijze van toediening kunnen anders zijn in het geval er een 
bloedbaan infectie verwacht wordt dan als een gelokaliseerde infectie 
waarschijnlijker is. Breed-spectrum antibiotica kunnen bijvoorbeeld meer 
opportuun gebruikt worden of er kan gekozen worden voor intraveneuze 
toediening van het middel in plaats van oraal. Het belang van het 
identificeren van klinische voorspellers van bloedbaan infectie die deze 
therapeutische beslissingen ondersteunen is het grootst in situaties waar 
geld en middelen voor radiologisch en laboratorium onderzoek schaars zijn. 
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Figuur 14. Diagram met strategieën die in deze thesis geëvalueerd zijn voor de diagnostiek 
en behandeling van bloedbaan infectie. De verschillende strategieën zijn aangegeven met 
een dubbele streep. PCR, polymerase ketting reactie; FISH, fluorescentie in situ 
hybridisatie. 
 
Het Queen Elizabeth Central Hospital (QECH) in Malawi, een land in sub-
Sahara Afrika, is een goed voorbeeld van een locatie waar goede kennis 
over klinische voorspellers van bloedbaan infectie uiterst zinvol is. Bijna 
één miljoen mensen in dat land zijn geïnfecteerd met het Humaan 
Immunodeficiëntie Virus (HIV), een belangrijke risicofactor voor bloedbaan 
infectie [14-16]. Microbiologische en radiologische faciliteiten zijn er beperkt 
en patiënten worden veelal empirisch behandeld. Om die reden hebben we 
aan QECH een studie gedaan naar de epidemiolgoie en klinische 
voorspellers van bloedbaan infectie zoals beschreven in hoofdstuk 2 en 3. 
Ongeveer éénderde van alle volwassen patiënten die met koorts 
opgenomen werden op de afdeling Algemene Geneeskunde had een 
bloedbaan infectie. De meest voorkomende micro-organismen waren non-
typhi salmonellae (NTS), Streptococcus pneumoniae en Mycobacterium 
tuberculosis. De meerderheid van patiënten met NTS bacteriëmie had geen 
duidelijk klinisch focus, terwijl de presentatie van S. pneumoniae 
bacteriëmie meestal secundair was aan een lokale infectie. De sterke 
voorspellende waarde van splenomegalie en lichaamstemperatuur boven 
de 39°C voor NTS bacteriëmie is een belangrijke observatie die van 
waarde kan zijn bij de behandeling van patiënten met HIV infectie en koorts 
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op plaatsen waar de middelen schaars zijn. Onze studie toont ook een 
hoge prevalentie van M. tuberculosis bacteriëmie. In andere studies is door 
verschillende auteurs gepleit om routinematig mycobacteriële bloedkweken 
te verrichten voor diagnostiek naar M. tuberculosis bacteriëmie in gebieden 
met een hoge prevalentie van HIV infectie en tuberculose, inclusief Malawi 
[17,18]. De voornaamste reden is de hoge mortaliteit die geassocieerd is 
met onbehandelde mycobacteriëmie. Echter, mycobacteriële bloedkweken 
zijn duur en hebben mogelijk weinig invloed op het klinisch beleid omdat 
patiënten met M. tuberculosis bacteriëmie meestal al overleden of 
ontslagen zijn uit het ziekenhuis voordat de resultaten van de kweek 
beschikbaar zijn [19-22]. In die context zijn klinische voorspellers en de 
standaard microbiologische testen voor detectie van tuberculose zeer 
bruikbaar voor de diagnose van M. tuberculosis bacteriëmie, zoals 
beschreven in hoofdstuk 3. Klinische indicatoren voor M. tuberculosis 
bacteriëmie waren hoest, chronische koorts, ernstige anemie en HIV 
infectie. Tuberculose werd gediagnosticeerd met routine testen (sputum 
microscopie, röntgenfoto en fijne naald aspiratie van lymfeklieren) in de 
ruime meerderheid van de patiënten met M. tuberculosis bacteriëmie. In 
QECH manifesteert M. tuberculosis bacteriëmie zich dus met een 
detecteerbaar focus van infectie en niet primair als een intravasculaire 
infectie zoals door anderen is gesuggereerd [18,19,23]. Verder onderzoek 
is echter hard nodig om de groep patiënten met M. tuberculosis bacteriëmie 
zonder focus van tuberculose verder te karakteriseren. Een belangrijke 
waarneming in onze studie is de hoge prevalentie van M. tuberculosis 
bacteriëmie bij patiënten die een diagnostische proefbehandeling met 
tuberculostatica kregen. Dit suggereert dat de indicaties voor de 
proefbehandeling meer diagnostische waarde hebben dan de behandeling 
zelf. De proefbehandeling draagt in onze studie dus weinig bij aan de 
diagnostiek van tuberculose, mede omdat slechts een klein aantal 
patiënten de proefbehandeling met tuberculostatica heeft gekregen. Hwt 
lijkt echter reëler, gezien de hoge prevalentie van M. tuberculose 
bacteriëmie onder de groep patiënten die in aanmerking komt voor de 
proefbehandeling, om die patiënten direct te behandelen met short-course 
chemotherapy, alhoewel klinische validatie van deze aanpak in een groot 
cohort patiënten gewenst is. De beschikbaarheid van bloedkweken voor de 
routinematige detectie van bacteriëmie en mycobacteriëmie lijkt niet 
haalbaar in situaties waar de middelen schaars zijn, zoals aan QECH in 
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Malawi. In plaats van geld en inspanning te steken in het opzetten van een 
dergelijke dienst, zou het beter zijn om de aandacht te richten op de 
verbetering van klinisch onderwijs en versterken van basale laboratorium 
faciliteiten. Niettemin is een intermitterende evaluatie van de verwekkers 
van bloedbaan infectie in enkele ziekenhuizen belangrijk om inzicht te 
krijgen in het epidemiologie van verwekkers van bloedbaan infectie. Deze 
epidemiologische gegevens kunnen gebruikt worden bij het bepalen van de 
keuze van empirische antimicrobiële behandeling indien geen bloedkweek 
faciliteiten beschikbaar zijn. De laatste jaren zijn verschillende programma’s 
opgezet om highly active antiretrovial therapy (HAART) te verstrekken aan 
patiënten met HIV infectie in Malawi [24]. HAART was niet routinematig 
beschikbaar op het moment dat onze studie werd verricht. De grootschalige 
behandeling van patiënten met HIV infectie kan leiden tot een verandering 
van incidentie, klinische presentatie en epidemiologisch spectrum van 
ernstige bacteriële infecties, waaronder bloedbaan infectie [25,26]. Dit 
maakt het noodzakelijk om de klinische voorspellers van bloedbaan infectie 
opnieuw te evalueren op het moment dat de meerderheid van HIV 
geïnfecteerde patiënten in Malawi behandeld wordt met HAART. 
Voor de identificatie van klinische voorspellers van bloedbaan infectie 
aan QECH hebben we multiple logistische regressie (MLR) analyse 
gebruikt. Hoewel MLR modellen inzicht verschaffen in de voorspellende 
waarde van individuele factoren, kan de vertaling naar de klinische praktijk 
lastig zijn. Als alternatief voor MLR analyse kan een risico stratificatie 
gedaan worden of een beslisboom ontworpen met classification and 
regression tree (CART) analyse, zoals beschreven in hoofdstuk 4 [27-29]. 
De beslisboom die we ontworpen hebben voor het voorspellen van 
bloedbaan infectie bij patiënten met koorts op de afdeling Inwendige 
Geneeskunde is redelijk accuraat en presteert beter dan het MLR model. In 
beide modellen zijn piek temperatuur, albumine dalwaarde en 
thrombocyten dalwaarde voorspellend voor bloedbaan infectie, maar 
procalcitonine (PCT) concentratie enkel is opgenomen in de beslisboom. 
Sterker nog, PCT had de sterkst discriminerende waarde voor bloedbaan 
infectie in die beslisboom. Dit toont aan dat de waarde van voorspellers 
voor bloedbaan infectie afhankelijk kan zijn van het gebruikte model. De 
sterke onderscheidende waarde van PCT in de beslisboom komt overeen 
met andere studies die aantonen dat PCT een specifiekere marker voor 
bloedbaan infectie is dan het C-reactief proteïne (CRP) of leukocytenaantal 
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[30-34]. Het programma dat we voor CART analyse gebruikt hebben, was 
niet beschikbaar op het moment dat we de data van het Malawi cohort 
analyseerden. Indien we op die data CART analyse wordt gedaan, dan zijn 
lichaamstemperatuur en splenomegalie de belangrijkste voorspellers voor 
de aan- en afwezigheid van bacteriëmie in de beslisboom (RPH Peters, 
persoonlijke observatie).  
Vanwege het kleine aantal patiënten met bloedbaan infectie hebben we 
geen prospectieve validatie gedaan van de modellen zoals beschreven in 
hoofdstuk 2, 3 en 4. Andere studies tonen dat de reproduceerbaarheid 
van dergelijke modellen in andere ziekenhuizen of patiënt populaties zeer 
wisselend is [35,36]. Prospectieve bevestiging van onze MLR en CART 
modellen voor voorspelling van bloedbaan infectie is dus noodzakelijk om 
de mogelijke klinische toepasbaarheid vast te stellen. Het doen van 
dergelijke studies is gemakkelijker geworden met de opkomst van het 
elektronisch patiëntendossier en de toename van het gebruik van kleine 
zakcomputers. Daarop kunnen beslissingsmodellen worden geïnstalleerd 
en vervolgens gebruikt voor de automatische berekening van de kans op 
bloedbaan infectie aan het bed van de individuele patiënt. Hoewel het 
gebruik van dergelijke zakcomputers kan helpen bij het nemen van 
beslissingen over empirische therapie, mag het nooit zo zijn dat computer 
berekeningen als alternatief gelden voor het kritisch denken en de klinische 
verantwoordelijkheid van de arts. 
De bloedkweek is de gouden standaard voor de diagnostiek van 
bloedbaan infectie. De resultaten van een bloedkweek hebben echter een 
relatief beperkte invloed op het klinisch beleid omdat er relatief veel tijd 
nodig is voordat resultaten beschikbaar zijn, de kweken een lage 
gevoeligheid hebben voor moeilijk kweekbare micro-organismen, en de 
opbrengt van kweken die afgenomen zijn onder antibiotica beperkt is [37-
40]. As gevolg hiervan wordt de meerderheid van de therapeutische 
beslissingen gerelateerd aan bloedbaan infectie genomen op het moment 
dat bloed wordt afgenomen voor kweek, en op het moment dat de uitslag 
van de Gram-kleuring van positieve bloedkweken bekend wordt [41]. 
Moleculaire testen waaronder FISH en PCR kunnen gebruikt worden om de 
identificatie van micro-organismen in kweekpositieve bloedkweken te 
versnellen [42,43]. In hoofdstuk 5 wordt het gebruik van FISH voor 
identificatie van micro-organismen in kweekpositieve bloedkweken in de 
dagelijkse praktijk geëvalueerd. De nadruk in die studie ligt op de tijd die 
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verstrijkt voordat de diagnose gesteld kan worden met FISH in vergelijk met 
de routinematige identificatie met kweek. Met FISH kon de meerderheid 
van de micro-organismen worden geïdentificeerd binnen 3-4 uur, met name 
de Gram-positieve. De prestatie van de FISH test die we gebruikt hebben 
zou nog beter kunnen zijn indien er een aantal extra probes in de test 
opgenomen zouden worden, bijvoorbeeld probes voor de identificatie van  
Enterobacter cloacae of Proteus mirabilis. Hoewel het gebruik van FISH 
een duidelijke tijdwinst oplevert vergeleken met de voorlopige en definitieve 
kweek, is het maar de vraag of FISH standaard in de diagnostiek gebruikt 
zal gaan worden, helemaal in laboratoria waar routinematig een voorlopige 
kweek identificatie wordt gedaan. De voornaamste reden hiervoor is dat 
clinici na de uitslag van de Gram-kleuring waarschijnlijk niet nog 3-4 uur 
zullen wachten op de resultaten van de FISH alvorens behandeling te 
starten of empirische antimicrobiële therapie aan te passen. Om die reden 
hebben we de standaard FISH procedure aangepast tot een FISH test 
waarbij de resultaten binnen een uur beschikbaar kunnen zijn, zoals 
beschreven in hoofdstuk 6. Deze aangepaste FISH test preseteert 
vergelijkbaar aan de standaard FISH techniek. Aangezien uitslag van FISH 
beschikbaar kan zijn binnen een uur na de Gram-kleuring zullen clinici 
waarschijnlijk wel wachten op de uitslag van FISH analyse voordat zij 
overgaan tot initiatie of aanpassing van antimicrobiële therapie. Het gebruik 
van FISH voor snelle identificatie van micro-organismen in bloedkweken 
kan een duidelijke klinische implicatie hebben, zoals getoond in figuur 7.  
Recent is aangetoond dat therapeutische interventies gebaseerd op 
snelle identificatie van micro-organismen in positieve bloedkweken met 
FISH kunnen leiden tot een reductie van het gebruik van antibiotica, een 
verkorte opnameduur en verminderde ziekenhuis kosten [44-46]. In die 
studies werd FISH gebruikt om Candida albicans te onderscheiden van 
non-albicans Candida species, en om te differentiëren tussen S. aureus en 
coagulase-negative staphylokokken. Die studies zijn verricht in een 
laboratorium in de Verenigde Staten waar geen voorlopige kweek 
identificatie werd verricht. Het is onduidelijk of de waargenomen reductie in 
het gebruik van antibiotica na FISH identificatie ook verkregen kan worden 
door de implementatie van een voorlopige kweek identificatie, hetgeen in 
ieder geval goedkoper is. Daar komt bij dat die studies zich richten op twee 
klinische situaties waar een duidelijke therapeutische consequentie 
verbonden is aan het resultaat van de FISH identificatie. Hoewel de studies 
Chapter 13 
230 
een duidelijke eerste stap vormen in het vaststellen van de 
kosteneffectiviteit van FISH voor identificatie van micro-organismen in 
positieve bloedkweken, is het sterk gewenst om een prospectieve 
gerandomiseerde studie te doen, bij voorkeur multicenter, teneinde de 
klinische invloed, bruikbaarheid en kosteneffectiviteit van FISH in de 
dagelijkse praktijk vast te stellen. 
De identificatie van micro-organismen in positieve bloedkweken met FISH 
of PCR kan leiden tot het starten of aanpassen van antimicrobiële 
behandeling. De keuze voor het type antibiotica is gebaseerd op het 
epidemiologisch meest waarschijnlijke gevoeligheidspatroon van het 
betreffende micro-organisme. De bepaling van antimicrobiële gevoeligheid 
van isolaten wordt normaal gedaan met disk diffusie testen of met het 
automatische VITEK systeem. Als alternatief kan een Etest gedaan 
worden direct op positieve bloedkweken, zonder eerst de betreffende 
species te kweken [47]. De directe Etest, gekozen op basis van FISH 
resultaten, kan gebruikt worden voor een gevoeligheidsbepaling te doen 
van micro-organismen in kweekpositieve bloedkweken binnen 24 uur, zoals 
beschreven in hoofdstuk 7. In het algemeen leidt de directe Etest tot een 
vergelijkbare classificatie van antimicrobiële resistentie als de disk diffusie 
test, hoewel in enkele gevallen een meer conservatief resultaat verkregen 
wordt. Op basis van de directe Etest zouden dus slechts enkele patiënten 
met andere antibiotica behandeld zijn dan op grond van disk diffusie of 
VITEK, maar dit zou altijd gebeurd zijn met antibiotica waarvoor het 
microorganisme gevoelig is. Echter, de kosteneffectiviteit van de directe 
Etest is twijfelachtig en dient verder onderzocht te worden. 
Hoewel het met FISH mogelijk is om micro-organismen in kweekpositieve 
bloedkweken sneller te identificeren, moet de meest tijdrovende stap, de 
kweek voorafgaand aan de identificatie, nog altijd verricht worden. Door 
een PCR direct op bloedmonsters te doen, zonder voorafgaande kweek, 
kan deze stap overgeslagen worden. Dergelijke PCR testen bieden een 
sneller alternatief voor de bloedkweek en worden waarschijnlijk niet nadelig 
beïnvloed door het gebruik van antibiotica [48,49]. Hoofdstuk 9 en 10 zijn 
gewijd aan de detectie van Staphylococcus aureus en Enterococcus 
faecalis DNA in bloed met kwantitatieve PCR (QPCR) tijdens bacteriëmie 
bij patiënten op de Intensive Care, terwijl hoofdstuk 11 de klinische 
relevantie van Streptococcus pneumoniae DNA in bloed van patiënten die 
verdacht zijn voor community-acquired pneumonie of meningitis beschrijft. 
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De sensitiviteit van deze drie QPCR testen ten opzichte van de bloedkweek 
ligt rond de 70-80%. Deze op het oog lage sensitiviteit kan voor een groot 
deel worden verklaard door het kleine volume bloed (200µL) dat wordt 
getest in QPCR vergeleken bij een veel groter volume (10mL) dat in 
bloedkweek flesjes geïnoculeerd wordt, wat kan leiden tot een fout in 
bemonstering. De huidige technische ontwikkelingen zijn dan ook gericht 
op het vergroten van het volume bloed dat verwerkt kan worden in DNA 
isolatie, waarbij de simultane toename van remmende effecten op PCR 
opgelost moet worden [50-52].  
De specificiteit van onze QPCR testen voor de detectie van bloedbaan 
infecties rechtstreeks in volbloed varieert tussen de 92 en 96%. Het is 
echter sterk de vraag of positieve PCR resultaten terwijl de gelijktijdige 
bloedkweek negatief blijft klinisch als foutpositief beschouwd moeten 
worden. De meerderheid van de patiënten met positieve PCR reacties voor 
S. aureus, E. faealis en S. pneumoniae zonder groei in gelijktijdige 
bloedkweken had een klinisch manifest focus van infectie met het 
betreffende micro-organisme, hetgeen bleek uit positieve microbiologische 
kweken van andere lichaamsmaterialen dan bloed. Daar komt bij dat een 
aanzienlijk aantal van die bloedmonsters was afgenomen nadat gestart 
was met antimicrobiële therapie. Het gebruik van antibiotica vermindert de 
opbrengst van bloedkweken sterk, maar heeft waarschijnlijk geen effect op 
de PCR [39,49]. Het is niet mogelijk om te onderscheiden of deze positieve 
PCR reacties bij negatieve bloedkweken gerelateerd zijn aan een echte, 
niet-gedetecteerde bacteriëmie, aan circulerende dode bacteriën, of vooral 
aan lekkage van DNA naar bloedbaan vanuit een lokale infectie of zelfs 
kolonisatie. Om die reden lijkt het beter om bij de interpretatie van 
resultaten van QPCR op bloed de term ‘DNAmie’ te gebruiken in plaats van 
‘bacteriëmie’, omdat dit geen uitspraak doet over de origine van het DNA of 
de viabiliteit van de bacteriën in de bloedbaan. In de toekomst moeten 
studies moeten gericht zijn op het verkrijgen van meer inzicht in de 
klinische relevantie van een dergelijke ‘DNAmia’. Het bepalen van de 
bacteriële DNA load (BDL) in bloed als een kwantitatieve marker van 
DNAmie kan mogelijk helpen bij het maken van onderscheid tussen infectie 
en kolonisatie. Als alternatief zou ook de verhouding tussen DNA en RNA 
als maat voor viabiliteit gemeten kunnen worden [53]. 
De uitslag van PCR direct op bloedmonsters kan binnen enkele uren na 
afname van bloed beschikbaar zijn en duidelijke invloed hebben op de 
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keuze voor antimicrobiële therapie. Bijvoorbeeld, een positief PCR resultaat 
voor een bloedmonster van een patiënt die verdacht wordt van endocarditis 
kan de diagnose rond maken en leiden tot directe behandeling in een vroeg 
stadium. Een nadeel is echter dat in de praktijk verschillende micro-
organisme specifieke PCRs gedaan moeten worden om alle mogelijke 
verwekkers te dekken die verantwoordelijk kunnen zijn voor de klinische 
presentatie van de patiënt. In plaats van al die PCR testen gelijktijdig te 
doen, kan een PCR algoritme gebruikt worden dat gebaseerd is op de 
meest waarschijnlijke verwekkers voor de aandoening waarmee de patiënt 
zich presenteert. Door de immer afnemende tijd die nodig is voor PCR 
amplificatie wordt deze aanpak steeds meer bruikbaar [43]. 
In plaats van bloedmonsters met een aantal micro-organisme specifieke 
PCRs te testen, kan ook een broad-range, universele PCR gedaan worden. 
Deze universele PCRs detecteren theoretisch al het bacterieel of fungaal 
DNA in slechts één PCR en  zijn in het algemeen gebaseerd op de detectie 
van het sterk geconserveerde 16S gen van bacteriën (eubacterieel) of van 
het 18S gen van de internal transcribed spacer (ITS) regio van fungi 
(panfungaal) [54-56]. Eubacteriële en panfungale PCRs zijn gebruikt voor 
de snelle detectie van bloedbaan infectie in patiënten die zich presenteren 
op de spoedeisende hulp, bij neutropene patiënten en bij neonaten [57-59]. 
De prestatie van deze PCRs varieert aanzienlijk en lijkt beter te zijn bij  
bloedmonsters van neonaten (sensitiviteit 96-100% en specificiteit 58-98%) 
dan in bloedmonsters van volwassenen (54-100% en 93-99%) [57-64]. 
Hoewel er geen duidelijke reden is voor het verschil tussen bloedmonsters 
van neonaten en van volwassenen, zou een mogelijke verklaring kunnen 
zijn dat de concentratie aan micro-organismen hoger is in het bloed van 
neonaten. Een positief PCR resultaat met de universele PCR geeft geen 
specificatie van het micro-organisme waarvan het betreffende DNA 
aanwezig is in de bloedbaan. Om het DNA te specificeren is sequentie 
analyse nodig van het amplificatie product, maar het routinematig doen van 
een dergelijke analyse is niet wenselijk vanwege de hoge kosten en relatief 
lange tijd die daarvoor nodig is [65]. Een ander nadeel van de universele 
PCR is dat niet alleen klinisch relevant, maar ook contaminerend DNA 
wordt gedetecteerd. Dit contaminerend DNA kan op allerlei manieren 
geïntroduceerd worden in de test, inclusief door commercieel verkrijgbare 
kits voor DNA isolatie [66,67]. Misinterpretatie van (fout)positieve resultaten 
als gevolg van contaminatie kan mogelijk ernstige klinische consequenties 
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hebben, zoals beschreven in hoofdstuk 8. Het is daarom zeer belangrijk 
om contaminatie in diagnostische testen te reduceren. Hoewel op dit vlak 
veel vooruitgang is geboekt met de introductie van zogenaamde ‘gesloten’ 
real-time PCR systemen, zijn de ontwikkelingen om contaminatie tijdens 
DNA isolatie te verminderen slechts schaars geweest. Het is cruciaal om 
deze situatie te verbeteren teneinde in de toekomst gebruik te kunnen 
maken van universele PCR testen in de standaard diagnostiek. De 
klinische rol van universele PCR assays is op dit moment beperkt tot de 
diagnostiek van patiënten met een onduidelijke ziekte bij wie allerlei andere 
microbiologische testen negatief zijn, bijvoorbeeld bij koorts van onbekende 
origine. Het gebruik van een algoritme of een combinatie van species-
specifieke PCRs is een beter alternatief als er een duidelijk zichtbaar focus 
van infectie is. 
De BDL in bloed biedt een kwantitatieve maat voor bacteriëmie en wordt 
besproken in hoofdstuk 10 en 11. De waarde van de receiver operating 
characteristic (ROC) curves voor S. aureus, E. faecalis en S. pneumoniae 
BDL suggereren dat BDL een betere, en ieder geval specifiekere marker is 
voor bacteriëmie dan de ontstekingsparameters leukocytenaantal en CRP 
die standaard gebruikt worden. Indien de tijd die nodig is voor PCR analyse 
nog korter wordt, wordt het zinvol om tegelijkertijd bloedmonsters af te 
nemen voor hematologische en chemische bepalingen en voor BDL; 
resultaten kunnen dan geïntegreerd gebruikt worden in het diagnostische 
proces. Er is een positieve correlatie tussen de waardes van BDL en CRP 
bij patiënten op de Intensive Care met een positief PCR resultaat, terwijl de 
correlatie van S. pneumoniae BDL met CRP manifest is voor het volledige 
cohort van patiënten verdacht voor community-acquired pneumonie of 
meningitis. Het verschil in correlaties tussen beide cohorten kan verklaard 
worden door de veel prominentere rol van S. pneumoniae als verwekker 
van bacteriële luchtweg infecties vergeleken bij de meer diverse etiologie 
van ziekten waarvoor bloedkweken afgenomen worden op de Intensive 
Care. Als gevolg daarvan heeft een veel grotere proportie van IC patiënten 
een stijging van het CRP door andere aandoeningen dan bij patiënten met 
community-acquired luchtweg infecties. Aan de andere kant kan het zijn dat 
door het continu monitoren van IC patiënten de bloedmonsters bij die 
patiënten in een ander stadium van de ziekte afgenomen zijn dan bij 
patiënten met community-acquired episodes. Omdat de respons van CRP 
op infectie relatief traag op gang komt, kan de CRP concentratie bij die 
Chapter 13 
234 
patiënten nog laag zijn ondanks de aanwezigheid van bloedbaan infectie. 
Beide hypotheses worden ondersteund door de lage discriminatoire waarde 
van leukocytenaantal en CRP in het IC cohort in vergelijk met de sterkere 
onderscheidende waarde van die variabelen in het andere cohort, 
suggererend dat de patiënten populatie op de IC heterogener is. De 
positieve associatie tussen BDL en CRP suggereert niettemin dat BDL 
gerelateerd is aan de mate van ontsteking, waarbij een hogere BDL een 
sterkere inflammatoire reactie opwekt. Deze hypothese wordt ondersteund 
door de associaties tussen S. aureus en E. faecalis BDL en de 
microbiologische invasiviteit en klinische ernst van infectie, en door de 
hogere S. pneumoniae BDL bij patiënten die voldoen aan de systemic 
inflammatory response syndrome (SIRS) criteria bij presentatie. Ondanks 
deze associaties, is de relatie van BDL met klinische symptomen, ernst van 
ziekte en prognose nog altijd onduidelijk. De casus die beschreven is in 
figuur 10 suggereert dat het beloop van S. aureus BDL mogelijk 
vergelijkbaar is met het beloop van de temperatuur tijdens bacteriëmie, 
maar uit deze anekdote mogen geen algemene conclusies getrokken 
worden. In tegenstelling tot onze data is er bij patiënten met systemische 
meningokokken infectie wel een correlatie beschreven voor BDL bij 
opname met ernst van ziekte en korte termijn prognose [68,69]. Echter, de 
gemiddelde waardes van de meningokokken BDL in bloed zijn veel hoger 
en hebben bovendien een grotere spreiding dan de waardes voor BDL in 
onze cohorten. Dit is mogelijk gerelateerd aan de meer fulminante aard van 
invasieve meningokokken infectie. Het zou dus kunnen zijn dat het aantal 
patiënten in onze cohorten te klein is om associaties tussen BDL en ziekte 
ernst en prognose aan te tonen. 
De verschillende methoden om bloedbaan infectie te diagnosticeren en te 
behandelen zijn gestaag verbeterd tijdens de laatste eeuw. Met de opkomst 
van verschillende moleculaire testen worden de eerste stappen gemaakt 
naar een rigoureuze verandering in de diagnostiek van bloedbaan infectie. 
Deze nieuwe ontwikkelingen zullen mogelijk nog meer effect hebben op de 
dagelijkse klinische praktijk dan de introductie van automatische detectie 
systemen in de jaren 60. Op korte termijn zullen de ontwikkelingen 
voornamelijk gericht zijn op de snelle identificatie van micro-organismen in 
positieve bloedkweken met FISH analyse of PCR algoritmes. Hoewel dat 
veelbelovende technieken zijn om te komen tot een snellere identificatie 
van het verantwoordelijke pathogeen, blijft het voor deze aanpak 
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noodzakelijk om eerst een tijdrovende kweek te doen. Om die reden mag 
verwacht worden dat de lange termijn ontwikkeling zich zal richten op de 
directe, kwantitatieve, moleculaire detectie van circulerende bacteriën en 
bacteriële DNA fragmenten in de bloedbaan als nieuwe standaard voor de 
diagnose bloedbaan infectie. Om dit te bereiken moet de sensitiviteit en 
specificiteit van de huidige QPCR testen verder verbeterd worden, het 
risico van contaminatie terug gedrongen, en de benodigde tijd nog verder 
verkort. Een bijkomende ontwikkeling door de toenemende kennis van het 
bacteriële genoom en antimicrobiële resistentie mechanismen is dat het 
steeds gebruikelijker zal worden om moleculaire testen voor de bepaling 
van antimicrobiële resistentie op te nemen als onderdeel van de standaard 
diagnostische test. Een recente studie laat bijvoorbeeld zien dat met een 
DNA microarray gelijktijdig identificatie en bepaling van genotypische 
antimicrobiële resistentie van S. aureus, Escherichia coli en Pseudomonas 
aeruginosa verkregen kan worden [70]. De integratie van moleculaire 
testen voor identificatie en gelijktijdige bepaling van antimicrobiële 
resistentie zal een belangrijk speerpunt worden in toekomstige technische 
ontwikkelingen. De klinische interpretatie van de DNAmie die aangetoond 
wordt met deze testen zal zich verder ontwikkelen met voortschrijdende 
kennis over de relatie van BDL met klinische en microbiologische 
karakteristieken van de patiënt. De potentiële waarde van het monitoren 
van BDL tijdens behandeling is aantrekkelijk en vergt nader onderzoek van 
de kinetiek van DNA in bloed. Het beloop van BDL in bloed kan mogelijk 
voorspellend zijn voor de prognose, gebruikt worden om response op 
behandeling te monitoren, of als een surrogaat marker in klinisch trials naar 
efficiëntie en duur van antimicrobiële therapie bij bacteriëmische 
aandoeningen zoals endocarditis. Uiteindelijk moet de individuele patiënt 
degene zijn die voordeel heeft bij deze technische ontwikkelingen doordat 
hij in een zo vroeg mogelijk stadium adequate, antimicrobiële, behandeling 
krijgt. BDL biedt een nieuw stukje van de klinische puzzel die de clinicus op 
moet lossen wanneer hij beslissingen maakt over empirische therapie aan 
het bed van de patiënt. De klinische behandeling van patiënten verdacht 
van bloedbaan infectie zal dan ook altijd een geïntegreerde aanpak blijven 
gebaseerd op risico factoren, klinische symptomen en laboratorium 
bepalingen. Dit kan enkel ondersteund, maar nooit vervangen worden door 
high-tech laboratorium faciliteiten. 
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Dankwoord 
Het is nu juni 2007 en na ruim 6 jaar ben ik weer terug in Blantyre, Malawi, 
de plaats waar de eerste woorden van dit proefschrift geschreven zijn. Na 
een ontnuchterende avond in de Blue Elephant zit ik nu in het Afrikaanse 
winterzonnetje en realiseer met dat er veel gebeurd is tijdens het schrijven 
van dit proefschrift: werken in de avonduren vanwege het Bijlmer-
onderzoek, een afgewezen subsidieaanvraag, het stopzetten van de FISH 
multicenter studie en problemen met DNA isolatie kits vormen de dalen 
waarlangs de mooie bergen van publicaties, uitdagende discussies, mijn 
artsexamen, gezellige congressen en borrels met collega’s oprijzen. Eens 
te meer realiseer ik me dat ik veel mensen dank verschuldigd ben voor hun 
inspanning, ondersteuning en stimulans welke mede geleid hebben tot het 
ontstaan van dit boekje. 
 
Ten eerste wil ik mijn promotoren bedanken voor hun steun. Prof.dr. 
Vandenbroucke-Grauls, beste Christina, je enthousiasme toen wij elkaar 
voor het eerst spraken maakte dat ik wist dat ik voor de juiste omgeving 
koos. Onze pittige discussies heb ik als uitermate prettig en uitdagend 
ervaren en ik hoop dat er nog vele zullen volgen. Prof.dr. Danner, hartelijk 
dank dat u mij de gelegenheid heeft geboden om naar het VUmc te komen. 
Uw woorden tijdens ons eerste gesprek “er ligt helemaal niets; je bent gek 
dat je hier naartoe komt, maar ik vind het wel leuk als je het doet”, zijn meer 
tot stimulans geweest dan u zich waarschijnlijk ooit gerealiseerd heeft. 
 
Op de tweede plaats wil ik graag mijn copromotoren dr. van Agtmael en 
prof.dr. Savelkoul bedanken; de motoren achter dit proefschrift. Ik prijs me 
gelukkig en trots dat jullie degenen zijn die mij gevormd hebben. Michiel, 
het ambitieuze plan dat we ruim 6 jaar geleden hadden toen we samen uit 
Rotterdam vertrokken is met dit boekje verwezenlijkt, mede door onze 
gezamenlijke eigenwijsheid. Laten we binnenkort samen weer een eitje 
bakken, opnieuw op de toekomst. Paul, de afgelopen jaren heb ik ontdekt 
dat wij veel meer gemeen hebben dan het onderzoek beschreven in dit 
proefschrift. Ik heb erg genoten van onze discussies over microbiologie en 
van het filosoferen over wetenschap, bestuur en cultuur in het algemeen. Ik 
hoop van harte dat we dit nog lang kunnen voortzetten. 
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Prof.dr. Groeneveld, beste Johan, je bent mijn stille en absolute steun in de 
rug geweest en daar ben ik je voor altijd dankbaar voor.  
Prof.dr. Zijlstra, beste Ed, de ‘Fever study’ is voor mij dé prikkel geweest 
om deze weg in te slaan. Het is een zeer dierbare herinnering met hopelijk 
binnenkort een volgend hoofdstuk. 
Dr. Simoons-Smit, beste Ina, bedankt voor onze discussies over de 
‘conventionele’ microbiologie; dit heeft er zeker aan bijgedragen dat ik met 
beide moleculaire benen op de klinische grond ben blijven staan. 
Dr. Roosendaal, beste Robert, bedankt voor onze prettige samenwerking 
bij het schrijven van het ‘Etest manuscript’. 
Prof.dr. Twisk, beste Jos, dank voor je statistische ondersteuning bij het 
‘beslisboom’ manuscript. 
 
De samenwerking met het Laboratorium voor Infectieziekten in Groningen 
is vanaf het begin af aan prettig en uitdagend geweest, ondanks de 
reisafstand. Hopelijk kunnen we ook de laatste artikelen mooi afronden. 
Richard, Tim, Mirjam, Maike en Ton, bedankt! 
 
De samenwerking met collega’s is de hoeksteen van elk proefschrift. Ik wil 
dan ook graag iedereen van de afdeling Medische Microbiologie & 
Infectiepreventie bedanken voor hun ondersteuning en gezelligheid. In het 
bijzonder het ‘Baclab’ voor hun inzet en geduld bij de ‘FISH studie’ en de 
mensen van de Virologie voor het schijnbaar eindeloos uitvullen van de 
“Remco’s”. Verder wil ik de unit ‘Moleculaire diagnostiek’ bedanken, in het 
bijzonder Arnold en Johan, voor hun ondersteuning en dagelijkse 
samenwerking. Petra en Jorien, ik heb ervan genoten om met jullie aan de 
FISH studie te werken. Tenslotte wil ik mijn analiste Sonja bedanken voor 
haar enorme inspanning en betrokkenheid bij mijn onderzoek; mede door 
jouw inzet is er zoveel werk verzet. 
Daarnaast wil ik mijn collega’s van de afdelingen Algemene Inwendige 
Geneeskunde en Endocrinologie bedanken voor de gezellige tijd in de 
Meander. Als vreemde ‘infectieziekten eend’ in de bijt tussen al die 
liefhebbers van diabetes en vaatstijfheid onderzoek heb ik me altijd thuis 
gevoeld en genoten van onze discussies, lunches en borrels. Jullie 
vormden de noodzakelijke dagelijkse ontspanning en uitlaatklep. Michiel, 
Daniel, Nynke, Mathijs, Maarten Luuk, Lucia, Renate, Jacqueline, Marit, 
Wouter, Jennifer en Bas: bedankt! 
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Verder wil ik mijn kamergenoten van het eerste uur op de Microbiologie 
bedanken voor hun steun in de eerste stappen van mijn onderzoek: 
Xander, Wil, Leo, Gert en Elise: bedankt! Ook Tami wil ik bedanken voor de 
jaren van gezellige samenwerking en onze gesprekken over cultuur en 
maatschappij. 
 
Maarten, Floris, Laura, Diana, Michiel, Saskia, Josine, Bart, Janneke en 
Frederik: mijn ontspanning, sportieve inspanning en uitlaatklep heb ik altijd 
bij jullie gevonden. Bedankt voor de vele geweldige berg-, hardloop- en 
kroegentochten! 
Rob, de FISH studie heeft ons op een aantal interessante plekken 
gebracht. Onze prikkelende discussies over microbiologie en bergsport 
tijdens de lange autoritten heb ik uitermate gewaardeerd en hoop ik nog 
lang te kunnen voortzetten. 
 
Mijn paranimfen Maarten en Michiel wil ik bedanken voor hun enorme 
steun bij het tot stand komen van dit proefschrift. Maarten, naast onze 
voorliefde voor bergtochten en infectieziekten heeft het verblijf in Malawi 
ons een sterke band gegeven die nooit meer weg gaat. Succes met je 
opleiding tot microbioloog; ik weet zeker dat we in de toekomst nog eens 
samen een project zullen doen. Michiel, mijn ‘tardis roomie’, de laatste twee 
jaar op de meander zijn bijzonder fijn geweest. We hebben er een echt 
‘AIO hok’ van gemaakt en ik zal de gezelligheid en ons uitzicht missen. 
 
Tenslotte wil ik mijn ouders bedanken voor hun onvoorwaardelijke steun, 
begrip, motivatie, gezelligheid en liefde. Mijn broers Erwin en Stefan wil ik 
bedanken voor de talloze biertjes en discussies samen; ik ben benieuwd 
wie van jullie als volgende promoveert. Femke, sweetie, het proefschrift is 
af: op naar Afrika! 
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Curriculum vitae 
De auteur van dit proefschrift werd op 7 januari 1978 geboren in Bergen op 
Zoom en heeft vanaf zijn zesde levensjaar in Teteringen gewoond. Na het 
behalen van zijn VWO diploma aan het Stedelijk Gymnasium Breda in 1996 
ging hij geneeskunde studeren aan de Erasmus Universiteit Rotterdam. De 
doctoraal fase van die studie heeft hij eind 2000 afgerond met een 
afstudeeronderzoek in Blantyre, Malawi onder supervisie van prof.dr. 
Zijlstra en prof.dr. Wilson. Na zijn afstuderen heeft hij korte tijd gewerkt 
voor het Erasmus Vaccin Centrum Rotterdam waarna hij op 1 april 2001 
aan het VU Medisch Centrum in Amsterdam begon aan het onderzoek 
beschreven in dit proefschrift. Eerst als onderzoeker, later als AIO bij de 
vakgroepen Algemene Inwendige Geneeskunde en Medische Microbiologie 
& Infectie-preventie. Nadat hij was overgeschreven als student van de 
Erasmus Universiteit Rotterdam naar de Vrije Universiteit in Amsterdam, 
heeft hij vanaf januari 2003 het doen van onderzoek afgewisseld met het 
volgen van co-schappen, waarna hij in augustus 2006 cum laude zijn 
artsexamen behaalde. Tijdens deze periode is hij voor een korte klinische 
stage in Nicaragua geweest, heeft hij een oudste co-schap gedaan in 
Botswana en is hij zeer recent in Malawi terug geweest om opnieuw mee te 
werken aan onderzoek naar tuberculose. Na de verdediging van dit 
proefschrift zal hij nog korte tijd werkzaam zijn aan het VUmc waarna hij 
rond de jaarwisseling voor werk langere tijd naar de tropen hoopt te 
vertrekken. 
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